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SUMMARY 
 
Post-translational modification by conjugation of Ubiquitin- and Ubiquitin-like 
molecules contributes to extend the functionality of eukaryotes proteomes. SUMO (Small 
Ubiquitin-related Modifier) is added and deleted from many cellular substrates to control 
activity, localization, and recruitment of other SUMO-recognizing protein complexes. The 
dynamic nature of this modification and its low abundance in cells make it challenging to study, 
with susceptibility to deSUMOylases further complicating its analysis. In this work we 
developed a new methodology to isolate and analyze SUMOylated proteins in cultured cells and 
in a tissue-specific manner in flies. SUMOylated substrates are labelled by in vivo biotinylation, 
which facilitates their subsequent purification using Neutravidin-based affinity chromatography 
under stringent conditions and with very low background. Based on the success of bioSUMO in 
Drosophila, we have applied the same technology to mammalian Ubiquitin-like (UbL) proteins, 
using modular multicistronic vectors previously developed in our laboratory. We present here 
our current toolbox of vectors for application in mammalian cells and insects to isolate proteins 
that are modified with UbLs of choice, including SUMOs, Ubiquitin, NEDD8, FAT10, ISG15, 
UFM1, URM1 and other. 
In the second part of this Thesis, we focused our investigation on SALL (Spalt-like) 
proteins SUMOylation. Those proteins are zinc finger transcription factors conserved from C. 
elegans to mammals. In Drosophila, the two paralogs (salm and salr) control the expression of 
genes involved in wing and central nervous system development, including cell adhesion and 
cytoskeletal proteins. In vertebrates, mutations in these genes cause hereditary human diseases as 
Townes-Brocks and Okihiro syndromes. Human SALL1 and Drosophila Salm are SUMOylated 
in vitro. Here we demonstrate their SUMOylation in cells and we investigate the role of a 
putative SALL E3 ligase, using mammalian cells and Drosophila as models. 
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RESUMEN 
 
La modificaciones post-traduccional debidas a la conjugación de Ubiquitina y de 
proteínas similares a la Ubiquitina (UbLs) contribuyen a extender y diversificar la funcionalidad 
de los proteomas eucariotas. SUMO (Small Ubiquitin-related Modifier) se une de manera 
reversible a muchos substratos celulares para controlar su actividad y su localización, así como el 
reclutamiento de complejos proteicos que puedan reconocer la molécula de SUMO. La 
naturaleza dinámica de esta modificación y su escasa abundancia en las células hace que el 
estudio de la SUMOilación sea a menudo difícil de encarar técnicamente. Además, la 
susceptibilidad de las proteínas modificadas a las deSUMOilasas complica aún más su análisis. 
En este trabajo hemos desarrollado una nueva herramienta para aislar y analizar proteínas 
SUMOiladas en cultivo celulares y de manera específica de tejido en Drosophila. Mediante esta 
técnica, los substratos SUMOilados son biotinilados in vivo, lo cual facilita su subsiguiente 
purificación, en condiciones astringentes y con muy poco fondo inespecífico, utilizando 
cromatografía de afinidad basada en Neutravidin. Tras la aplicación exitosa de la tecnología de 
bioSUMO en Drosophila, aplicamos la misma técnica a otras proteínas similares a Ubiquitina en 
mamíferos, utilizando para ello vectores multicistrónicos modulares desarrollados previamente 
en nuestro laboratorio. Presento en esta Tesis la batería de herramientas elaboradas que se 
puedan utilizar en células de mamífero y de Drosophila para aislar proteínas modificadas por 
una variedad de UbLs, incluidas SUMO, Ubiquitina, NEDD8, FAT10, ISG15, UFM1, URM1 y 
otras. 
En la segunda parte de esta Tesis, nos enfocamos en la investigación sobre la 
SUMOilacion de las proteínas SALL (Spalt-like). Estas proteínas son factores de trascripción del 
tipo dedo de zinc, conservadas desde C. elegans hasta mamíferos. En Drosophila, los dos 
parálogos (salm and salr) controlan la expresión de genes involucrados en el desarrollo del ala y 
del sistema nervioso central, incluyendo moléculas de adhesión y proteínas del citoesqueleto. 
Mutaciones en estos genes provocan enfermedades humanas hereditarias, tales como el 
Síndrome de Townes-Brocks y el Síndrome de Okihiro. Tanto el homólogo humano SALL1 y 
como Salm en Drosophila están SUMOiladas in vitro. Aquí demostramos su SUMOilación en 
células e investigamos el papel de una posible E3 ligasa de SALL, utilizando células de 
mamífero y Drosophila como modelos. 
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1. Post-translational modifications 
 
The eukaryotic proteome is modulated by a variety of post-translational 
modifications (PMTs) that contribute to maintain the cellular homeostasis. These modifications 
could involve small chemical molecules as it occurs in phosphorylation, acetylation, methylation 
and sulfation, or proteins could be covalently modified by other proteins. This is the case of the 
modification by Ubiquitin (Ub), which is the result of sequential reactions catalyzed by several 
enzymes. Proteins similar to Ub, either in sequence or in their three-dimensional structure, form 
the family of Ub-like modifiers (UbL), which can modify target proteins is a manner similar to 
the Ub cycle (Fig. 1). Nearly 20 UbL proteins have been described in mammalian cells, which 
are conserved among eukaryotes and are object of an increasing interest in investigation. The 
main members of the UbL family include SUMO1-4 (Small Ub-like Modifier1-4), NEDD8 
(Neural precursor cell expressed developmentally down-regulated 8), ISG15 (Interferon-
stimulate gene 15), FAT10 (HLA-F-adjacent transcript 10), UFM1 (Ub fold modifier 1), Atg-8 
and Atg-12 (autophagy-related Ub-like modifier 8 and 12) and URM1 (Ub-related modifier 1) 
(reviewed by van der Veen & Ploegh 2012). The work presented in Results Part I section of this 
PhD Thesis is focused on SUMOylation, one of the most studied UbL post-translational 
modifications, and on UFMylation, one of the less studied UbL modifications. 
 
 
 
Figure 1. Structure of Ub and UbL proteins. Representation of three-dimensional structure of Ub, 
SUMO, NEDD8 and Ufm1 proteins that show a common secondary structure. Adapted from Sorokin et 
al. 2009. 
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1.1. SUMOylation and SUMO proteins  
 
SUMOylation is a reversible modification involved in diverse cellular and biological 
processes such as DNA replication, cell cycle progression, transcription regulation, modulation 
of protein-protein interactions, protein translocation and nuclear trafficking. 
At least one SUMO precursor protein was found in all eukaryotes tested since its 
discovery in 1997 by Mahajan and co-workers (Mahajan et al., 1997). Yeast, Caenorhabditis 
elegans and Drosophila melanogaster are among the species expressing only a single SUMO 
protein; in vertebrates, four SUMO paralogs were identified, denominated SUMO1-4 (reviewed 
by Flotho & Melchior 2013). Mature human SUMO2 and SUMO3 are very similar (97% 
sequence identity) and, since they cannot be distinguished by available antibodies, usually both 
proteins are referred to as a sub-group SUMO2/3. On the other side, SUMO1 diverges from 
SUMO2/3, sharing only 47% sequence identity. Despite diversity between the two sub-groups, 
all SUMO proteins are characterized by the Ub fold (globular β-grasp fold) and a C-terminal 
glycine-glycine motif that is exposed after their maturation. SUMO4 was described in human 
cells, its sequence being 87% similar to SUMO2 and its maturation being observed in lysates 
from starved-cells. However, the details of its processing and whether the conjugation to specific 
targets is actually occurring, are still unclear (Guo et al., 2004; Wei et al., 2008). 
Human SUMO paralogs show different ability to form polySUMO chains in vitro 
and in vivo (Tatham et al., 2001). SUMO2 and SUMO3 contain an internal consensus site for 
SUMOylation that allow the covalent linkage by other SUMOs molecules; SUMO1 could be 
also incorporated in these chains, but the lack of SUMO consensus site limits the elongation after 
its incorporation (Matic et al., 2008). Formation of polySUMO1 chains has been reported only in 
vitro in presence of an excess of SUMO1 and a target protein (RanBP2, Ran-binding protein 2) 
(Pichler et al., 2002). In yeast, Smt3 is able to form polySUMO chains regulated by the 
isopeptidase Ulp2 while, recently, it has been demonstrated that orthologs of human SUMO3 in 
insects have lost the capability to form polySUMO chain (Bylebyl et al., 2003; Ureña et al., 
2015) 
 
 
1.2. The SUMOylation pathway 
 
Like ubiquitination, the process of SUMOylation consists of an enzymatic cascade 
involving the activation, conjugation and ligation of the SUMO moiety by E1, E2 and E3 
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enzymes, respectively (Fig. 2). Despite differences between SUMO2/3 and SUMO1, the same 
catalytic enzymes activate and conjugate diverse SUMO moieties to target proteins. The case of 
SUMO4 is different, mainly due to the presence of a proline residue (Pro90) at the C-terminus 
that blocks the enzymatic reaction of activation. Data are not available and still is not clear how 
the maturation process occurs for this paralog (Owerbach et al., 2005).  
 
 
 
Figure 2. Schematic representation of SUMOylation cycle. Adapted from Flotho & Melchior 2013. 
See text for details. 
 
 
Prior to the first conjugation cycle, a nascent SUMO needs to be cleaved by a 
SUMO-specific protease belonging to the Ulp/SENP family. The elimination of the C-terminal 
residues allows the exposure of the glycine-glycine motif. In the first step, the heterodimeric E1, 
composed by SUMO activating enzymes 1 and 2 (SAE1 or AOS1 and SAE2 or UBA2), 
activates the C-terminus of a mature SUMO moiety by ATP hydrolysis and forms a thioester 
bond with a cysteine residue in SAE2. In the second step a unique E2, called UBE2I or UBC9, 
binds to SAE2 and accepts the SUMO moiety from the E1 on its active cysteine by a 
transthiolation reaction. Finally, an E3 ligase catalyzes the transfer of SUMO from the E2 to a 
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target protein forming an isopeptidic bond between the ε-amino group of a lysine in the substrate 
protein and the C-terminal glycine in the SUMO moiety (reviewed by Eifler & Vertegaal 2015). 
SAE1 and SAE2 are encoded by unique genes in the human genome. As mentioned, 
the E2 is represented by one protein, in contrast to the 35 conjugating enzymes involved in the 
ubiquitination machinery. Despite being the only SUMO E2, UBC9 plays a regulatory role in 
target protein selection (Knipscheer et al., 2008). Modulation of the UBC9 expression influences 
the entire SUMOylation process and has been demonstrated that high concentration of E2 in 
presence of E1 is able to SUMOylate target proteins in absence of E3 ligases (Bernier-Villamor 
et al., 2002).  
Despite this, the E3 SUMO ligases promote SUMOylation under physiological 
conditions, and confer specificity to the substrate. In contrast with the ubiquitination pathway, 
only a few SUMO ligases have been described. These are classified in two sub-families: (i) the 
Siz/PIAS RING ligase sub-family and (ii) the nucleoporin RanBP2 sub-family. Six PIAS 
(Protein inhibitor of activated STAT) members belong to the first group and are characterized by 
three conserved motifs: (I) a N-terminal PINIT domain that plays a unique role in substrate 
recognition, (II) a central zinc finger RING-like domain (SP-RING), which recognizes the 
cognate E2 into a complex and facilitates the SUMO conjugation, and (III) a C-terminal domain 
(SP-CTD) required for the interaction with SUMO. Like it occurs during ubiquitination, the 
RING domain provides the scaffold to bring UBC9 and the substrate together (Yunus and Lima, 
2009). The other ligases group is characterized by RanBP2 protein that is part of the nuclear pore 
complex (NPC) and is localized in cytoplasmic filaments, implying that the SUMOylation 
process is not exclusive of the nucleus. In contrast to the RING E3 ligases, RanBP2 does not 
bind to the target protein but enhance its SUMOylation, as demonstrated in the case of Sp100 
(Pichler et al., 2002) or Ran GTPase activating protein 1, RanGAP1 (Werner et al., 2012).  
Several other proteins have been identified as E3 ligases that could not be classified 
in these two sub-families. Among these, the human Polycomb (Pc) CBX4/Pc2, component of the 
multimeric Polycomb repressive complex 1 (PRC1), which enhances the SUMOylation of C-
terminal binding protein 1 (CTBP1) (Kagey et al., 2003), the CCCTC-binding factor (CTCF) 
(MacPherson et al., 2009), or the DNA methyltransferase 3, Dmnt3 (Li et al., 2007). Also, it 
regulates the recruitment of the Pc complex protein BMI1 at DNA-damaged sites trough 
SUMOylation (Ismail et al., 2012).  
SUMOylation is a dynamic and reversible process. DeSUMOylation is catalyzed by 
SUMO isopeptidases that are, in some cases, also SUMO proteases, a family of cysteine 
proteases necessary for the SUMO moiety maturation prior to the activation and conjugation 
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cycle. The first protein family of SUMO protease described was Sentrin/SUMO specific 
peptidase (Ulp/SENP). Human genome encodes for SENP1, SENP2, SENP3, SENP5, SENP6 
and SENP7, that show conserved catalytic domain localized at the C-terminus of the proteins. 
The subcellular distribution of isopeptidases contributes to the specificity for their targets: 
SENP1 and SENP2 are concentrated in the nuclear envelope trough their interaction with the 
NPC; SENP3 and SENP5 localize in the nucleolus where they participate in the early step of 
ribosome maturation; SENP6 and SENP7 exhibit a nucleoplasmic distribution. SENP members 
are also characterized by the different affinity for diverse SUMO moieties: SENP1 shows a 
mayor affinity for SUMO1 in SUMO processing and SUMO deconjugation; SENP2 catalyzes 
more efficiently the deconjugation for SUMO2; the couple SENP3-SENP5 acts on SUMO2/3 for 
processing and deconjugation; and SENP6-SENP7 exhibit preference for deconjugation of 
polySUMO2/3 chains (reviewed by Nayak & Müller 2014). Other SUMO isopeptidases have 
been described: the DeSI family composed by DeSI-1 and DeSI-2 that shown only isopeptidase 
activity; and the Ubiquitin-specific protease-like 1 (USPL1), a Cajal body protein efficient only 
in SUMO deconjugation with preference for polySUMO2/3 chains (Schulz et al., 2012) . As E3 
ligases, SUMO isopeptidase show specificity for their targets (Shin et al., 2012). 
 
 
1.3. SUMOylation consensus motifs versus SUMO interaction 
 
The identification of hundreds of SUMOylated targets, propitiated by the 
development of Mass Spectrometry strategies to identify the SUMO insertion sites, contributed 
to demonstrate that the interaction of the SUMO moiety occurs on a lysine. Based on 
experimental evidences, and in contrast with ubiquitination, it was possible to develop 
bioinformatics tools to predict SUMOylation consensus sites as SUMOplot program or GPS-
SUMO (Zhao et al., 2014). In addition, SUMO proteins could also interact with proteins in a 
non-covalent way trough specific recognition sequences called SUMO Interaction Motifs or 
SIMs. SUMO consensus motifs and SIMs will be described more in detail in the next paragraphs 
to distinguish between SUMO conjugation and SUMO interaction. 
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1.3.1. SUMO consensus motif 
 
SUMOylation targets are modified by the covalent attachment of SUMO to a lysine 
generally present in the canonical SUMO consensus motif ΨKxD/E, where Ψ is a hydrophobic 
residue, K is the conjugation lysine, x is any amino acid, and D or E are aspartic or glutamic 
acids, respectively (Rodriguez et al., 2001). Other sequences, different from the canonical 
consensus motif, were described in several studies: an inverted consensus motif D/ExKΨ (Matic 
et al., 2010); an hydrophobic cluster SUMOylation motif (HCSM), consistent of an extended 
consensus motif where the target lysine is preceded by a cluster of at least three hydrophobic 
amino acids (Matic et al., 2010) and a phosphorylation-dependent SUMOylation motif (PDSM), 
composed of a SUMO consensus site and an adjacent proline-directed phosphorylation site 
(Hietakangas et al., 2006). A large-scale site-specific analysis of SUMOylation sites suggests 
that ΨKxE could be a better substrate than ΨKxD for sites with the forward consensus motif, 
while in the inverted consensus motif the presence of aspartic or glutamic acids was found in the 
same proportion in the identified targets (Tammsalu et al., 2014).  
 
 
1.3.2. SUMO non-covalent interactions  
 
The first evidence of a specific sequence that mediates a non-covalent binding with 
SUMO was reported in 2000, when a short stretch of branched hydrophobic residues forming a 
SIM was identified by yeast two-hybrid screen (Minty et al., 2000). Few years later, the presence 
of three residues (valine, V, leucine, L, or isoleucine, I) was reported as essential. These residues 
could be arranged as V/I-x-V/I-V/I or V/I-V/I-x-V/I/L and could bind SUMO in the two 
orientations (Song, 2005). SIM domains interact with the SUMO moieties in a very specific way. 
Three-dimensional structural studies revealed that this motif could be consider as a “code of 
specificity” for SUMO isoforms: the affinity for SUMO1 depends on the presence of negative 
charges close to the SIM, while the hydrophobic core of the SIM stabilizes the interaction with 
SUMO2 without necessity of additional charge (Hecker et al., 2006).  
The interaction SUMO-SIM has been identified in numerous SUMO targets and 
enzymes, being involved in SUMOylation and in the regulation of protein-protein interactions. 
Non-covalent interaction between SUMOylated UBC9 and its targets trough SIMs stimulates 
proteins SUMOylation and promotes chain formation (Knipscheer et al., 2007). SIMs are present 
in various E3 ligases: RanBP2 catalytic activity depends on its SIM; PIASα is phosphorylated 
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within its SIM, which influences its binding to SUMO; CBX4 SUMOylation depends on its 
SIMs, necessary also for its E3 ligase activity (reviewed by Flotho & Melchior 2013; Kagey et 
al. 2005; Merrill et al. 2010). 
A different role for SIM motifs was identified for the RING finger protein 4 (RNF4), 
an Ubiquitin E3 ligase that recognizes, through its SIMs, the polySUMO chains of 
Promyelocytic Leukemia (PML) and targets the SUMOylated protein for degradation mediated 
by ubiquitination. This represents an example of a cellular mechanism that involves a cross-talk 
between two post-translational modification (Tatham et al. 2008, Xu et al. 2014). 
To conclude this paragraph on SIM motifs, it should be mentioned the recent 
characterization of ZNF451, a representative member of a new vertebrate family of proteins that 
are E3 ligases showing a new E4 elongase activity. This consist on the capability to extend a 
SUMO chain by adding SUMO2/3 moieties, while showing an inefficient initial conjugation of 
the modifier to the target (Eisenhardt et al. 2015; Cappadocia et al. 2015),  
 
 
1.4. Strategies to study SUMO modification 
 
Multiple strategies have been used to study the post-translational modification of 
target proteins. Despite the increasing number of SUMOylated targets identified during the last 
years, the analysis of SUMOylated proteins is still challenging compare to the study of other 
PTM as ubiquitination or phosphorylation. The main reason is that the general SUMO 
expression level is lower than the one exhibited by Ub, and this is reflected on the small 
proportion of SUMOylated fraction in the total pool of a given protein. In addition, the 
susceptibility to deSUMOylases further complicates the isolation of SUMOylated proteins. In 
the next paragraphs I will briefly describe the advantages and disadvantages of the different 
approaches available for the detection of SUMOylated proteins. 
An efficient SUMO target enrichment is achieved by the fusion of the N-terminus of 
SUMO to a tag, single or in tandem repeats, like for example His6, His10, FLAG, Myc, His6-
FLAG, His6-HA, FLAG-TEV or ProtA-TEV-CBP, which could be expressed transient or stably 
in cell lines, as well as in transgenic organisms (Denison, 2005; Ganesan et al., 2007; Hannich et 
al., 2005; Nie et al., 2009; Schimmel et al., 2014; Tirard et al., 2012; Vertegaal et al., 2004; 
Wohlschlegel et al., 2004). Depending on the tag, the conditions used for purification of the 
modified proteins could be more or less stringent, which is important to inactivate deSUMOylase 
activities. For example, in the case of His6 or His10, guanidine or urea buffers are conveniently 
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used but, on the other hand, endogenous proteins that naturally contain histidine rich sequences 
are also purified with the nickel chromatography. These N-terminal fusions require the 
exogenous expression of SUMO, which could not reflect the endogenous conditions in terms of 
expression levels and, consequently, could influence global SUMOylation. A very important 
advantage of those SUMO fusions is the possibility to mutate SUMO isoforms by point 
mutations as Q87R, T90R and T90K, which generates an additional cleavage site near the C-
terminus to facilitate Mass Spectrometry analysis (Tammsalu et al., 2014). This approach is very 
useful for the identification of SUMO target lysines, although it is necessary to verify that the 
functionality of the mutant SUMO, in terms of conjugation and deconjugation, reflects the wild 
type (WT) one. Recently, a method for identification of SUMOylation sites without using 
SUMO variants has been developed, based on the chemical blocking of all free lysines, followed 
by treatment with SUMO speciﬁc proteases and subsequent identiﬁcation of the ‘freed’ lysines 
by high-resolution Mass Spectrometry (Hendriks et al., 2015). 
The best hypothetical approach is the identification of modified targets under 
completely endogenous condition. In 2013, Becker and co-workers identified 600 SUMO targets 
by using monoclonal antibodies against the glycine-glycine C-terminal dimer (Becker et al., 
2013). The biggest advantage of this method is the possibility to use these antibodies for any 
type of sample, including primary cells that are hard to transfect for exogenous expression or 
rare patient material. However, this method is relatively expensive and requires large amounts of 
sample material, as well as a complex purification protocol. Finally, SUMO-traps have been 
developed to isolate endogenous modified proteins. In this case, the affinity is very high for 
poly- or multi-SUMOylated proteins and requires as well large amounts of sample material 
(Bruderer et al. 2011, Da Silva-Ferrada et al. 2013).  
 
 
1.5. The SUMOylation process in Drosophila 
 
1.5.1. Drosophila melanogaster as a model system 
 
The fruit fly Drosophila melanogaster is a versatile model organism that has been 
used over a century for genetic and developmental studies. There are many technical advantages 
for using Drosophila over vertebrate models: it is easy and inexpensive to culture in laboratory 
conditions, there are numerous established techniques for genetic manipulation, the life cycle is 
relatively short (11 days at 25°C) and the offspring production is quite large.  
INTRODUCTION 
21 
 
Drosophila life cycle consists in four morphologically distinct stages. Once 
fertilized, the embryo develops from the egg and molts into larval stages after 24 hours at 25°C. 
The larval stages consist of three instars, LI, LII and LIII, over five days, where most of the body 
growth occurs and the animal attains its final size. After the larval stages, the animal enters into 
pupariation for 4-5 days, during which metamorphosis occurs. Finally, the adult fly emerges 
from the pupa. All these developmental transitions are regulated by peaks of steroid hormones 
necessary to pass from one stage to another (Fig. 3) (Dubrovsky, 2005). A series of enzymatic 
steps within the endocrine organ of the insect, the prothoracic gland (PG), converts cholesterol 
into 20-hydroxyecdysone (20E), the most important steroid hormone in insects. 20E is then 
liberated into the hemolymph and reaches the target tissues. 
 
 
 
 
Figure 3. Levels of 20E and juvenile hormone (JH) during Drosophila development. Schematic 
representation of Drosophila life cycle with indication of the number of days for each stage. A dotted line 
indicates levels of juvenile hormone and a continue line represents levels of 20E. Developmental 
transitions are determined by an increase of 20E. Adapted from Dubrovsky 2005. 
 During metamorphosis, most of the larval tissues are destroyed. Most of the adult tissues 
such are wings, legs or eyes, develop from the imaginal discs. These are groups of epithelial cells 
that will form the epidermal structures in the adult. The imaginal discs are present from early 
embryonic stages, growing in size during larval stages. During the pupal stage they evert and 
finally develop into the adult structures. 
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1.5.2. SUMOylation pathway in Drosophila 
 
Yeast, Drosophila and nematodes genomes encode for a single SUMO gene. 
Drosophila smt3 shares 52% and 73% sequence identity with human SUMO1 and SUMO2, 
respectively. smt3 is expressed during development, principally during embryogenesis, imaginal 
discs and in adult female (Ohsako & Takamatsu 1999; Long & Griffith 2000; Lehembre et al. 
2000; Kanakousaki & Gibson 2012). The factors involved in the conjugation pathway are also 
highly conserved in eukaryotes (Talamillo et al. 2008). A component of Ulp/SENP family is 
involved in Smt3 maturation: after elimination of just two amino acids, Drosophila Smt3 enters 
into the three steps process of activation and conjugation to the target proteins, as described 
before for vertebrates. In Drosophila the activating enzyme E1 is an heterodimer composed by 
two proteins Aos1 and Uba2 (Long & Griffith 2000; Bhaskar et al. 2000). The unique E2 
homolog of UBC9 is encoded by a gene called lesswright (lwr) (Lehembre et al., 2000), and the 
E3 ligases identified, Su(var)2-10 and Tonalli, contain a SP-RING as the PIAS family (Hari et 
al. 2001; Monribot-Villanueva et al. 2013). The deconjugation enzymes characterized are: Ulp1, 
a protease associated to the NPC responsible of the maintenance of SUMOylated proteins into 
the nucleus (Smith et al., 2004); and Veloren (Velo), an isopeptidase directly involved in 
deSUMOylation of Pc (Gonzalez et al., 2014) and with a role in regulation of neuron projection 
(Berdnik et al., 2012).  
The general localization of Smt3 is nuclear and, like the mammalian homologs, 
Drosophila Smt3 localizes in sub-nuclear bodies. The nature of these bodies is still unclear. In 
mammalian cells, SUMO localizes in PODs (Promyelocytic Leukemia, PML, oncogenic 
domains) that contain SUMO-conjugated proteins. However, Drosophila does not encode for a 
homolog of PML, therefore the nuclear bodies might contain other proteins that are not yet 
identified. 
 
 
1.5.3. The role of SUMOylation in Drosophila  
 
SUMOylation in Drosophila has been involved in embryogenesis (Epps and Tanda, 
1998), growth and proliferation of the imaginal discs (Kanakousaki & Gibson Development 
2012), development of the nervous system (Badenhorst et al. 2002; Lehembre et al. 2000), wing 
morphogenesis (Takanaka and Courey, 2005), metamorphosis (Talamillo et al. 2008) and the 
immune response (Bhaskar et al., 2002).  
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Alterations in the expression of smt3 or of the SUMOylation machinery cause 
dramatic developmental defects and early lethality due to the regulation of proteins required in 
the early Drosophila embryo (Nie et al., 2009). For example, smt3 transcripts reduction in 
embryos is lethal before the second larval instar (Nie et al., 2009); the E2 lwr mutation semushi 
is lethal at late embryonic stages, as the nuclear import of Bicoid (a morphogenetic protein that 
forms a concentration gradient along the anterior-posterior axis) is blocked during the early 
embryogenesis (Epps and Tanda, 1998); the consequence of Uba2 overexpression is an increase 
of Smt3-conjugated proteins that is associated to lethality when occurs in neurons (Long and 
Griffith, 2000); silencing smt3 expression in the PG blocks development at the end of LIII due to 
reduction in the production of 20E, which does not reach the levels necessary to entry into 
pupariation (Talamillo et al. 2008). 
Numerous SUMOylation target have been identified in Drosophila. Most of them are 
transcription factor, as for example p53 that has a fundamental role in the activation of apoptosis; 
the transcriptional corepressor Groucho (Gro), expressed in the embryo and in the imaginal 
discs, that regulates several processes from embryonic patterning to neurogenesis; the 
transcriptional repressor Tramtrack69 (Ttk69) that antagonizes neuronal fate determination in the 
peripheral nervous system; Dorsal and STAT92E implicated in the immune response; or the zinc 
finger transcription factors Spalt major (Salm) and Spalt-related (Salr) that control growth and 
vein formation in wing morphogenesis (reviewed by Smith et al. 2012). We will talk more 
extensively about the Salm and Salr factors in the paragraphs below. 
 
 
1.6. UFM1 and the UFMylation pathway 
 
UFM1 is a 9.1 KDa protein with a low sequence identity with Ub but with a very 
similar tertiary structure. In contrast with Ub and other UbLs, Ufm1 possesses a single active 
glycine at the C-terminus, being synthesized as an inactive precursor form that has 2 additional 
amino acids beyond the conserved glycine. Like described above for SUMOylation, UFM1 
conjugation utilizes a three-step enzyme system: UBA5 as activating enzyme, UFC1 as E2 
conjugating enzyme and UFL1 as an E3 ligase (Fig. 4). Modification of proteins with UFM1 is 
also reversible. Two novel cysteine proteases have been identified to date (UFSP1 and UFSP2) 
which cleave UFM1-peptide C-terminal fusions and also remove UFM1 from native intracellular 
conjugates. These proteases have no obvious homology to Ub deconjugating enzymes.  
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UFM1 system is conserved in animals and plant, but not in yeast, suggesting an 
important role in multicellular organism. The role of UFM1 modification is still not completely 
understood. Some of the identified targets are involved in the endoplasmic reticulum stress 
response (Lemaire et al., 2011), erythrocyte differentiation in mice (Tatsumi et al., 2011) or in 
human breast cancer (Zhang et al., 2012). Being one of the most unknown UbLs, its study 
represents an interesting research challenge. 
 
Figure 4. Schematic representation of UFMylation cycle. Adapted from Daniel & Liebau 2014. See 
text for details. 
 
 
2. The SALL family of transcription factors  
 
SALL (Spalt-like) proteins are zinc finger transcription factors conserved throughout 
evolution from C. elegans to mammals. SALL genes were identified for the first time in 
Drosophila, where two paralogs Salm and Salr are encoded (Kühnlein et al. 1994; Barrio et al. 
1996; de Celis & Barrio 2009). In C. elegans the only SALL gene described is sem-4, three 
genes were identified in zebrafish and in chicken (Farrell et al. 2001; Camp et al. 2003; 
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Barembaum & Bronner-Fraser 2004; de Celis & Barrio 2009), while the genome of mouse and 
human encode for four SALL genes (SALL1-4) (Buck et al. 2001; Kohlhase et al. 1998). 
In Drosophila melanogaster sall genes were identified as homeotic genes expressed 
during embryogenesis in the nervous and tracheal systems, as well as in the larval imaginal discs 
(Kühnlein et al. 1994; reviewed by de Celis & Barrio 2009). The contribution of Sall factors is 
essential for tracheal and nervous system development (Kühnlein & Schuh 1996; Cantera et al. 
2002), for the determination of wing patterning (De Celis and Barrio, 2000) and for sensory 
organ development (Barrio et al. 1999; Rusten et al. 2001). In C. elegans, sem-4 is implicated in 
fate determination of different cell types, as neurons, muscles and hypodermis (Toker et al., 
2003). Finally, in vertebrates, SALL proteins are required for the correct development of limbs 
and nervous system, as well as for organs such heart and kidneys. 
 As shown in Fig. 5 SALL proteins are characterized by the presence of zinc fingers 
with a precise pattern along the proteins. The first zinc finger domain (ZF1) corresponds to a 
single zinc finger C2HC type conserved only in vertebrates; the rest of the domains (ZF2-5) are 
organized in doublets or triplets of C2H2 type zinc fingers, connected by sequences conserved 
throughout evolution. The N-terminal part of SALL proteins contains a glutamine rich region 
conserved in vertebrates and invertebrates, which could have a role in protein dimerization or 
interaction with other proteins. (Kohlhase et al. 1998; Buck et al. 2000; Borozdin et al. 2006). In 
chickens, this domain is required for the interaction between SALL1 and SALL3 or with other 
SALL proteins. However, it is unclear whether the dimerization of the two SALL proteins occurs 
only trough the glutamine rich motif or the binding could be directed by other motifs or mediated 
through unrelated proteins (Sweetman et al., 2003). 
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Figure 5. Schematic representation of SALL proteins in vertebrates, Drosophila and C. elegans. 
Colored ovals indicate the zinc finger domains, the number of each domain being indicated in the top of 
the figure. Q represents the glutamine-rich region. Adapted from de Celis & Barrio 2009. 
 
 
The two Drosophila SALL paralogs have transcriptional repression activity acting 
through AT-rich DNA sequences (Sánchez et al. 2011; Barrio et al. 1996). Human SALL1 and 
SALL3 are classified also as transcriptional repressors, while SALL2 and SALL4 activate 
transcription, as described in mouse and in human trough CT- or GC-rich sequences. Two 
possible repression mechanisms have been described for SALL1: a conserved sequence 
composed by 12 amino acids at the N-terminus of the proteins is responsible for the Nucleosome 
Remodeling Deacetylase (NuRD) complex recruitment, one of the major corepressor complexes 
in mammalian cells, and its associated histone deacetylase activity (Lauberth and Rauchman, 
2006); the second mechanism requires the central region of the protein including ZF2 and ZF3 
(Netzer et al., 2006).  
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2.1. SALL proteins in human health 
 
The SALL family is very important in different aspects of human health, since they 
are associated to hereditary syndromes and involved in stem cell maintenance and cancer as 
tumor-suppressor factors. Mutations in SALL1 and SALL4 genes cause the Townes-Brocks 
(TBS) and the Okihiro syndromes (OS), respectively. 
 
 
 
 
Figure 6. Clinical features of TBS and OS syndromes. Patients affected by either of these two 
syndromes exhibit hand (polydactyly) and foot malformations, as well as external ear malformations. 
Pictures are taken form a patient suffering TBS. Adapted from Kohlhase et al. 1998.  
 
 
 TBS is an autosomal dominant syndrome characterized by thumb abnormalities, 
dysplastic ears and imperforated anus. Additional malformations have been described in patients 
with TBS including structural and functional renal anomalies, hand malformations, foot 
malformations, hearing loss, congenital heart defects, and eye anomalies. 
Since its discovery, many familiar and isolated cases have been described. More than 
60 point-mutations were described that cause premature stop codons by frame shifts, short 
insertions or deletions, mainly in a hot-spot region located between the N-terminal part of the 
protein and ZF2 (Kohlhase et al. 1998; Botzenhart et al. 2005; Botzenhart et al. 2007). In 
addition, three different deletions, including most part of the SALL1 coding region, have been 
reported in TBS patients (Borozdin et al. 2006; Miller et al. 2011). 
Haploinsufficiency was the first hypothesis to explain the symptoms of patients 
affected by TBS. However, deletion of murine Sall1 in heterozygous animals did not show the 
characteristic TBS phenotype, while in homozygosis only hypoplastic kidneys were observed 
(Nishinakamura et al., 2001). Further and independent studies suggested that truncated SALL1 
results into a dominant negative molecule interfering with the role of WT SALL1 and with its 
nuclear localization (Botzenhart et al., 2007).  
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OS is characterized by hearing dysfunction, external ear malformation, renal 
abnormalities, atrial septal defects and facial asymmetry. Mutations and deletion in the gene 
SALL4 are directly connected with the symptoms observed in OS patients. Unlike SALL1 
mutations in TBS, the mutations observed in OS cases do not cluster around a critical region of 
SALL4 and haploinsufficiency has been shown to be the cause of this disorder (Kohlhase et al. 
2002; Borozdin et al. 2004; Borozdin et al. 2007).  
SALL2 and SALL3 have not been traditionally associated to genetic syndromes. Only 
recently, mutations in SALL2 have been identified as responsible for ocular coloboma in human 
and in mice, a congenital defect resulting from failure in the optic fissure normal closure 
(Kelberman et al., 2014).  
In recent years, a very important role is assigned to SALL proteins in stemness and 
cancer biology. SALL4 is critical for maintaining pluripotency in mouse embryonic and 
hemapoietic stem cells (ESC) (Sweetman & Münsterberg 2006; Wu et al. 2006; Yang et al. 
2010; Xiong 2014), showing also a role in DNA damage response in ESCs by interaction with 
the epigenetic machinery (Xiong et al., 2015). SALL2 has been described as a suppressor of 
ovarian cancer (Sung et al., 2013). Reduced levels of expression of SALL2 are associated to 
different tumors as lung, colorectal, breast and prostate cancers, while high levels of the protein 
are detected in Willm’s Tumors (Ma et al. 2001; Li et al. 2002; Liu et al. 2007). In respect to 
SALL3, it was shown that its methylation is significantly increased in bladder cancer (Yu et al., 
2007) and a reduction of SALL3 expression is observed in human hepatocellular carcinoma 
(Yang et al. 2012). 
 
 
2.2. Post-translational modification of SALL proteins 
 
Regulation and localization of transcription factors activity could be modulated by 
post-translation modifications. In Drosophila, SALL proteins can be SUMOylated. This 
modification alters their nuclear localization and, in addition, their SUMOylation state influences 
their role in vein pattern formation in the wing (Sánchez et al., 2010), as well as their 
transcriptional repressor activity (Sánchez et al 2011). Phosphorylation of Sall1 by protein kinase 
C modifies its transcriptional repression activity in Xenopus laevis (Lauberth et al., 2007). Yeast-
two-hybrid screen performed using a human library identified UBC9 and SUMO1 as interactors 
of SALL1 (Netzer et al., 2011). The binding between the E2 and SALL1 and the conjugation of 
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SUMO1 to the lysine 1086 of SALL1 were confirmed by in vitro assays (Netzer et al., 2002) 
(Fig. 7).  
 
 
        
 
Figure 7. SALL1 SUMOylation in vitro. Above, schematic representation of human SALL1, where a 
potential SUMOylation site is indicated. Below, Western blot showing the result of an in vitro 
SUMOylation assay. A fragment of SALL1 (aminoacids 689-1324) was translated in vitro and incubated 
in absence (-) or presence (+) of an assay mix containing SUMO1, UBC9 and AOS1/UBA2. 
SUMOylated SALL1 is indicated by an asterisk, while the arrowhead indicates the unmodified protein. 
Substitution of lysine 1086 for an arginine abolished the conjugation of SUMO1 to this fragment of 
SALL1. Adapted from Netzer et al. 2002. 
 
 
SALL4B, the major splicing variant of SALL4, is phosphorylated, ubiquitinated 
and SUMOylated. SUMOylation occurs on four lysines and is important for the stabilization and 
localization of the protein (Yang et al. 2012).  
 
 
2.3. Role of SALL proteins during wing development in Drosophila 
 
Drosophila salm and salr are the main effectors downstream of Decapentaplegic 
(Dpp), one of the most important morphogens necessary for the correct development of many 
tissues, Dpp signaling pathway being required for growth and patterning of the fifteen imaginal 
discs during larval development. 
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2.3.1. Development of the wing imaginal disc 
 
Most of external structures of the Drosophila body develop from the imaginal discs 
that, as mentioned previously, are larval epithelial structures originated by proliferation of cells 
localized in the embryonic ectoderm (Bate and Arias, 1991). Growth and patterning of the 
imaginal discs take place during larval stages. Although the cells in the growing discs appear 
undifferentiated, their developmental fate is already determined. During pupal stages the discs 
evert and elongate, the central portion of the disc becoming the distal part of the corresponding 
appendage (wing, leg, antenna, etc.). 
Each wing imaginal disc differentiates into one wing proper and one hemithorax 
during pupal development. Multiple signaling pathways are involved in wing disc development, 
including Engrailed (En), Hedgehog, Notch, Wingless, Epidermal growth factor receptor and 
Dpp signaling pathways. They stabilize morphogenetic gradients that contribute to define the 
wing disc blade and to subdivide the wing disc along the proximodistal axis. Differential 
expression of en and apterous defines the posterior and the dorsal compartments. Dpp signaling, 
during pupal stages, directs cells towards vein formation.  
Drosophila wings have four complete longitudinal veins (LII–LV) distributed over 
the length of the wing, two transverse veins (anterior and posterior cross-veins; a-cv and p-cv) 
that connect the longitudinal LIII–LIV and LIV–LV, respectively, and two incomplete veins (LI 
and LVI) (rewieved by de Celis 2003) (Fig.8). 
 
 
 
Figure 8. Drosophila vein pattern in wing. WT adult wing showing four complete veins LII-LV, two 
incomplete veins LI and LVI and the two transverse veins a-cv and p-cv. Adapted from Sánchez et al. 
2010.  
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2.3.2. SALL function during wing development 
 
salm is activated by Dpp trough a specific enhancer that is expressed in the central 
region of the wing including veins LII, LIII and LIV (Barrio & de Celis 2004; De Celis & Barrio 
2000). Sall proteins mediate the effect of Dpp signaling during wing development by repressing 
or activating a large number of target genes (Organista et al., 2015). Removal or exogenous 
expression of sall genes in the wing imaginal discs provoke phenotypes that can be detected in 
the adult wing (Fig. 9). 
 
 
 
Figure 9. sall genes expression contribute to vein patterning. A. When salm and salr genes are not 
expressed vein LII is not formed and veins LIV and LV are fused. B. Immunostaining of WT third instar 
wing imaginal disc. Vein LII forms in the anterior compartment in the region, where Salm is expressed at 
low levels. The high levels of Salm coincide with the respective area of veins LIII and LIV. In the 
posterior compartment, Salm expression is adjacent to the corresponding area of vein LV. Adapted from 
Barrio & de Celis 2004. 
 
 
 SUMOylation of Salm is necessary for promoting ectopic vein LIII in the LII/LIII 
intervein region when ectopically expressed (Sánchez et al., 2010). It also promotes changes in 
the localization of Salm in the cells of the wing disc, showing a diffuse distribution when 
SUMOylation is enhanced (Sánchez et al., 2010). Conversely, Salr shows the opposite behavior, 
as SUMOylation promotes the formation of large aggregates when expressed in cells and lack of 
SUMOylation promotes ectopic vein formation when overexpressed in the wing (Sánchez et al., 
2010). The stereotypical function of Sall proteins and SUMOylation in the wing can be used as a 
paradigm to study changes in Sall proteins function/SUMOylation in vivo. 
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The long term aim of the laboratory was to identify SUMOylated proteins in steroidogenic 
tissues. We focused in the following specific objectives:   
 
I. To develop new technology for the isolation and identification of SUMOylated proteins 
in Drosophila cells and in vivo. 
 
 
II. To generate new tools for the analysis of post-translational modifications by UbLs in 
mammalian cells. 
 
 
III. To demonstrate that SALL transcription factors are SUMOylated in cells. 
 
 
IV. To identify possible SUMO E3 ligases for SALL factors, focusing on the Pc family of 
ligases. 
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In the first part of this Thesis, I focused on the development of methods to study 
SUMOylation and other post-translational modifications in vivo and in cells. Many strategies in 
the last 20 years were used in different models to perform global screenings for the identification 
of SUMOylated proteins. Recently, a new methodology based on the in vivo biotinylation of 
modified proteins was employed in the ubiquitination field (Franco et al., 2011). We 
hypothesized that the same approach could be used for in the identification of SUMOylated 
proteins in vivo, taking advantage by the strong interaction biotin/streptavidin. The combination 
of this strategy with Mass Spectrometry would allow us to identify modified proteins in a 
particular tissue. We also hypothesized that the same methodology could be applied in 
mammalian cells and for other Ubiquitin-like post-translational modifications. 
 
In the second part of this Thesis, I focused on the SUMOylation of SALL proteins, 
based on the existing evidences in vitro for the Drosophila and human homologs (Netzer et al., 
2002; Sánchez et al., 2010). We hypothesized that the human and Drosophila homologs were 
SUMOylated in cells and that E3 ligases might be involved in this process. Based on 
colocalization and interaction analysis by Mass Spectrometry, we hypothesized that the E3 
ligases of the Pc family might be involved in SALL1 SUMOylation, Pc in the case of Drosophila 
and CBX4 in humans. 
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1. Generation of vectors 
 
The following vectors were used in this study (Table 1). Those constructs for this 
work were done by Dr. J. D. Sutherland, unless otherwise specified. 
 
Name Reference Parental vectors Cloning sites/notes 
CAG-bioSUMO1-
T2A-BirA
opt
-T2A-
Ubc9 
This work CAG-bioSUMO1-
T2A-BirA
opt
-T2A-
GFPpuro 
GFPpuro exchanged for UBC9 
using NheII-XhoII (AMP) 
CAG-bioSUMO3-
T2A-BirA
opt
-T2A-
Ubc9  
This work CAG-bioSUMO3-
T2A-BirA
opt
-T2A-
GFPpuro 
GFPpuro exchanged for UBC9 
using NheII-XhoII (AMP) 
CAG-bioUbL-T2A-
BirA
opt
-T2A-
GFPpuro (*) 
This work CAG-bioNEDD8-
T2A-BirA
opt
-T2A-
GFPpuro 
EcoRI-NotI bioUbL; internal 
BamH1-BglII for 
concatemerization (AMP) 
CAG-bioUFM1-T2A-
BirA
opt
-T2A-UFC1 
This work CAG-bioUFM1-
T2A-BirA
opt
-T2A-
GFPpuro 
GFPpuro exchanged for UFC1 
using NheII-XhoII (AMP) 
CAG-BirA
opt
-T2A-
GFPpuro 
This work CAG-bioNEDD8-
T2A-BirA
opt
-T2A-
GFPpuro 
Acc65I-HindIII; bioNEDD8-T2A 
removed, Kozak added (AMP) 
CAG-BirA
opt
-T2A-
puro 
This work CAG-BirA
opt
-T2A-
GFPpuro 
GFPpuro exchanged for puro 
using NheI-XhoI (AMP) 
CAG-BirA
opt
-T2A-
Ubc9 
This work CAG-BirA
opt
-T2A-
GFPpuro 
GFPpuro exchanged for UBC9  
using NheII-XhoII (AMP) 
CAG-Myc-BirA*-
SALL1 
This work CAG-Myc-BirA*-
2A-GFPpuro 
NotI-XbaI; (SALL1 has stop 
codon) (AMP) 
CAG-Myc-BirA*-
SALL1(826) 
This work CAG-Myc-BirA*-
2A-GFPpuro 
NotI-XbaI; (SALL1 has stop 
codon) (AMP) 
CB6-GFP-SALL1 This work CB6-GFP-N CB6 has CMV promoter and 
confers neo selection; contains 
GFP and MCS; SALL1 generated 
by high-fidelity PCR (AMP) 
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CB6-HA-CBX4 This work CB6-HA-N NotI-EcoRI (CB6 has CMV 
promoter and confers neo 
selection) (AMP) 
CB6-HA-N M. Way lab 
(CRUK, 
London) 
CB6 CB6 has CMV promoter and 
confers neo selection; contains 
HA epitope and MCS (AMP) 
CMV-CBX4-BirA* This work CMV-SALL1-
BirA* 
CBX4 (PCR amplified) 
exchanged for SALL1 using 
EcoR1-Sal1 (KAN) 
CMV-CFP-
HisMycSalm 
Sánchez et 
al., 2010 
pEGFP-C1 (KAN) 
CMV-CFP-
HisMycSalm
IKDP
 
(Sánchez et 
al., 2010) 
pEGFP-C1 (KAN) 
CMV-EGFP-β-
galactosidase 
This work pEGFP-N1 LacZ subcloned from pIND/lacZ 
(Invitrogen) 
CMV-Pc-BirA*  This work CMV-SALL1-
BirA* 
Drosophila Pc (PCR amplified) 
exchanged for SALL1 using 
EcoR1-Sal1 (KAN); Pc source: 
Addgene #1927 
CMV-SALL1-2xHA This work CMV-SALL1-YFP YFP exchanged for 2xHA using 
SalI-NotI (KAN) 
CMV-SALL1-4KR-
2xHA 
This work CMV-SALL1-4KR-
YFP 
YFP exchanged for 2xHA using 
SalI-NotI (KAN) 
CMV-SALL1-4KR-
YFP 
This work CMV-SALL1-YFP EcoRI-SalI; mutants introduced 
by overlap extension PCR (KAN) 
CMV-SALL1-BirA*  This work CMV-SALL1-YFP YFP exchanged for BirA* using 
Sal1-Not1 (KAN) 
CMV-SALL1-GFP (Netzer et al., 
2006) 
pEGFP-C1 (KAN) 
CMV-SALL1-YFP This work pEYFP-N1 EcoRI-SalI (KAN); SALL1 
generated by high-fidelity PCR 
CMV-SALL1(826)-
2xHA 
This work CMV-SALL1(826)-
YFP 
YFP exchanged for 2xHA using 
SalI-NotI (KAN) 
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CMV-SALL1(826)-
YFP 
This work pEYFP-N1 EcoRI-SalI (KAN); SALL1 
(C826T) generated by high-
fidelity PCR 
pAc5-10xUAS-
bioSmt3-T2A-
BirA
opt
-T2A-lwr 
This work pAc5-10xUAS-
bioSmt3-T2A-
BirA
opt
-T2A-
GFPpuro  
GFPpuro exchanged for lwr using 
NheI-XhoI (AMP) 
pAc5-10xUAS-
FlagCherry-T2A-
BirA
opt
-T2A-lwr 
This work pAc5-10xUAS-
FlagCherry-T2A-
BirAopt-T2A-
GFPpuro  
GFPpuro exchanged for lwr using 
NheI-XhoI (AMP) 
pAc5-bioSmt3-T2A-
BirA
opt
-T2A-
GFPpuro 
This work pAc5-STABLE2-
neo 
Acc65I-Not1 (bioSmt3); XbaI-
HindIII (BirA
opt
); Neo exchanged 
for GFPpuro using NheI-XhoI 
(AMP) 
pAc5-BirA
opt
-T2A-
GFPpuro 
This work pAc5-STABLE1-
neo 
Acc65I-HindIII (BirA
opt
); Neo 
exchanged for GFPpuro using 
NheI-XhoI (AMP) 
pAc5-Gal4 Addgene 
#24344 
pAc5c (AMP) 
pcDNA3 Invitrogen pcDNA3 (AMP) 
pEGFP-N1, pEYFP-
N1 
Clontech commercial (KAN) 
pEYFP-C1, pEGFP-
C1 
Clontech commercial (KAN) 
pUAST-bioSmt3-
T2A-BirA 
This work pUASTattb Acc65I-HindIII (AMP) 
pUAST-
bioSmt3::BirA  
This work pUAST This plasmid was constructed by 
So Young Lee (AMP) 
pUAST-BirA (Franco et 
al., 2011) 
pUAST (AMP) 
pUAST-CFP-
HisMycSalm 
(Sánchez et 
al., 2010) 
pUAST (AMP) 
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pUASTattB-Flag-
βFtz-f1 
(Talamillo et 
al., 2013) 
pUAST-attB (AMP) 
 
Table 1. Vectors used in this study. 
(*) CAG-bioSUMO1-T2A-BirA
opt
-T2A-GFPpuro, CAG-bioSUMO2-T2A-BirA
opt
-T2A-GFPpuro, CAG-
bioSUMO3-T2A-BirA
opt
-T2A-GFPpuro, CAG-bioUb-T2A-BirA
opt
-T2A-GFPpuro, CAG-bioNEDD8-T2A-
BirA
opt
-T2A-GFPpuro, CAG-bioFAT10-T2A-BirA
opt
-T2A-GFPpuro, CAG-bioISG15-T2A-BirA
opt
-T2A-
GFPpuro and 2 CAG-bioUFM1-T2A-BirA
opt
-T2A-GFPpuro. MCS: multiple cloning sites; (AMP): 
ampicillin resistant; (KAN): Kanamycin resistant. 
 
 
2. Cell culture  
 
Drosophila S2R+ and Kc167 cells were obtained from DGRC 
(https://dgrc.cgb.indiana.edu) and cultured at 25ºC in an incubator without CO2 in Drosophila 
Schneider’s medium (Invitrogen) supplemented with 10% fetal bovine serum (Gibco) and 1% 
penicillin/streptomycin (Gibco). 
 HEK (human embryonic kidney) 293 FT cells (Invitrogen) were maintained at 37ºC 
with 5% of CO2 in DMEM (Dulbecco’s modified Eagle’s medium; Gibco) supplemented with 
10% FBS, 1% penicillin/streptomycin (GIBCO).  
 
 
2.1. Cell transfections 
 
S2R+ Drosophila cells were plated at 50% of confluence. Transient transfections 
were performed using calcium phosphate in 5 dishes of 10 cm with 10 g of DNA in complete 
medium supplemented with 50 μM of biotin using different sets of plasmids: 
 2 μg of pAc5-Gal4 and 8 μg of pUAST-bioSmt3::BirA or pUAST-BirA. 
 10 μg of pAc5-bioSmt3-T2A-BirAopt-T2A-GFPpuro or pAc5-BirAopt-T2A-
GFPpuro. 
 2 μg of pAc5-Gal4 and 8 μg of pAc5-10xUAS-bioSmt3-T2A-BirAopt-T2A-lwr or 
pAc5-10xUAS-FlagCherry-T2A-BirA
opt
-T2A-lwr. 
 5 μg of pUASTattB-Flag-βFtz-f1 and 5 μg of pAc5-bioSmt3-T2A-BirAopt-T2A-
GFPpuro or pAc5-BirA
opt
-T2A-GFPpuro. 
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HEK 293FT cells were plated at 25-30% of confluence the day before to have 50% 
confluence at the moment of transfection. Transient transfections were performed using calcium 
phosphate in 10 cm dishes with 10 μg of DNA in complete medium supplemented with 50 μM of 
biotin using different sets of plasmids: 
 Experiments for isolation of bioSUMO3-conjugates (Results 2.2., Part I) coupled 
with Mass Spectrometry analysis were performed in 10 dishes of 10 cm using 10 μg 
of CAG-bioSUMO3-T2A-BirA
opt
-T2A-GFPpuro or CAG-BirA
opt
-T2A-GFPpuro. 
 Experiments for isolation of UFM1-conjugates (Results 2.5, Part I) coupled with 
Mass Spectrometry analysis were performed in 10 dishes of 10 cm using 10 μg of 
CAG-bioUFM1-T2A-BirA
opt
-T2A-UFC1 or CAG-BirA
opt
-T2A-puro. 
 BioID experiments (Results 3.1, Part II) for isolation of possible interactors of 
SALL1 and SALL1(826) coupled with MS analysis were performed using 10 dishes 
of 10 cm with 10 μg of CAG-Myc-BirA*-SALL1 or CAG-Myc-BirA*-SALL1(826). 
 For BioID validation (Results 3.1.1, Part II) 1 dish of 10 cm was transfected with 
10 μg of total DNA mixing 5 μg of CMV-CBX4-BirA* or CMV-Pc-BirA* in 
combination with 5 μg of CMV-SALL1-2xHA or CMV-SALL1(826)-2xHA. Cells 
transfected with 5 μg of each plasmid separately were used as controls. The empty 
vector pcDNA3 was used as a filler to have cells transfected with same amount of 
DNA.   
 Analysis of SALL SUMOylation (Results 1.1 and 2.1, Part II) was executed using 
cells in a 10 cm dish transfected with the following plasmids: 7 μg of CMV-SALL1-
YFP, CMV-SALL1-2xHA, CMV-SALL1-4KR-2xHA, CMV-CFP-HisMycSalm or 
CMV-CFP-HisMycSalm
IKDP
 and 3 μg of CAG-bioSUMO-T2A-BirAopt-T2A-GFPpuro 
or CAG-BirA
opt
-T2A-GFPpuro.  
 
For functional analysis of SALL1-CBX4 interaction experiments (Results 3.3.1, Part 
II) 1 dish of 10 cm was transfected with 5 μg of CMV-SALL1-YFP, 2.5 μg of CAG-bioSUMO1-
T2A-BirA
opt
-T2A-GFPpuro or CAG-bioSUMO3-T2A-BirA
opt
-T2A-GFPpuro and 2.5 μg of CB6-
HA-CBX4. The empty vector pcDNA3 was used as a filler to have cells transfected with same 
amount of DNA. 
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2.2. NeutrAvidin pulldown 
 
Transfected cells were collected after 24-48 hours (HEK 293FT) or 3 days (S2R+), 
washed 3 times with 1x phosphate buffered saline (PBS) and lysed in 1 ml of Lysis Buffer per 10 
cm dish [8 M urea, 1% SDS, 50 mM of deSUMOylation inhibitor N-ethylmaleimide in PBS and 
1x cOmplete Mini-EDTA free protease inhibitor (Roche)]. Samples were sonicated two times at 
10 microns for 15 seconds without overheating the samples. After 20 minutes of top-table 
centrifugation at maximum speed, samples were diluted by adding 0.5 (HEK 293 FT) or 3 
volumes (S2R+) of Binding Buffer [3 M urea, 1 M NaCl, 0.25% SDS] and incubated overnight 
at room temperature (RT) with 50 μl per dish of a suspension of high capacity NeutrAvidin-
agarose resin (ThermoScientific).The following day the supernatant was carefully separated from 
the beads and saved as the flow-through fraction (FT).Washes were done with different Washing 
Buffers (WB) using 10 times the beads’ volume, according to Franco and coworkers (Franco et 
al., 2011): 2x WB1, 3x WB2, 1x WB3, 3x WB4, 1x WB1, 1x WB5 and 3x WB6. Tubes were 
inverted 3-4 times, centrifuged at 1000 rpm and the supernatants were discarded with gentle 
aspiration after every wash. WB1: 8 M urea, 0.25% SDS in PBS; WB2: 6 M guanidine 
hydrochloride in PBS; WB3: 6.4 M urea, 1 M NaCl, 0.2% SDS in PBS (pre-warmed); WB4: 4 M 
urea, 1 M NaCl, 10% isopropanol, 10% ethanol, 0.2 % SDS in PBS; WB5: 8 M urea, 1% SDS in 
PBS; WB6: 2% SDS in PBS.  
For the elution, samples were heated for 5 minutes at 95ºC in 4x Laemmli sample 
buffer with 100 mM DTT. The eluted samples were separated carefully from the beads after 5 
minutes of centrifugation at maximum speed. 
 
2.3. GFP-Trap co-pulldown 
 
HEK 293FT cells were plated at 25-30% of confluence. Transient transfections were 
performed using calcium phosphate in a 10 cm dish with 5 μg of CMV-SALL1-GFP and 5 μg of 
CB6-HA-CBX4 or CB6-HA in complete medium. Differently from NeutrAvidin pulldowns, the 
protocol for GFP-Trap should be performed at 4°C. Two days after transfection, cells were 
washed 2 times with cold 1x PBS and detached from the dish with a scraper. Cells of 10 cm 
dishes were lysed by adding 1 ml of Lysis Buffer followed by incubation on a rotating wheel for 
30 minutes at 4°C. After 15 minutes of top-table full speed centrifugation at 4°C, supernatants 
were transferred to a new tube and incubated on a rotating wheel overnight at 4°C with 25 μl of 
suspension beads (GFP-Trap, ChromoTek) previously washed 2 times with Lysis Buffer. After 
incubation, beads were washed 5 times with 500 μl of WB. For the elution, 35 μl of 2x Laemmli 
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buffer were added to beads. After 5 minutes at 95°C and centrifugation at top speed, samples 
were analyzed by Western blot. Lysis Buffer: 25 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM 
EDTA, 1% NP-40, 0.5% TritonX-100, 5% glycerol and 1x cOmplete Mini-EDTA free protease 
inhibitor (Roche). WB: 25 mM Tris-HCl pH 7.5, 300 mM NaCl, 1 mM EDTA, 1% NP-40, 0.5% 
TritonX-100 and 5% glycerol. 
 
2.4. Immunofluorescence in cultured cells 
 
For immunostaining and microscopy, cells were placed on 12 mm diameter round 
coverslips that were prepared by immersion in a solution of 1 N HCl overnight at RT. After 
several washes with H2O to remove the HCl, coverslips were dried and sterilized. 
 S2R+ Drosophila cells are considered semi-adherent and, to prevent their 
detachment during the immunofluorescence process, we used coverslips treated with 
ConcanavalinA (ConA, Sigma). We incubated the coverslips with a sterile solution of 0.5 mg/ml 
of ConA for 15 min. After that, we washed them once with 1x PBS and we placed them in 24-
well plates. We transfected the S2R+ cells in 6-well plates with 2 μg of total DNA using calcium 
phosphate with the following plasmids: 2 μg of pAc5-bioSmt3-T2A-BirAopt-T2A-GFPpuro or 
pAc5-Gal4 and 1 μg of pUAST-CFP-HisMycSalm with 1 μg of pAc-Gal4. After 3 days, we 
transferred the transfected cells to 24-well plates with ConA treated-coverslips and let them 
attach overnight to be ready for processing. 
U2OS adherent mammalian cells were plated directly in 24-well plates with 
coverslips HCl-treated and transfected using Linear PEI (MW 25 kDa; Polyscience #23966) 
according to the manufacturer’s instructions with different set of plasmids: 
 Experiments for the localization of different bioUbLs (Results 2.3, Part I): 2 μg of 
CAG-bioUbL-T2A-BirA
opt
-T2A-GFPpuro or 2 μg of CAG-BirAopt-T2A-puro as a 
control. 
 Experiments for SUMOylation of SALL proteins (Results 1.2, 1.2.1, 2.2 and 
3.2.1, Part II): 2 μg of CB6-GFP-SALL1 or pEGFP-N1, 2 μg of CMV-SALL1-YFP or 
pEYFP-C1, 2 μg of CMV-SALL1-4KR-YFP or pEYFP-C, 1.5 μg of CMV-SALL1-
YFP with 0.5 μg CAG-bioSUMO1-T2A-BirAopt-T2A-Ubc9, CAG-bioSUMO3-T2A-
BirA
opt
-T2A-Ubc9 or CAG-BirA
opt
-T2A-Ubc9, 2 μg CMV-CFP-HisMycSalm or CMV-
CFP-HisMycSalm
IKDP
. 
After 2 days, cells transfected were ready to be processed for immunofluorescence. 
Wells with transfected cells (either S2R+ or U2OS) were washed 3 times with 1x PBS to remove 
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dead cells. Cells were fixed in 4% paraformaldehyde (Santa Cruz) for 20 min, after which they 
were washed twice with 1x PBS. Permeabilization was performed with 0.1% Triton X-100 in 1x 
PBS for 15 min. Coverslips were then washed 3 times with 1x PBS to remove the detergent. 
Blocking was performed using 2% bovine serum albumin (BSA) and 2% fetal bovine serum 
(Gibco) in 1x PBS for 1 h at RT. Incubation with primary antibodies diluted in blocking solution 
was performed during 1 h at 37°C in a humidity chamber or overnight at 4°C. The following 
primary antibodies were used in S2R+ Drosophila cells: mouse monoclonal anti-GFP (1:500, 
Roche #11814460001); rabbit polyclonal anti-Smt3 (1:150; Smith et al. 2004); rabbit polyclonal 
anti-Pc (1:200; Gonzalez et al. 2014). The following primary antibodies were used in U2OS 
cells: rabbit polyclonal anti-SALL1 (1:200, Abcam #31905); mouse monoclonal anti-GFP 
(1:500, Roche #11814460001); mouse monoclonal anti-PML (1:100, Santacruz #sc-966); mouse 
monoclonal anti SC-35 (1:100, BD biosciences #556363); rabbit polyclonal anti-CBX4 (1:100, 
Proteintech #18544-1-AP); rabbit polyclonal anti-SUMO2/3 (1:100, Eurogentec #AV-SM23-
0100); mouse monoclonal anti SUMO1 (1:100, The Developmental Studies Hybridoma Bank, 
DSHB, #21C7); mouse monoclonal anti-SUMO2 (1:100, DSHB #8A2).  
After incubation with the primary antibody, cells were gently washed 3 times with 1x 
PBS and then incubated with the secondary antibody in the dark for 1 h at RT. The secondary 
antibodies conjugated to fluorofore used were: anti-mouse or anti-rabbit Alexa Fluor 488, Alexa 
Fluor 568 or Alexa Fluor 647 (1:200, Molecular Probes); Alexa Fluor 594 streptavidin-
conjugated (1:200, Jackson ImmunoResearch). To visualize the nuclei we incubated the cells 
with DAPI (1:15000, Roche #10236276001) for 5 minutes at RT. Another 3 washes were 
performed to remove unbound secondary antibody. Finally, coverslips were mounted using 
Prolong Gold antifade reagent (Molecular Probes #P36930) and stored in the dark at 4°C.  
Stained cells were visualized using an Upright Fluorescent Microscope Axioimager 
D1 or a Leica DM IRE2 confocal microscope using Blue diode, Blue Ar/ArKr, DPSS and HeNe 
lasers for excitation, and 63x lens for magnification. Pictures were analyzed with the Leica 
confocal software and the Adobe Photoshop program. 
For functional analysis of SALL1-CBX4 interaction (Results 3.3.2, Part II), U2OS 
cells were transfected in 24 well plate with 500 ng of CMV-SALL1-YFP, 500 ng CMV-
SALL1(826)-YFP or 500 ng CMV-EGFP-β-galactosidase. After 2 days, cells were processed for 
immunofluorescence as explained above but directly in the well and analyzed with an automated 
fluorescent microscope ImageXpress (Molecular Devices). Rabbit polyclonal anti-CBX4 (1:100, 
Proteintech #18544-1-AP), Alexa Fluor 568 (1:200, Molecular Probes) and DAPI (1:15000, 
Roche #10236276001) were used. 64 pictures per well were taken to detect SALL proteins or β-
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galactosidase as control (green), CBX4 (red) and DAPI (blue). The analysis was performed using 
the Multi-Wavelenght-Cell-Scoring Application Module of MetaXpress image analysis software 
(Molecular Devices). PcG (Protein group) bodies were counted in transfected cells. These 
experiments were performed in triplicates. The statistical analysis was done taking into account a 
minimum of 100 cells per condition. One Way ANOVA analysis was performed using GraphPad 
Prism 5 software. 
 
 
3. Western blot 
 
Input, FT and Elution samples were generated at different steps of the pulldowns. As 
described before, samples were eluted by adding Laemmli buffer 4x supplemented with 100 mM 
of DTT directly to the beads. Input and FT samples were prepared by mixing with the same 
buffer. Samples were boiled at 95° for 5 minutes before being loaded into the gel. Proteins were 
separated on SDS polyacrylamide gels using a Mini-PROTEAN system (BioRad). The gels were 
prepared as shown in the following tables, adjusting for gel percentage according to protein 
target size. 
 
 
Table 2. Composition of polyacrilamide gels. 
 
For isolation of UbL-conjugates, Mini-PROTEAN precast gradient gels at 4-15% 
were used (BioRad). Gels were run at 80-100 V for 1 h and transferred to PVDF membranes 
GEL% 7.5% 10% 12.5% STACK 4% 
30% Acrylamide/Bis (BioRad #1610158) 1.352 ml 1.81 ml 2.25 ml 0.54 ml 
0.5 M Tris-HCl pH 6.8    0.75 ml 
1.5 M Tris-HCl pH 8.8 1.325 ml 1.325 ml 1.325 ml  
10% SDS (Fluka # 05030) 55 µl 55 µl 55 µl 30 µl 
TEMED (Sigma #GE17-1312-01) 6 µl 6 µl 6 µl 3 µl 
10% Ammonium persulfate (Sigma 
#A3678) 
27.5 µl 27.5 µl 27.5 µl 15 µl 
H2O 2.4 ml 2.23 ml 1.750 ml 1.650 ml 
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(Millipore) at 70-80 V/gel for 1,5 h using the wet system of BioRad. Membranes were blocked 
in 1x PBS with 0.1% Tween-20 (PBS-T) and 5% non-fat dry milk (blocking buffer) for 1 hour, 
or with Casein Blocking Buffer 1x (Sigma #B6429), necessary when the anti-biotin antibody 
was used. After that, membranes were incubated in blocking buffer for 1 hour at RT or overnight 
at 4°C with the following primary antibodies: chicken polyclonal anti-BirA (1:1000, Abcam 
#ab14002); mouse monoclonal anti-Flag M2 (1:1000, Sigma #F3165); mouse monoclonal anti-
USP (1:200; Christianson et al. 1992); mouse monoclonal anti-Osa (1:50, DSHB); mouse 
monoclonal anti-Lamin Dm0 (1:500, DSHB # ADL84.12); rabbit polyclonal anti-Fax (1:1000; 
Gates et al. 2009); rabbit polyclonal anti-eIF4E (1:1000; Lachance et al. 2002); rabbit polyclonal 
anti-SIRT1 (1:1000, Cell Signaling Technology #D739); mouse monoclonal anti-RanGAP1C-5 
(1:1000, SantaCruz #sc-28322); rabbit polyclonal anti-PARP (1:1000, Cell Signaling 
Technology #9542); rabbit polyclonal anti-PML (1:1000, Bethyl Laboratories); rabbit polyclonal 
anti-Ub (1:1000, Sigma #U5379); mouse monoclonal anti-GFP (1:1000, Roche #11814460001); 
mouse monoclonal anti-HA (1:1000, Sigma #H3663); mouse monoclonal anti-actin AC-74 
(1:5000, Sigma #A2228).  
After three washes with PBS-T, the blots were incubated for 1 h in blocking buffer 
with secondary antibodies: HRP-conjugated anti-mouse (1:5000, Jackson ImmunoResearch); 
HRP-conjugated anti-rabbit (1:5000, Jackson ImmunoResearch); HRP-conjugated anti-chicken 
(1:2000, Abcam #ab97135); HRP conjugated anti-biotin (1:1000, Cell Signaling Technology 
#7075); HRP conjugated anti-tubulin (1:5000, Proteintech #66031); HRP conjugated anti-
GAPDH (1:5000, Proteintech #60004). Membranes were washed again three times in PBS-T and 
then developed using chemiluminescence with ECL Western Blotting Detection Reagents 
(Amersham GE Healthcare) or Clarity Western ECl substrate (Bio-Rad).  
 
 
4. In vitro SUMOylation and SUBEs pulldown 
 
In vitro SUMOylation assays were performed by Dr. Valerie Lang in the Laboratory 
of Dr. Manuel S. Rodriguez (Inbiomed, San Sebastian). SALL1-2xHA and CBX4 were 
transcribed/translated in vitro using the TNT ® Quick Coupled Transcription/Translation System 
(Promega) according with the manufacturer’s instruction and then were incubated in a buffer 
containing an ATP regenerating system [(50 mM Tris pH 7.5, 10 mM MgCl2, 2 mM ATP, 10 
mM creatine phosphate (Sigma), 3.5 U/ml of creatine kinase (Sigma), and 0.6 U/ml of inorganic 
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pyrophosphatase (Sigma)], 10 μg of SUMO1 or a combination of 5 μg of SUMO2 and SUMO3, 
0.325 μg Ubc9 and 0.8 μg of purified SAE1/2 (ENZO Life Sciences). SALL1 or CBX4 
SUMOylation were checked adding 2 μl of in vitro transcribed/translated protein in the 
SUMOylation assay. Reactions were incubated at 30°C for 2 hours and stopped by addition of 
SDS sample buffer. For pulldown assays, 1/10 of the input was saved and the rest of the reaction 
was incubated with 75 μl of GST-agarose beads containing 75 μg of SUBEs (Da Silva-Ferrada et 
al., 2013) and 1 mM DTT for 2 h, at 4°C. After incubation, beads were pulled down by 
centrifugation for two minutes at 1000 rpm at 4°C. Subsequently, the  beads were washed with 
30 column volumes of binding buffer (50 mM Tris pH 8.5, 50 mM NaCl, 5 mM EDTA and 1% 
Igepal) and were resuspended in one column volume of 2x Laemmli buffer. 
 
 
5. Proximity Ligation Assays 
 
The experiments of this part of the PhD Thesis were done during a short term stay in 
the laboratory of Dr. A. Vertegaal (LUMC, Leiden, Netherlands) and were supported by a grant 
from the COST Action PROTEOSTASIS (BM1307). U2Os cells were plated and transfected by 
P-PEI in 6-well plates with 2 µg of CMV-SALL1-2xHA, CMV-SALL1-4KR-2xHA or pcDNA3. 
After 2 days, cells were transferred to a 8-well chamber slide (LabTek #177410) and let them 
attach for 12 hours. Proximity Ligation Assay (PLA) was performed using the Duolink In Situ 
Red kit (Olink Biosciences; Gullberg et al. 2004; Söderberg et al. 2006) according to the 
manufacturer’s instructions. Primary antibodies used: mouse monoclonal anti-SALL1 (1:250, 
R&D Systems #K9814); rabbit polyclonal anti-SUMO2/3 (1:250; Vertegaal et al. 2004); rabbit 
polyclonal anti CBX4 (1:100, Proteintech #18544-1-AP). Images were recorded on a Leica SP8 
confocal microscope system using 488 nm and 561 nm wavelengths for excitation and a 63x lens 
for magnification, and were analyzed with the Leica confocal software, Adobe Photoshop and 
ImageJ software. 
 
 
6. Mass Spectrometry 
Mass Spectrometry experiments were realized by Jón Otti Sigursson in the laboratory 
of Dr. Jesper Olsen (University of Copenhagen, Denmark). Pulldown elutions were separated in 
SDS-page and stained with Brilliant Blue G-Colloidal Concentrate (Sigma #B2025) according 
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with manufacturer’s instructions. Proteins were in-gel digested, extracted, concentrated and 
analyzed using and EASY nLC system (Proxeon) connected to Q exactive orbitrap 
(ThermoFisher) trough a nanoelectrospray ion source. Raw Mass Spectrometry files were 
processed with a MaxQuant software (version 1.4.0.3, Max Planck Institute of Biochemistry, 
Department of Proteomics and Signal Transduction). 
The lists of proteins identified by Mass Spectrometry were analyzed as follows. First, 
contaminants and proteins identified by only one peptide were eliminated. Then, only those 
proteins with 4 fold of iBAQ (intensity-based absolute quantification) in the experiment samples 
versus the controls were considered as positive hits. Calculation was done taking into account a 
baseline for the control, which corresponds to the minimum value of iBAQ registered in each 
control of every experiment. 
The functional interpretation of the data was performed with Vlad free access 
software for Drosophila proteins (proto.informatics.jax.org/prototypes/vlad-1.0.3) and with 
innateDB for the mammalian proteins (Breuer et al., 2013). 
 
 
7. Drosophila husbandry and stocks 
 
Fly stock were raised on standard Drosophila medium (flour, yeast, glucose, polenta, 
agar and propionic acid) at 25°C. Genetic crosses were performed generally at 25°C, except 
when indicated at 18°C or 29°C. 
Binary system Gal4/UAS (Brand and Perrimon, 1993) was used to direct tissue-
specific gene expression. The following Gal4 lines were used: 
 
Genotype Name used in the text Reference 
w;phm-Gal4,UAS-
mCD8::GFP/TM6B,Tb 
phm-Gal4 Mirth et al. 2005 
w
*
; P{Gal4-Hsp70.PB}89-2-1 hs-Gal4 Bloomington #1799 
w
*
;P{Gal4-ninaE.GMR}12 GMR-Gal4 Bloomington #1104 
w;sal
EPV
-Gal4 Sal
EPV
-Gal4 Barrio & de Celis 2004 
  
Table 3. Gal4 lines used in this work 
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phm-Gal4 drives expression in the prothoracic gland (Mirth et al., 2005); GMR-Gal4  
drives expression in the developing eye; hs-Gal4 drives expression in the whole body after heat 
shock (hs) at 29°C or 37°C; Sal
EPV
-Gal4 drives expression in the wing disc regulated by a salm 
wing-specific enhancer (Barrio and de Celis, 2004). 
 Table 4 shows the UAS lines used for RNA interference or overexpression. 
Genotype Name used in the text Reference 
w;If/CyO-GFP;UAS-bioSmt3::BirA/TM6B UAS-bioSmt3::BirA This work 
w;UAS-smt3i8/CyO-GFP;UAS-
biosmt3::BirA,phm-Gal4/TM6B 
w;UAS-Smt3i,UAS-
bioSmt3::BirA/CyO-
GFP;phm-Gal4/TM6B 
This work 
w,GMR-Gal4,UAS-smt3i8/CyO;TM2/TM6B GMR-Gal4,UAS-
smt3i8/CyO;TM2/TM6B 
Ugo Mayor 
w;Bl/CyO-GFP-GFP;UAS-BirA/TM6B w;Bl/Cy-GFPO;UAS-
BirA/TM6B 
Ugo Mayor 
w;UAS-Smt3i/CyO-GFP;UAS-bioSmt3-T2A-
BirA
opt
/TM6B 
UAS-Smt3i/CyO;UAS-
bioSmt3-T2A-
BirA
opt
/TM6B 
This work 
w;UAS-Smt3i/CyO-GFP;UAS-BirA w;UAS-Smt3i/CyO-
GFP;UAS-BirA 
This work 
w;UAS-Pc-RNAi/TM6B UAS-Pci NIG-FLY 
#32443R-1 
w;UAS-Ubxi (37825) UAS-Ubxi VDRC #37825 
w;UAS-Ubxi (37823) UAS-Ubxi VDRC #37823 
w;UAS-CFP-sal-6.1/CyO;UAS-nls-
eGFP/TM6B 
UAS-salm,UAS-GFP Sánchez et al. 2010 
w;UAS-CFP-sal-6.1/CyO;smt3i-13/TM6B UAS-salm,UAS-smt3i Sánchez et al. 2010 
w;UAS-nls-eGFP/CyO;UAS-YFP-
salR1/TM6B 
UAS-GFP,UAS-salr Sánchez et al. 2010 
w;UAS-nls-eGFP/CyO;MKRS/TM6B UAS-GFP Sánchez et al. 2010 
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w,UAS-
CFPsal6.1::smt3deg/CyO;UASnlsGFP/TM6B 
UAS-smt3::salm,UAS-
GFP 
Sánchez et al. 2010 
w;UAS-CFPsal6.1(IKPD)/CyO; 
UASnlsGFP/TM6B 
UAS-salm
IKPD
,UAS-GFP Sánchez et al. 2010 
w;UASnlsGFP/CyO;UAS-
YFPsalR1::smt3deg/TM6B 
UAS-GFP,UAS-smt3::salr Sánchez et al. 2010 
w;UASnlsGFP/CyO;UAS-YFP-
salR1
IKEA,IKVA
/TM6B 
UAS-GFP,UAS-
salr
IKEA,IKVA
 
Sánchez et al. 2010 
 
Table 4. UAS lines used in this work. 
NIG-FLY, Fly Stocks of National Institute of Genetics, Japan; VDRC, Vienna Drosophila Resource 
Center.  
 
 
Table 5 shows the mutant lines used to study the relationship between salm, Pc and 
the SUMOylation machinery. 
 
Genotype Name used 
in the text 
Reference 
Pc[3]/TM1 Pc[3] Consolider collection 
P{PZ}lwr[05486],cn1/CyO;ry506 lwr[05486] Bloomington #11410 
y,w;lwr[4-3],P{ry[+t7.2]=neoFRT}40A/CyO,y+ lwr[4-3] Bloomington #9321 
y,w;lwr[5]b[1]cn[1]bw[1]/CyO, y+ lwr[5] Bloomington #9317 
P{PZ}smt[304493],cn1/CyO;ry506 smt3[04493] Bloomington #11378 
w;Df32FP-5/CyO,w+,GFP Df5(2.42) Barrio et al. 1999 
w;Df32FP-5/CyO,twist-Gal4,UAS-GFP Df5(3.04) This work 
 
Table 5. Drosophila mutant lines used in this work. 
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7.1. Generation of transgenic flies 
 
To generate UAS-bioSmt3::BirA and UAS-bioSmt3-T2A-BirA transgenic lines, 
pUASTattB-bioSmt3::BirA and pUASTattB-bioSmt3-T2A-BirA vectors (described in Section 1 of 
Materials and Methods) were used respectively. Injection in embryos and transgenic fly 
selection were committed to the Consolider Drosophila transgenesis service (Genshape project, 
Consolider CSD 2007-008-25120, CBMSO, Madrid). Transgenic lines were selected, balanced 
and crossed in collaboration with Dr. Coralia Perez. Adult flies were crossed with white mutant 
flies and flies with red eyes were selected. Those animals were crossed with w-;Bl/CyO-
GFP;TM2/TM6B balancer line to map the insertion of the transgene and to generate balanced 
stable lines. 
 
 
7.2. Isolation of bioSmt3 conjugates in vivo 
 
 Isolation of SUMOylated proteins from the ring gland was performed using the 
recombinant line w;UAS-Smt3i,UAS-bioSmt3::BirA/CyO-GFP;phm-Gal4/TM6B. Approximately 
100 larvae at the L3 instar were dissected in cold 1x PBS. Ring glands attached to brain 
complexes were selected and lysed in 25 µl of cold Protein extraction Buffer [50 mM of NEM, 
1X cOmplete Mini-EDTA free protease inhibitor (Roche) in 1x PBS]. Tissue lysates were used 
to perform NeutrAvidin pulldowns as described previously using 100 µl of suspension beads. As 
control, the w;phm-Gal4/TM6B line was used. 
For the isolation of SUMOylated proteins from adult eyes, we used the recombinant 
line w,GMR-Gal4,UAS-smt3i/CyO-GFP;UAS-bioSmt3::BirA/TM6B, obtained by crossing 
w,GMR-Gal4,UAS-smt3i/CyO;TM2/TM6B and w;If/CyO-GFP;UAS-bioSmt3::BirA/TM6B. 20 ml 
of 10 days-old flies were collected and, with a sieve, heads were separated from the bodies. All 
passages were done at very cold temperature to avoid protein degradation. Heads were crushed 
by using an homogenizer and lysed in 2.5 ml of Lysis Buffer (Section 2.2 of Materials and 
Methods). After 2x 5 minutes centrifugation in a top-table centrifuge at maximum speed at 4°C, 
supernatants were used to perform NeutrAvidin pulldowns by using 200 µl of suspension beads. 
As control, we used the w;GMR-Gal4,UAS-smt3i/CyO-GFP;UAS-BirA/TM6B line obtained from 
crossing w;Bl/CyO-GFP;UAS-BirA/TM6B and w;GMR,UAS-Smt3i/CyO;TM2/TM6B lines. 
For the isolation of SUMOylated proteins from the whole larva, w;UAS-
Smt3i/CyO;UAS-bioSmt3-T2A-BirA
opt
/TM6B line was crossed with w;hs-Gal4/TM6B and 
w;UAS-Smt3i/+;bioSmt3-T2A-BirA
opt
/hs-Gal4 larvae were selected at L2 instar, choosing larvae 
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without GFP and TM6B markers. As controls, we used w;UAS-Smt3i/+;UAS-BirA/hs-Gal4 
larvae selected as explained before from the cross between w;UAS-Smt3i/CyO-GFP;UAS-BirA 
and w;hs-Gal4/TM6B, taken at the same larval stage. 50 μM biotin was added to the food. 
Approximately 200 larvae were collected per condition and three hs events were performed in 
the following way: first hs at 37°C for 30 minutes at L2 instar stage followed by 12 hours at 
25°C, a second hs at 37°C for 30 minutes followed by 6 hours at 25°C, and a third and last hs at 
37°C for 30 minutes followed by recovery at 25°C for 2 hours before dissection. To reduce the 
proportion of non-proliferating tissues during the dissection, only the anterior part of the larvae 
was collected, where brain, ring gland and most of the imaginal discs are located. Dissections 
were performed in cold 1x PBS and the lysis was done by using 1 ml of Lysis Buffer (Section 
2.2 of Materials and Methods). With the help of an homogenizer, larval tissues were smashed 
and after top speed centrifugation at 4°C, the supernatants were used for NeutrAvidin pulldowns 
(previously described in Section 2.2 of Materials and Methods) using 100  l of suspension 
beads. 
 
 
7.3. Analysis of adult wing phenotype 
 
To study genetic interaction between sall, Pc and smt3, we collected wings of the 
following genotypes obtained by crossing the pertinent stocks indicated in Table 6.   
 
Genotype Name used in the text Reference 
w;Sal
EPV
-Gal4/+;UAS-Pci/UAS-GFP Sal
EPV
-Gal4>UAS-Pci,UAS-
GFP 
This work 
w;Sal
EPV
-Gal4/+;UAS-Pci/UAS-Ubxi Sal
EPV
-Gal4>UAS-Pci,UAS-
Ubxi 
This work 
w;Sal
EPV
-Gal4/UAS-salm;UAS-GFP Sal
EPV
-Gal4>UAS-salm,UAS-
GFP 
Sánchez et al. 2010 
w;Sal
EPV
-Gal4/UAS-salm;UAS-
Pci/UAS-Ubxi 
Sal
EPV
-Gal4>UAS-salm,UAS-
Pci,UAS-Ubxi 
This work 
w;Sal
EPV
-Gal4/UAS-GFP;UAS-salr/+ Sal
EPV
-Gal4>UAS-GFP,UAS-
salr 
Sánchez et al. 2010 
w;Sal
EPV
-Gal4/UAS-GFP;UAS- Sal
EPV
-Gal4>UAS-GFP,UAS- This work 
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salr/UAS-Pci salr,UAS-Pci 
w;Sal
EPV
-Gal4/UAS-smt3-salm;UAS-
GFP/UAS-GFP+ 
Sal
EPV
-Gal4>UAS-smt3-
salm,UAS-GFP,UAS-GFP 
Sánchez et al. 2010 
w;Sal
EPV
-Gal4/UAS-smt3-salm;UAS-
Pci/UAS-Ubxi 
Sal
EPV
-Gal4>UAS-smt3-
salm,UAS-Pci,UAS-Ubxi 
This work 
w;Sal
EPV
-Gal4/UAS-salm
IKPD
;UAS-
GFP/UAS-GFP 
Sal
EPV
-Gal4>UAS-
salm
IKPD
,UAS-GFP,UAS-GFP 
Sánchez et al. 2010 
w;Sal
EPV
-Gal4/UAS-salm
IKPD
;UAS-
Pci/UAS-Ubxi 
Sal
EPV
-Gal4>UAS-
salm
IKPD
,UAS-Pci,UAS-Ubxi 
This work 
w;Sal
EPV
-Gal4/UAS-GFP;UAS-salr/+ Sal
EPV
-Gal4>UAS-GFP,UAS-
smt3-salr 
Sánchez et al. 2010 
Sal
EPV
-Gal4/UAS-salr;UAS-Pci/+ Sal
EPV
-Gal4>UAS-salr,UAS-Pci This work 
w;Sal
EPV
-Gal4/UAS-GFP;UAS-smt3-
salr/+ 
Sal
EPV
-Gal4>UAS-GFP,UAS-
smt3-salr 
Sánchez et al. 2010 
w;Sal
EPV
-Gal4/+;UAS-smt3-salr/UAS-
Pci/+ 
Sal
EPV
-Gal4>UAS-smt3-
salr,UAS-Pci 
This work 
w;Sal
EPV
-Gal4/UAS-GFP;UAS-
salr
IKEA,IKVA
/+; 
Sal
EPV
-Gal4>UAS-GFP,UAS-
salr
IKEA,IKVA
 
Sánchez et al. 2010 
w;Sal
EPV
-Gal4/+;UAS-
salr
IKEA,IKVA
/UAS-Pci/+; 
Sal
EPV
-Gal4>UAS-
salr
IKEA,IKVA
,UAS-Pci 
This work 
w;Sal
EPV
-Gal4/UAS-salm; UAS-
smt3i;UAS-GFP 
Sal
EPV
-Gal4>UAS-salm,UAS-
smt3i,UAS-GFP 
J. Sánchez, PhD 
Thesis. 
w;Sal
EPV
-Gal4/UAS-GFP;UAS-
Pci/UAS-smt3i 
Sal
EPV
-Gal4>UAS-GFP,UAS-
Pci,UAS-smt3i 
This work 
w;Sal
EPV
-Gal4/UAS-salm;UAS-
Pci/UAS-smt3i 
Sal
EPV
-Gal4>UAS-salm,UAS-
Pci,UAS-smt3i 
This work 
 
Table 6. Genotypes used to study interaction between salm, Pc and smt3. 
 
Adult wings were also collected from transheterozygous lines: Pc[3];lwr[05486], 
Pc[3];lwr[4-3], Pc[3];lwr[5], Pc[3],smt3[04493], Df-5;Pc[3]. 
Wings were dissected in ethanol at 95% and mounted in a solution of lactic 
acid:ethanol 50:50 with the help of Dr. Coralia Perez. Pictures were taken with a Canon 
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PowerShot S70 camera coupled to a Leica DM 1000 microscope with a 4x objective. For size 
quantification, slides with the mounted wings were scanned in a EPSON scanner at 4800 dpi 
resolution. Images were treated in Adobe Photoshop and analyzed using ImageJ. For the 
calculation of the wing size, the squared pixels obtained from ImageJ were multiplied by 4800 x 
4800 obtaining the size in µm. 
 
 
7.4. Immunohistochemistry 
 
Wing imaginal discs and ring glands of L3 larvae were dissected  in cold 1x PBS and 
fixed in 4% paraformaldehyde for 20 minutes, after which they were washed 3 times with PBT 
(1x PBS, 0.03% Triton X-100) for 20 minutes. Blocking was performed for 1 hour in PBT with 
1% of BSA. Incubation with the primary antibodies diluted in blocking solution was done 
overnight at 4°C. The following antibodies were used: polyclonal anti-Salm (1:200; Barrio et al. 
1999); mouse anti-Ubx (1:10; White & Wilcox 1984); rabbit polyclonal anti-Pc (1:200; 
Gonzalez et al. 2014). The following day, samples were rinsed 3 times in PBT and, after two 
washes of 30 minutes in PBT, were incubated with the secondary antibodies conjugated to 
fluorophores for 2 hours in the dark at RT. The following secondary antibodies were used: anti-
mouse, anti-rabbit or anti-rat Alexa Fluor 488, Alexa Fluor 568 or Alexa Fluor 647 (1:200, 
Molecular Probes). Larvae were rinsed again 3 times with PBT and washed 3 times for 20 
minutes with PBT. After that, samples were rinsed in 1x PBS and the tissues of interest were 
dissected, mounted in Vectashield medium (Roche) and visualized by a confocal Leica DM 
IRE2 microscope. Pictures were processed with the Adobe Photoshop program. 
 
 
8. Statistical analysis 
 
Statistical analyses were performed with GraphPad Prism 5 software. Student’s t test or One 
Way ANOVA were applied to determine significance, as required.
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PART I: ANALYSIS OF POST-TRANSLATIONAL MODIFICATIONS BY 
UBIQUITIN-LIKES 
 
 
1. Identification of SUMOylated proteins in Drosophila melanogaster. 
 
Smt3 is necessary for Drosophila development and, as mentioned in the 
Introduction, SUMOylation has an important role in Drosophila steroidogenesis. Conditional 
knockdown of smt3 in the PG stops the larval development at the third instar (Talamillo et al. 
2008). Since our long term aim is to identify SUMOylated proteins responsible of this strong 
phenotype, we developed a system based on the in vivo biotinylation of Smt3 for the 
identification of the Smt3-subproteome.  
 
1.1. New methodology for the isolation of SUMOylated proteins in Drosophila cells 
 
The new technology was based on the method implemented by Franco and 
coworkers (Franco et al., 2011) to identify ubiquitinated proteins in vivo in Drosophila 
melanogaster and was developed in collaboration with Dr. J. D. Sutherland in the laboratory. We 
cloned a specific sequence (bio) at the N terminus of deg-smt3 [a degenerated sequence of smt3 
at the nucleotide level that was insensitive to the dsRNA against smt3 and, therefore, was still 
translated when the endogenous smt3 was silenced (Sánchez et al., 2010) ], generating the 
transgene bioSmt3. The bio sequence is recognized by BirA, an enzyme from E. coli that 
attaches a biotin molecule to it. We expressed BirA and bioSmt3 together with or without a 
selectable marker. The bioSmt3 peptide will carry the biotin moiety, rendering SUMOylated 
targets that are at the same time biotinylated and that will be isolated by NeutrAvidin 
chromatography (Fig. 10). The very high affinity between biotin and NeutrAvidin allows 
perform pulldown analysis under stringent conditions, which generates high yields with 
consequent low background in the experiments.  
To check whether this technology was useful in the investigation of SUMOylation in 
Drosophila, first we explored its possibilities in cultured cells. We generated the vector pUAST-
bioSmt3::BirA, which could be used for the generation of transgenic flies or for the expression in 
cultured cells in combination with pAc5-Gal4. The usage of this vector depended on the correct 
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release of BirA from bioSmt3 by endogenous Ulp proteases present in the cellular environment 
after translation of the linear polypeptide. For the NeutrAvidin pulldown, we introduced some 
important modifications to the protocol developed by Franco and coworkers (Franco et al., 
2011). These modifications were required in order to adapt the method to the isolation of 
SUMOylated proteins, which are less abundant than ubiquitinated proteins and normally 
represent a small percentage of the total pool of proteins. These modifications are described in 
detail in Materials and Methods. 
 
 
 
Figure 10. Schematic representation of the bioSmt3 methodology. See text for details. 
 
 
We transformed S2R+ cells with pUAST-bioSmt3::BirA, accompanied or not with 
pAc5-Gal4, and proceeded with the pulldown experiments. However, our results showed that the 
efficiency of the bioSmt3::BirA processing was approximately 50% (Fig. 11) indicating that, 
differently than what occurs with the bioUb::BirA fusion (Franco et al., 2011), the endogenous 
Ulp proteases where not sufficient to process totally the bioSmt3::BirA fusion protein.  
We decided to optimize the system by introducing some modifications in the pUAST-
bioSmt3::BirA vector. First, to avoid the deficient processing of the bioSmt3::BirA fusion 
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protein by the endogenous Ulps, we used the multicistronic vector pAc5-STABLE2-Neo 
(González et al., 2011). Here, the bioSmt3 and BirA sequences were separated by “T2A” or “2A-
like” sequences, also called CHYSEL (cis-acting hydrolase element) peptides, which are viral 
signals that direct self-cleavage of polyproteins into individual proteins (González et al., 2011). 
Second, we introduced eukaryote codon optimization for BirA to facilitate the translation of this 
protein in Drosophila cells and in vivo. This optimized protein was called BirA
opt
. 
 
 
 
Figure 11. Efficiency comparison between bioSmt3 and bioSmt3::BirA. A. Schematic representation 
of the plasmids pAc5-bioSmt3-2A-BirA
opt
-2A-GFPpuro (pAc-bioSmt3) and pUAST-bioSmt3::BirA. B. 
Anti-BirA Western blot of S2R+ transfected with pAc5-bioSmt3-2A-BirA
opt
-2A-GFPpuro or pUAST-
bioSmt3::BirA. Black arrow indicates polypeptide bioSmt3::BirA not cleaved (50 KDa) and asterisks 
indicate free BirA. BirA in the lane of bioSmt3 appears shifted due to the presence of part of the 
polypeptide 2A. Molecular weight markers are shown to the left. 
 
 
S2R+ cells were transfected with the new pAc5-bioSmt3-T2A-BirA
opt
-T2A-GFPpuro 
(pAc5-bioSmt3) vector or with pAc5-BirA
opt
-T2A-GFPpuro (pAc5-BirA
opt
) vector as a control. 
GFPpuro was introduced in the last module of the vector as a tool to control the efficiency of cell 
transfection. The utility to have a selectable marker (puromycin resistant, puro), that allows the 
generation of stable cell lines, will be treated more extensively in the Discussion. After pulldown 
with the NeutrAvidin beads, we saw a notable enrichment of biotinylated proteins in the sample 
(Fig. 12). Therefore, the system resulted to be an efficient tool that could be used to isolate 
SUMOylated protein in Drosophila cells. 
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Figure 12. Enrichment of bioSmt3 conjugates using the vector pAc5-bioSmt3. Anti-biotin Western 
blot of S2R+ pulldown. Drosophila cells were transfected with pAc5-bioSmt3 (bioSmt3). The (+) Elution 
lane shows the enrichment of the bioSmt3 conjugates. Arrow indicates the free bioSmt3.  
 
 
1.2. Localization of bioSmt3 in Drosophila cells 
  
As described in the Introduction, Smt3 localization is mainly nuclear and, as in the 
case of the SUMOs mammalian homologs, Smt3 aggregates in discrete domains (Bhaskar et al., 
2000; Lehembre et al., 2000; Smith et al., 2004). To confirm the functionality of the biotin-
conjugation system, we analyzed the localization of bioSmt3 in the cells. Our purpose was to 
check whether the exogenous bioSmt3 could reproduce the subcellular localization of the 
endogenous protein. We transfected S2R+ cells with pAc5-bioSmt3 and bioSmt3 were visualized 
using streptavidin conjugated to a fluorescent dye. To identify the endogenous Smt3, we used 
anti-Smt3 antibodies in cells transfected with empty pAc5 vector or in non-transfected cells (Fig. 
13). The comparison of the immunofluorescence experiments revealed that bioSmt3 localized in 
a way similar to the endogenous Smt3. In both cases, the proteins were mainly nuclear and 
localized in nuclear bodies. 
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Figure. 13. Localization of Smt3 and bioSmt3. A. Anti-Smt3 antibody was used to visualize 
endogenous Smt3 (green) in S2R+ cells. B. Anti-streptavidin conjugated to Alexa Fluor 594 was used to 
visualize bioSmt3 (red) in S2R+ cells transfected with pAc5-bioSmt3. Nuclei were marked with DAPI 
(blue). A’, B’. Green and red channels are shown independently in black and white. Pictures were taken 
with a confocal microscope.  
 
1.3. SUMOylation of Ftz-f1 by bioSmt3 
 
To analyze the efficiency of our system, we decided to study the SUMOylation of a 
specific target using the pAc5-bioSmt3 vector in S2R+ Drosophila cells. For this, we chose Fushi 
tarazu transcription factor 1 (Ftz-f1), a nuclear receptor homologous to the mammalian 
Steroidogenic factor 1, SF1, which is involved in steroids synthesis in the mammalian adrenal 
gland (Buaas et al., 2012). As it was published for SF1 (Chen et al., 2004), previous results from 
the laboratory showed that Ftz-f1 was modified in vitro by SUMO1. We used the bioSmt3 
system to check the SUMOylation of Ftz-f1 in Drosophila cells. S2R+ cells were transfected 
with pUASTattB-Flag-βFtz-f1 together with pAc5-bioSmt3 or pAc5-BirAopt. After a NeutrAvidin 
chromatography column, we visualized the SUMOylated form of Ftz-f1 in a Western blot by 
using anti-Flag antibodies. As shown in Fig. 14, Ftz-f1 appeared at the expected size in the Input 
panel in presence or absence of bioSmt3, while in the Elution panel two bands of a higher 
molecular weight than the non-modified Ftz-f1 appeared only in presence of bioSmt3. We 
performed the same experiment with the vector pUAST-bioSmt3::BirA. When we compared the 
results with the two vectors, we could confirm that pAc5-bioSmt3 conferred a higher efficiency 
of target conjugation than pUAST-bioSmt3::BirA. The results on Ftz-f1 SUMOylation were 
published as part of the work done in the laboratory on the role of SUMO and Ftz-f1 during 
Drosophila steroidogenesis (Talamillo et al., 2013). 
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Figure 14. SUMOylation of Ftz-F1 (Talamillo et al., 2013). A. in vitro SUMOylation of Ftz-F1. In 
presence of SUMO1 (+) modified form of Ftz-F1 indicated by asterisks. Arrowhead indicate Ftz-F1 non-
modified form that appeared in both lane. Arrow indicate nonspecific band. Molecular weight markers are 
shown to the left. as published in ( ref). . B, C. Western blot of pulldowns to analyze the SUMOylation of 
Ftz-F1 in S2R+ cells. In B the new vector pAc5-bioSmt3 was used while, in C, pUAST-bioSmt3::BirA 
was used. Asterisks in the Elution panels indicate modified forms of Ftz-F1 that are present in higher 
proportion in panel B than in C. Arrowheads indicate Ftz-F1 non-modified form that appeared in the 
Elution lane, probably due to non-specific interaction to the NeutrAvidin beads. Molecular weight 
markers are shown to the left. 
 
 
 
 In view of our results, we concluded that the bioSmt3 system could be applied in 
cultured cells for the identification of specific SUMOylated proteins. Then, we hypothesized that 
the system could be used in combination with Mass Spectrometry for the identification of new 
SUMOylated targets in Drosophila. 
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1.4. Isolation and identification of new bioSmt3 conjugates in Drosophila cultured 
cells 
 
In order to facilitate the Mass Spectrometry large-scale experiments, we introduced 
an additional improvement to the pAc5-bioSmt3 vector. As mentioned before, the multicistronic 
pAc5-STABLE2-Neo vector was used as backbone to introduce bioSmt3 and BirA
opt
. pAc5-
STABLE2 vectors are characterized by having different independent modules that could be easily 
substituted. To increase the efficiency of the bioSmt3 conjugation we decided to switch the 
selectable marker GFPpuro by the E2 Drosophila enzyme lwr. At the same time, we introduced 
ten repetitions of the UAS sequence in the pAc5 promoter, which increased significantly the level 
of expression of bioSmt3. S2R+ cells were transfected with the pAc510XUAS-bioSmt3-T2A-
BirA
opt
-T2A-lwr (pAc510XUAS-bioSmt3-lwr) vector, or with pAc5-10xUAS-FlagCherry-T2A-
BirA
opt
-T2A-lwr (pAc510XUAS-BirA
opt
-lwr) as a control, in presence of pAc5-Gal4. After the 
pulldown performed with NeutrAvidin beads, total protein eluates were resolved on a SDS-
PAGE and stained with Colloidal Coomassie (Fig. 15). 
 
            
 
Figure 15. bioSmt3-conjugates in S2R+ Drosophila cells. Gel stained with Colloidal Coomassie. A and 
B correspond to two replicates of pulldown elution performed with S2R+ cells transfected with 
pAc510XUAS-BirA
opt
-lwr (Ctrl) or pAc510XUAS-bioSmt3-lwr (bioSmt3). A single asterisk indicates 
unconjugated bioSmt3, 2 asterisks indicate the bioSmt3-BirA not processed fusion and the vertical line 
indicates the high molecular weight bioSmt3 conjugates. Molecular weight markers are shown to the left. 
 
 
 Bands were excised from the gel, subjected to trypsin digestion and analyzed by 
Mass Spectrometry in collaboration with the group of Dr. Jesper Olsen at the University of 
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Copenhagen (Denmark). We identified 1341 proteins from this Mass Spectrometry analysis. 
After our analysis of the intensities ratio between the experimental samples and the controls 
(explained in Materials and Methods), we obtained a list of 980 putative SUMOylated proteins 
that are enriched in the elution fraction of the bioSmt3 transfected cells (Appendix I). 
We performed a bioinformatics analysis of the 980 selected proteins. When 
comparing our bioSmt3 list with the Mass Spectrometry analysis of SUMOylated proteins 
performed by Nie and coworkers in Drosophila embryos (Nie et al., 2009), we saw that a third of 
the proteins identified (134) were present in the bioSmt3 list (Fig. 16A). We considered this as a 
good overlap, taking into account that we were comparing two different biological systems (cells 
and embryos). The Gene Ontology (GO) analysis revealed that the putative SUMOylation targets 
in Drosophila cells were involved in different biological process that could be grouped in 4 
categories: metabolism, development, component organization or localization and transport. The 
majority of the 980 proteins were localized in the nucleus, distributed as proteins associated to 
the nucleolus, the nuclear envelope or the nucleoplasm. The portion of proteins present in the 
cytoplasm was classified in different GO categories, from which the most representative are 
protein complexes and cytoskeleton (Fig 16B). In respect to the molecular function, most of the 
proteins identified were factors involved in gene expression regulation. GO categories emerging 
from the analysis were protein, RNA, DNA or ion binding proteins, as well as proteins involved 
in DNA catalytic activity (Fig. 16B). Approximately 20% of the bioSmt3-conjugates identified 
by Mass Spectrometry are involved in transcriptional regulation, which is considered to be the 
main target group for SUMOylation in the cell. Taken together these results, our analysis 
coincides with that made by others in Drosophila and other systems, reinforcing the validity of 
our method. To further confirm the targets identified in our Mass Spectrometry analysis, we 
performed validation experiments using the bioSmt3 system and Western blot analysis. 
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Figure 16. Analysis of bioSmt3-conjugated proteins identified by Mass Spectrometry in S2R+ 
Drosophila cells. A. Comparison between the bioSmt3 list and the list of SUMOylated proteins identified 
in Drosophila embryos (Nie et al., 2009) or with a list of the transcription factors known in Drosophila. 
B. GO analysis for biological process, cellular compartment and molecular function performed using 
Vlad. 
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1.5. Validation of bioSmt3 conjugates in Drosophila cultured cells 
 
For the validation experiments, we firsts chose some targets that we overexpressed in 
Drosophila cells. Three examples of candidates for SUMOylation, that were identified in the 
Mass Spectrometry analysis and we were able to validate, are shown in Fig.17: the homolog of 
NF-B in Drosophila, Relish (Rel), and two nuclear envelope proteins, Kugelkern (Kuk) and 
Otefin (Ote). For these experiments, S2R+ cells were transfected with the mentioned proteins 
fused to the Flag tag in presence of pAc510XUAS-bioSmt3-lwr, or pAc510XUAS-BirA
opt
-lwr, 
together with pAc5-Gal4. After the NeutrAvidin pulldowns, Western blots were developed with 
anti-Flag antibodies revealing the SUMOylated forms in the Elution panels only in presence of 
bioSmt3. 
 
 
Figure 17. Validation of exogenous SUMOylated proteins. Anti-Flag Western blot of pulldowns 
performed in S2R+ cells transfected respectively with Relish, Otefin or kugelkern fused to a Flag tag and 
pAc510XUAS-bioSmt3-lwr, (bioSmt3) (+) or pAc510XUAS-BirA
opt
-lwr (-) as a control. In the Elution 
panels, asterisks indicate the modified forms of each protein. For Relish, the non-modified form of the 
proteins is indicated with an arrowhead in the Elution panel. Tubulin was used as a loading control. 
Molecular weight markers are shown to the left. 
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Despite the small fraction of SUMOylated form in the general pool of each protein, 
we were able to validate the SUMOylation of some factors by using antibodies against 
endogenous proteins. This reflects the high specificity and power of the bioSmt3 method. These 
experiments were done in collaboration with Dr. Wendy Xolalpa in the laboratory. For the 
validation of the endogenous proteins, we were limited by the antibodies available. We 
transfected S2R+ cells, as we did for the Mass Spectrometry analysis, with pAc510XUAS-
bioSmt3-lwr or pAc510XUAS-BirA
opt
-lwr in presence of pAc5-Gal4. By using specific antibodies 
we validated five endogenous targets (Fig. 18). Three of them were previously identified as 
SUMOylated proteins: Ultraspiracle (Usp), a nuclear receptor involved in steroid signaling 
(Wang et al., 2014), the transcription factor (Monribot-Villanueva et al., 2013; Nie et al., 2009) 
and the Eukaryotic initiation factor 4E (eIF-4E) (Xu et al., 2010). The other two validated 
proteins were not previously described to be SUMOylated in Drosophila: the Glutathione S-
transferase involved in axonogenesis Failed axon connections (Fax) and the intermediate 
filament Lamin (Lam). While the mammalian homolog of Lam was demonstrated to be modified 
by SUMO (Zhang and Sarge, 2008), it is the first time that any Fax homolog is identified as a 
target of SUMOylation. Further analysis would be required to determine the in vivo function of 
these proteins SUMOylation.  
In conclusion, our analysis in cultured cells served as proof of principle for the 
bioSmt3 system. We decided then to apply this technology in vivo. 
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Figure 18. Validation of endogenous SUMOylated proteins. Western blot of pulldowns performed in 
S2R+ cells. Antibodies against specific endogenous proteins were used. In the Input panels, the non-
modified forms of the proteins are shown and in the Elution panels asterisks indicate the modified forms. 
Molecular weight markers are shown to the left. 
 
 
1.6. Isolation of bioSmt3 conjugates in vivo 
 
As described in the Introduction, Smt3 is necessary for steroidogenesis in 
Drosophila. Conditional knockdown of smt3 in the PG (phm-Gal4>pUASt-smt3i) blocks 
development at the end of L3 due to a reduction in the ecdysone levels (Talamillo et al. 2008). 
To check the functionality of the bioSmt3 construct, we analyzed the rescue capacity of the 
pUAST-bioSmt3::BirA transgene in a silenced smt3i background. Surprisingly, phm-
Gal4>pUAST-smt3i,pUAST-bioSmt3::BirA larvae underwent normal metamorphosis and 
generated fertile adults. This indicates that the bioSmt3 construct is totally functional, despite the 
RESULT PART I 
 
75 
 
reduced efficiency of the bioSmt3::BirA fusion processing. Importantly, in those larvae, the 
majority of Smt3 available in the cells is in the bioSmt3 form (scheme Fig. 19).  
 
 
Figure 19. bioSmt3 expression in vivo. A. Schematic representation of the functionality of 
bioSmt3::BirA. Larvae silenced for smt3 expressing bioSmt3::BirA are able to pupariate. B, C. Anti-
biotin Western blot of pulldowns performed using animals where bioSmt3 was expressed in the larval PG 
(B) or in the adult heads (C) of Drosophila silenced for smt3 and expressing bioSmt3::BirA. The Elution 
panels (+) show the enrichment of bioSmt3 conjugates. Arrowheads indicate the endogenous biotinylated 
proteins and arrows the bioSmt3::BirA not processed fusion. Molecular weight markers are shown to the 
left in B and C. 
 
 
In view of these results, we decided to use the phm-Gal4>UAS-smt3i,UAS-
bioSmt3::BirA larvae for the in vivo isolation of SUMOylated proteins, using phm-Gal4>pUAS-
smt3i as a control. We dissected the brain/ring gland complexes from larvae of these genotypes 
that were used to perform NeutrAvidin pulldowns. During the Western blot analysis using anti-
biotin antibodies, we could appreciate that the amount of biotinylated proteins extracted was not 
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sufficiently high to recover enough biotinylated proteins for the Mass Spectrometry procedure 
(Fig. 19). Probably, more tissue was needed to achieve enough material for Mass Spectrometry. 
However, the small size of the ring gland would make difficult to reach material enough for 
proteomics and, therefore, we decided to change strategy and isolate the SUMOylated proteins 
from GMR-Gal4>UAS-smt3i,UAS,bioSmt3::BirA flies. GMR-Gal4 drives expression under the 
control of Glass Multiple Reporter (GMR) promoter elements, expressed in the developing eye 
(Hay et al., 1997), a much larger organ than the ring gland. Adult heads were collected from 10 
days-old flies and tissue was used for a NeutrAvidin chromatography and Western blot analysis 
(Fig. 19). The Western showed an enrichment of the bioSmt3-conjugates in the Elution sample. 
However, the amount of protein was still not enough for the Mass Spectrometry analysis. 
According to Kanakousaki and Gibson (Kanakousaki and Gibson, 2012), 
SUMOylation occurs mainly in proliferating cells. Proliferation in the eye at adult stages is 
reduced, which could be the cause of the limited yield of biotinylated proteins in our pulldown 
experiments. Therefore, we decided to repeat our analysis in the L3
 
larval stage, where imaginal 
tissues are proliferating. In addition, we generated new transgenic flies expressing the transgene 
pUAST-bioSmt3-T2A-BirA
opt
, following the optimization strategy we adopted for cultured cells. 
To express the transgene in all the imaginal tissues and increase the yield of biotinylated 
proteins, we used the driver heat shock (hs)-Gal4 which gets activated upon temperature 
increase. In addition to activate the expression of the driver, the raise in temperature increased 
the SUMOylation levels in the cells, as SUMO is considered to be a response to various stresses, 
including heat (Schimmel et al., 2014).  
 
 
1.7. Localization of bioSmt3 conjugates in vivo 
 
Prior Mass Spectrometry, we analyzed the localization of the bioSmt3 transgene in 
vivo in collaboration with Dr. C. Pérez in the laboratory. We detected bioSmt3 using streptavidin 
labeled with a fluorescent dye in salivary glands from larvae silenced for endogenous smt3 (hs-
Gal4>UAS-smt3i,UAS-bioSmt3-T2A-BirA
opt
) or from control larvae (hs-Gal4>UAS-GFP). In 
addition, we added biotin in the food of the larvae and we performed several rounds of heat 
shock treatment at 37
o
C. In a smt3i background, with biotin in the food and after heat shock, we 
observed the accumulation of biotin in nuclear bodies in a pattern similar to the endogenous 
Smt3 (Fig.20). Therefore, we concluded that those were the suitable conditions for the Mass 
Spectrometry analysis.  
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Figure 20. Localization of bioSmt3 in vivo. A, B. Salivary glands from control larvae (hs-Gal4>UAS-
GFP) at 25°C or 37°C. C, D. Salivary glands from larvae expressing bioSmt3 (hs-Gal4>UAS-smt3i,UAS-
bioSmt3-T2A-BirA
opt
) at 25°C or 37°C. bioSmt3 was maked with streptavidin conjugated to a fluorescent 
dye. 
 
 
1.8. Identification of bioSmt3 conjugates in vivo 
 
For the Mass Spectrometry analysis of SUMOylated proteins in vivo, we performed 
several rounds of heat shock treatment at 37°C and collected L3 larvae of hs-Gal4>UAS-
Smt3i,UAS-bioSmt3-T2A-BirA
opt
 or hs-Gal4>UAS-Smt3i,UAS-BirA
opt
 genotypes. To reduce the 
proportion of non-proliferating tissues, we dissected the anterior part of the larval body where 
most of the imaginal discs are located. After pulldown performed with NeutrAvidin beads, we 
checked the enrichment of bioSmt3 conjugates (Fig 21A). Protein eluates were resolved on a 
SDS-PAGE and stained with Colloidal Coomassie (Fig. 21B). Bands were excised from the gel, 
subjected to trypsin digestion and analyzed by Mass Spectrometry in collaboration with the 
group of Dr. Jesper Olsen at the University of Copenhagen. The selection of positive targets was 
done in the same way than for the cell culture analysis (Results 1.4, Part I). We identified 92 
proteins as putative SUMOylation targets (Appendix II), which were selected based on a 4 fold 
increased intensity when compared with the control.  
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Figure 21. bioSmt3 conjugates in vivo. A. Anti-biotin Western blot of larval pulldowns. The Elution 
panel lane (+) shows the enrichment of bioSmt3-conjugates compared with the control (-). Arrowheads 
indicate endogenous biotinylated proteins and the arrow indicates bioSmt3::BirA not processed form. B. 
Gel stained with Colloidal Coomassie. A and B correspond to two replicates of the pulldown elution 
performed with hs-Gal4>UAS-Smt3i,UAS-BirA
opt
 (Ctrl) or hs-Gal4>UAS-Smt3i,UAS-bioSmt3-T2A-
BirA
opt
 (bioSmt3). Molecular weight markers are shown to the left. 
 
 
Our bioinformatics analysis revealed that approximately 60% of the proteins 
identified in vivo were present in the list of SUMOylated proteins obtained from cultured cells 
and 40% were present in the list of SUMOylated protein identified by Courey and coworkers in 
Drosophila embryos (Fig. 22A) (Nie et al., 2009). We could consider that those sets of data have 
a good overlap, considering the different developmental stages in which the in vivo experiments 
were performed. The GO analysis revealed that the putative SUMOylation targets in Drosophila 
were involved in similar biological process that we identified for the list of proteins identified in 
S2R+ cells: component organization, cellular process or localization and transport. In this case, 
there was a higher proportion of proteins localized in the cytoplasm, the category of lipid 
particle, protein complexes and microtubule cytoskeleton being strongly represented. In respect 
to the molecular function, as we observed in S2R+ cells, the proteins identified were involved in 
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nucleotide or GTP binding, or in pyrophosphatase or GTPase catalytic activity, which are linked 
to gene expression regulation and signaling (Fig. 22B). Another GO category emerging from the 
analysis was structural constituent of cytoskeleton (Fig. 22B). Our analysis in vivo let to the 
identification of less targets than the analysis in cells and further studies should optimize the 
protein extraction and pulldown from the tissues in vivo. Nevertheless, also in this case, our 
analysis coincides with that  
made by others in Drosophila or other systems, reinforcing the validity of our 
method. 
 Taken together, our results showed that the bioSmt3 system could be efficiently applied 
in cultured cells and in vivo in Drosophila to identify SUMOylated proteins. Based on this, and 
taking into consideration the modularity of the vectors, we wondered whether a similar approach 
could be applied to mammalian cells for the identification of SUMOylated proteins. 
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Figure 22. Analysis of bioSmt3-conjugated proteins identified by Mass Spectrometry in vivo A. 
Comparison between the list of bioSmt3-conjugated proteins in vivo and the bioSmt3-conjugated proteins 
in cells (left) or the list of  SUMOylated proteins identified in Drosophila embryos (right; Nie et al., 
2009). B. GO analysis for biological process, cellular compartment and molecular function was 
performed using Vlad. 
RESULT PART I 
 
81 
 
2. Development of bioUbiquitin-like (bioUbL) vectors for the analysis of 
post-translational modifications in mammalian cells 
 
 
2.1. New methodology for the isolation of SUMOylated proteins in mammalian cells 
 
The efficiency and the characteristics of the bioSmt3 system allowed us to apply the 
same approach to mammalian cultured cells. This part of the project was also done in 
collaboration with Dr. J. D. Sutherland in the laboratory. This new methodology could be used in 
different cultured cell systems to study diverse post-translational modifications. First, the 
modularity of the pAc5-STABLE2-Neo vector facilitated the switch of the promoter specificity 
from insects (Ac5) to mammalian (CAG) (González et al., 2011). Second, we substituted the 
Drosophila smt3 with mammalian SUMO1 or SUMO3 moieties. As we did for the Drosophila 
cells, we chose a specific target to test the efficacy of the system in mammalian cells. We chose 
the transcription factor SALL1 as target, which, as mentioned in the Introduction, it was 
previously described to be SUMOylated in vitro. The experiments performed to study the 
SUMOylation on SALL1 will be detailed in the Part II of the Results. Briefly, we were able to 
confirm the SUMOylation of SALL1, as well as its partial colocalization with SUMO, by using 
the bioSUMO constructs (Figs. 29,32). These results confirmed the suitability of the system also 
in mammalian cells.  
 
 
2.2. Isolation and identification of SUMO3 subproteome 
 
Once we demonstrated that the bioSUMO/BirA system was effective for the isolation 
of a particular SUMOylated protein in mammalian cells, we proceed to analyze whether the 
system was suitable for Mass Spectrometry analysis. For that, we transfected HEK 293FT cells 
with the vector CAG-bioSUMO3-T2A-BirA
opt
-T2A-GFPpuro or the control CAG-BirA
opt
-T2A-
GFPpuro, passed them through a NeutrAvidin column and analyzed them by SDS-PAGE. The 
Western blot analysis using anti-biotin antibodies showed the isolation of SUMO3-SUMOylated 
proteins in an appropriated yield to perform Mass Spectrometry (Fig. 23). Mass Spectrometry 
analysis was done by the Proteomics Platform at CIC bioGUNE in collaboration with Dr. F. 
Elortza. In the list of candidates to be SUMOylated by bioSUMO3 (Appendix III), we found 
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proteins that were previously described as SUMOylated, demonstrating the validity of the 
system. 
 
Figure. 23. Identification of bioSUMO3 conjugates and validation. A. Anti-biotin Western blot of 
pulldowns performed with HEK 293FT cells transfected with CAG-bioSUMO3-T2A-BirA
opt
-T2A-
GFPpuro (+) or CAG-BirA
opt
-T2A-GFPpuro as control (-). In the Elution lane with bioSUMO3 (+), 
conjugates were enriched (asterisk). The arrow indicates uncojugated bioSUMO3. B. Anti-Ub 
hybridization of the same Western blot shown in A after stripping, revealing the presence of Ub-
conjugates among the SUMO3-modified isolates (asterisk). C. Validation of SUMO3 targets. Different 
antibodies were used against endogenous proteins. Arrowheads indicate the modified proteins in the 
Elution lanes. Anti-GAPDH was used as a loading control. Molecular weight markers are shown to the 
left. 
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To validate the results, we performed pulldowns in a similar way than the ones done 
for the Mass Spectrometry analysis. These experiments were done in collaboration with A. Ruiz 
de Sabando and Dr. J. D. Sutherland in the laboratory. By Western blot using specific antibodies, 
we validated the SUMOylation by SUMO3 of several endogenous proteins such as Sirtuin 1 
(SIRT1), Ran GTPase-activating protein 1 (RANGAP1), Promyelocytic leukemia protein (PML) 
and Poly [ADP-ribose] polymerase 1 (PARP), all of them previously identified as SUMO targets 
(Fig. 23). GAPDH was used as loading control in the Input panels and a negative control for the 
Elution panels, as this protein did not appear in the Mass Spectrometry list. 
 These experiments demonstrated that the bioSUMO3 system was sufficiently 
sensitive to detect the SUMOylated fraction of these proteins without overexpressing them and 
without heat shocking the cells. Interestingly, we identified Ub as one of the targets of 
bioSUMO3. Furthermore, we detected Ub in the pulldown lane of the Western blot, which is 
compatible with the existence of SUMO3-Ub mixed chains (Fig. 23).  
Taken together, these results confirmed that the bioUbL method can be used in 
mammalian cells to check the modification of a particular protein, either endogenous or 
overexpressed, as well as to perform high throughput proteomics. 
 
 
2.3. New methodology for the isolation of proteins modified by other UbLs in 
mammalian cells 
 
The positive results mentioned in the previous section encouraged us to expand our 
repertoire of vectors by substituting the bioSUMO3 sequences by other UbLs, including those 
that are more studied like Ub or Nedd8 and those that are less studied like ISG15, FAT10 or 
UFM1. This, as I described before, could be easily done due to the modular nature of the 
multicistronic vectors (Fig. 24A). 
We first analyzed the expression and incorporation of the different bioUbLs to target 
proteins in HEK 293FT cells. The same number of cells were transfected in parallel with the 
different bioUbL constructs, cells extracts were passed through an NeutrAvidin column and 
analyzed by Western blot (Fig. 24B). The blot showed that all the UbLs were incorporated to 
target proteins, although the relative amount of proteins conjugated to the different UbL 
modifiers varied, as revealed with anti-biotin antibodies. For instance, bioUb and bioNEDD8 
showed a greater enrichment than the bioSUMOs, and those a greater enrichment than FAU or 
UFM1. 
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Figure 24. Isolation of bioUbLs-conjugates in mammalian cells. A. Schematic representation of the 
bioUbL plasmid collection. B. Anti-biotin Western blot of pulldowns performed in parallel using HEK 
293FT mammalian cells transfected with plasmids expressing the different UbLs. Molecular weight 
markers are shown to the left. 
 
 
We then analyzed the cellular distribution of the different bioUbLs by using 
NeutrAvidin conjugated to a fluorofore. The different bioUbLs showed a distinct pattern of 
expression, which suggested a distribution driven by the localization of the endogenous target 
proteins. Most of the UbLs are mainly nuclear although not exclusively, as for example the cases 
of bioUb, bioNEDD8 or bioFAT10 (Fig. 25). 
The heterogeneous distribution of the bioUbLs and their characteristic conjugation 
pattern suggested that each UbL was incorporated to a specific set of target proteins, supporting 
the specificity of the bioUbL system. 
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Figure 25. Cellular distribution of different bioUbLs. U2OS cells transfected with different plasmids 
expressing bioUbLs or BirA only as a control. Stainings were performed with streptavidin conjugated to 
Alexa Fluor 594. Pictures were taken with Upright Fluorescent Microscope Axioimager D1. 
 
 
2.4. Validation of the bioUFM1 system using a known target 
 
To further demonstrate the suitability of the bioUbL system, we chose one of the less 
studied UbL members, UFM1. To increase the efficiency of UFM1-conjugation, we substituted 
the last module of CAG-bioUFM1-T2A-BirA
opt
-T2A-GFPpuro by UFC1, the specific E2 enzyme 
involved in UFMylation.  
To validate our approach of bioUbLs as tool to isolate and identified modified 
targets, we decided to validate a known UFMylated target, as we did previously with the SUMO 
targets. We chose DDRGK1 (UFBP1) shown to be modified by UFM by two different 
laboratories. (Komatsu et al. 2004, Lemaire et al. 2011). DDRGK1 interacts with the E3 UFM1-
protein ligase, UFL1, and one of its substrates, TRIP4, and is required for TRIP4 UFMylation. 
Through TRIP4, UFMylation might regulate the transcription mediated by nuclear receptors 
(Yoo et al., 2014). DDRGK1 could play a role in NF-kappa-B-mediated transcription through 
regulation of the phosphorylation and the degradation of NFKBIB, the inhibitor of NF-kappa-B 
(Xi et al., 2013). It could also be involved in the cellular response to endoplasmic reticulum 
stress, as reported previously for the UFMylation process. Fig. 26 shows the modification of 
DDRGK when is overexpressed in presence of bioUFM1, but not in presence of BirA
opt
 alone. 
The modified forms of the protein, which are shifted compared with the non modified protein, 
could be observed in the Elution panel. These results showed the validity of the bioUFM1 
RESULTS PART I 
86 
 
method. We decided then to apply it to the discovery of new UFM1 targets by Mass 
Spectrometry. 
 
 
 
Figure 26. Validation of a UFMylation target. Anti-HA Western blot of a HEK 293FT cells pulldown. 
Cells were transfected with DDRGK-HA together with CAG-bioUFM1-UFC1 (bioUFM1) or CAG-
BirA
opt
 as control. In the Elution lanes, asterisks indicate the modified forms of the protein and the 
arrowhead indicates the non-modified protein. Molecular weight markers are shown to the left. 
 
2.5. Isolation and identification of UFM1 conjugates 
 
To further demonstrate the suitability of the bioUFM1 system for the high 
throughput proteomic analysis, HEK 293FT cells were transfected with CAG-bioUFM1-T2A-
BirA
opt
-T2A-UFC1 (CAG-bioUFM1-UFC1) or CAG-BirA
opt
-T2A-puro (CAG-BirA
opt
) as control. 
After pulldown performed with NeutrAvidin beads, total protein eluates were resolved on a 
SDS-PAGE and stained with Colloidal Coomassie (Fig. 27). 
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Figure 27. bioUFM1-conjugates in HEK 293FT cells. Gel stained with Colloidal Coomassie. A and B 
correspond to two replicates of pulldown elutions performed with cells transfected with CAG-BirA
opt
 
(Ctrl) or CAG-bioUFM1-UFC1 (bioUFM1). A single asterisk indicates the unconjugated bioUFM1, 2 
asterisks indicate the not processed bioUFM1-BirA and the vertical line indicates the bioUFM1 
conjugates. Molecular weight markers are shown to the left. 
 
Bands were excised from the gel, subjected to trypsin digestion and analyzed by 
Mass Spectrometry, in collaboration with the group of Dr. J. Olsen (UCPH, Copenhagen, 
Denmark). We identified 732 proteins. After our analysis (explained in Materials and Methods), 
we identified 60 proteins as targets of UFM-conjugation (Appendix IV). GO analysis showed 
that there was a significant enrichment in the biological process categories of translation and 
mitotic cell cycle. Proteins identified localized in the nucleus and in the cytoplasm (as shown in 
Figure. 28). In respect to the molecular function the most representative categories from GO 
analysis are nucleotide binding, in particular to mRNA5’-UTR. These results placed UFM1 in 
the gene expression regulation function, especially in mRNA and translation regulation. 
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Figure 28. Analysis of bioUFM1 conjugates by Mass Spectrometry. A. GO analysis for biological 
process, cellular compartment and molecular function performed using innate DB. 
 
 
Taken together the results shown in the Part I of this thesis, we can conclude that we 
developed a new efficient system to facilitate the study of SUMOylated proteins in Drosophila, 
in cultured cells and in vivo, either for Mass Spectrometry or for the detail analysis of a specific 
target. Also, we generated a versatile toolbox to facilitate the study of Ub and UbL subproteomes 
in mammalian cells.  
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PART II: ANALYSIS OF THE SUMOYLATION OF SALL PROTEINS 
 
 
1. SUMOylation and localization of human SALL1 
 
 
1.1. Human SALL1 is SUMOylated in cultured cells 
 
As mentioned in the Introduction, human SALL1 is modified post-translationally by 
SUMO1 in vitro (Netzer et al., 2002). Since our long term aim is to explore the role of 
SUMOylation on SALL protein’s function in vivo, we decided to check if this transcription 
factor can be modified by SUMO also in cultured cells. HEK 293FT cells were chosen to check 
the SUMOylation of SALL1 by using the bioSUMO system described in the Results, Part I 
section. 
SALL1 fused to YFP in the C-terminal part was overexpressed in presence of 
bioSUMO1, bioSUMO3 or the control vector BirA. These SUMO variants, that can be expressed 
and biotinylated in cells, facilitated the isolation of SUMOylated SALL1 under stringent 
condition using NeutrAvidin beads. We showed that SALL1-YFP can be modified by both 
bioSUMO1 and bioSUMO3, corroborating the results published in vitro using SUMO1 (Netzer 
et al., 2002). In Fig. 29A, the Western blot shows the identification of the SUMOylated forms of 
human SALL1-YFP using anti-GFP antibodies. Higher molecular weight bands were identified 
corresponding to the modified forms of the protein (Elution panel, asterisk), bigger in size than 
the non-modified SALL1-YFP (Input panel). As described in the Introduction, SALL1 can be 
SUMOylated in vitro at the lysine 1086, localized in the SUMO consensus site between zinc 
finger domains ZF4 and ZF5 (Fig. 29C): substitution of that lysine by an arginine abolished 
SUMOylation of a truncated form of SALL1, as it was shown by Netzer and coworkers in vitro 
(Netzer et al. 2002). However, those experiments were done using a truncated form of SALL1 
and we cannot discard the presence of other SUMOylation sites.  
In order to generate a SALL1 SUMO mutant to be used in our experiments in 
cultured cells using the bioSUMO system, we analyzed the full length amino acid sequence of 
SALL1 by the SUMOplot program (http://www.abgent.com/sumoplot). The program suggested 
7 possible SUMO consensus sites with a high probability score, that is, more than 0.5 in a range 
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between 0 to 1. To test the hypothetical SUMOylation consensus sites, we decided to take into 
account sequences with a score higher than 0.9. Only four sequences respected this very 
stringent condition and we mutated all of them by substituting each lysine (K571, K592, K982 
and K1086) with an arginine (SALL1-4KR; Fig. 29C). As predicted, the SALL1-4KR mutant 
lost the capacity to be SUMOylated in cells, as shown in Fig. 29B. Therefore, we considered 
SALL1-4KR a SUMO-null mutant of SALL1. 
 
 
 
Figure 29. SUMOylation of SALL1 in cultures cells. Western blot of pulldowns to check SUMOylation 
of SALL1 in HEK 293FT cells. A. SALL1 fused to YFP tag was SUMOylated in presence (+) of 
bioSUMO1 or bioSUMO3. Asterisk in the Elution panel indicates the modified SALL1 that is shifted if 
compared with the size of non modified SALL1 in the Input panel. Anti-actin antibodies were used as a 
loading control. Molecular weight markers are shown to the left. B. SALL1-4KR fused to HA tag is not 
SUMOylated in presence of bioSUMO3. Arrowhead indicates a non modified form of SALL1 and the 
asterisks the SUMOylated SALL1-HA that appears only in the second lane of the blot corresponding to 
the WT form. In the Input the expression of WT and SUMO mutant of SALL1 are shown. Anti-Tubulin 
antibodies were used as a loading control. Molecular weight markers are shown to the left. C. SALL1 
schematic representation. Ovals represent the zinc fingers (ZF) distributed along the protein. Q represents 
the poly-glutamine domain. In red, SUMO consensus sites mutated in SALL1-4KR and in blue the 
predicted SIMs. 
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1.2. SALL1 localizes in nuclear bodies in human cells 
 
Localization of SALL1 and its homologs in nuclear bodies has been reported in 
cultured cells and in vivo (Abedin et al., 2011; Kiefer et al., 2002; Netzer et al., 2001; Sánchez et 
al., 2010). Our aim was to visualize in cultured cells the correlation between SALL1 and the 
SUMO proteins. First, we tested our system by studying the subcellular localization of human 
SALL1 in different cell types. For the immunofluorescence experiments we decided to use 
human U2OS cell line, which expresses SALL1 endogenously and is easy to transfect. 
Endogenous proteins aggregate in discrete domains in the nucleus as shown in Fig. 30A-A’. 
Similar results were obtained using U2OS cells transfected with the constructs SALL1-YFP or 
GFP-SALL1 (Fig. 30B-B’). As a control, we used empty vectors that expressed single GFP or 
YFP molecules (pEYFP-C1 or pEGFP-N1), which showed homogenous distribution in the 
nucleus and cytoplasm (Fig. 30C-C’). The expression pattern of SALL1 in U2OS was similar to 
the pattern previously described in the literature and we concluded that this cell line could be 
used as a model to study the subcellular localization of SALL1.  
 
 
Figure 30. Localization of SALL1 in nuclear 
bodies in U2OS cells. Endogenous SALL1 
detected with anti-SALL1 antibodies (A). 
SALL1 fused to YFP (B) and YFP alone (C) 
detected with anti-GFP antibodies. SALL1 
proteins and YFP are shown in green, nucleus 
stained with DAPI in blue. A-C’. Green 
channel is shown independently in black and 
white. Pictures were taken with AxioD 
Fluorescent microscope with 63X objective. 
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The mammalian cellular nucleus is a complex organelle that includes several 
substructures called nuclear bodies (reviewed by Dundr & Misteli 2001). Aggregation of SALL1 
in nuclear foci suggested that the transcription factor could take part in the formation of one type 
of these nuclear bodies. In order to investigate the nature of those bodies, we performed 
colocalization experiments by immunofluorescence to analyze whether SALL1 is part of the 
most known nuclear structures such are the PML bodies or the nuclear speckles. Our results 
show that SALL1 does not colocalize with PML, except for a few bodies, neither with nuclear 
speckles as shown in Fig. 31A-B’’. Therefore, we could conclude that SALL1 localizes to 
nuclear foci seemingly independent of PML bodies or SC-35 speckles. 
 
 
 
Figure 31. Comparison between SALL1 nuclear bodies and PML bodies or speckles. SALL1 
endogenous protein (green) do not colocalize with PML bodies (red) (A) neither with speckles detected 
using anti-SC-35 antibodies (red) (B). Nuclei were stained with DAPI (blue). A’-B’’. Green and red 
channels are shown independently in black and white. Pictures were taken with an AxioD Fluorescent 
microscope using a 63X objective. 
 
 
1.2.1. Human SALL1 partially colocalizes with SUMO proteins 
 
Since we demonstrated the SUMOylation of human SALL1 in cultured cells, we 
decided to check by staining the possible colocalization between SALL1 and SUMO in 
mammalian cells. We transfected U2OS cells with SALL1-YFP together with bioSUMO1 or 
bioSUMO2 under the same conditions used in the pulldown (Fig. 32A-B’’). We also used 
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antibodies recognizing endogenous SUMO proteins to confirm the results. As shown in Fig. 32, 
there was a partial colocalization between SALL1 and SUMO proteins: some of the SALL1 
bodies clearly colocalized with SUMO1 and SUMO2/3, while other SALL1 bodies did not. 
Conversely, some SUMO1 and SUMO2/3 bodies colocalized with SALL1, while others did not 
(Fig. 32C-C’’). 
 
 
 
Figure 32. Partial colocalization between SALL1 proteins and SUMO in U2OS cells. SALL1-YFP 
(green) partially colocalizes with bioSUMO1, bioSUMO2 or endogenous SUMO2/3 (red) (A-C). Same 
result was observed for the SALL1-4KR mutant (D). Yellow arrows indicate colocalization, green arrows 
indicate domains where only SALL1 proteins are present and red arrows indicate domains where only 
SUMO proteins are present. Nuclei were stained with DAPI (blue). A’-D’’ Green and red channels are 
shown independently in black and white. Pictures were taken with a Leica DM IRE2 confocal microscope 
using a 63X objective. 
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As described in the previous section, we showed that mutation of four lysines located 
in consensus sites abolished SUMOylation of human SALL1-4KR mutant. We analyzed whether 
the mutation of those lysines influenced the subcellular localization of the protein and, 
consequently, the partial colocalization between SALL1 and SUMO. First, we showed that the 
aggregation of SALL1-4KR in nuclear bodies is similar to that of the WT protein (Fig. 32D’). In 
addition, SALL1-4KR also showed partial colocalization with the SUMO proteins (Fig. 32D-
D’’). Taken together, our results indicated that SALL1 partial localization in SUMO bodies was 
not affected by its SUMOylation status. 
It has been shown that PML bodies are highly SUMOylated (Zhong et al., 2000). 
Interestingly, we showed that not all the nuclear SUMO bodies colocalized with PML in U2OS 
cells (Fig. 33A-A’’). Intriguingly, SALL1 and PML seemed to be mutually exclusive when 
localizing in most of the SUMO bodies (Fig. 5B-B’’’). The possible functional meaning, if any, 
of this apparent mutual exclusion is unknown. This observation would deserve further analysis. 
 
 
Figure 33. PML bodies in U2OS. PML bodies (green) colocalize with SUMO2/3 (red) (A), but not all 
the SUMO spots colocalize with PML as indicated by the red arrows (A’’). B-B’’’. SALL1-YFP (green) 
does not colocalize with PML (blue). Yellow arrows indicate colocalization between SALL1-YFP and 
SUMO2/3 while violet arrows are for spots where PML and SUMO2/3 colocalize. Pictures were taken 
Leica DM IRE2 confocal microscope with 63X objective 
 
 
1.2.2. Human SALL1 interacts with SUMO proteins by PLA 
 
Proximity Ligation Assay (in situ PLA) is a technique that allows the detection of 
protein-protein interactions and protein modifications (Matic et al., 2010; Söderberg et al., 2006). 
Briefly, two primary antibodies raised in two different species are used to recognize target 
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antigens of interest. PLA probes, that are species-specific antibodies with a single strand DNA 
molecule attached, are used to bind specifically those primary antibodies. Only when the PLA 
probes are in close proximity generate a signal that could be detected by microscopy and 
indicates the presumable interaction of the antigens. The signal from each detected pair of PLA 
probes is visualized as an individual fluorescent spot. These PLA signals can be quantified 
(counted) and assigned to a specific subcellular location based on microscopy images (Söderberg 
et al., 2006). 
We used the PLA approach to detect the subcellular interaction of SALL1 with 
SUMO2/3, confirming the results previously obtained. In U2OS cells, we confirmed the 
interaction of human SALL1-WT with SUMO2/3 in the nucleus (Fig. 34A). The vector pcDNA, 
used as negative control, did not show interaction with SUMO2/3, as expected (Fig. 34C). In 
order to analyze whether this interaction was dependent on the SUMOylation status of the 
protein, we analyzed the SALL1-4KR mutant. Surprisingly, we detected interaction of the 
mutant SALL1 with SUMO2/3, despite the fact that this mutant is not SUMOylated in cells as 
described in the Section 1.1 of Results, Part II (Fig. 34B). 
 
 
 
Figure 34. PLA assay to detect the interaction between SALL1 and SUMO proteins. Confocal 
pictures of representative PLA assays performed in U2OS cells. Red spots indicate the interaction 
between the two proteins. In A and B, cells were transfected with SALL1-HA and SALL1-4KR-HA, 
respectively. The presence of red spots indicates the interaction between SALL1 and SUMO2/3 in the 
nucleus. C. Cells were transfected with the empty vector pCDNA3 used as negative control. In D and E, 
cells were transfected with SALL1-HA and PLA assay was performed using separately SALL1 antibodies 
(D) or SUMO2/3 antibodies (E) as negative controls. F. Quantification of PLA signals per cell of the 
described conditions A, B, C, D and E. Mean difference between A and B is not significant, but both 
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sample shown significant difference with the control samples C, D and E as indicated by asterisks. Error 
bars indicate standard error of the mean. Three asterisks indicate p<0.001, two asterisks indicates p<0.01 
calculated using One Way ANOVA test analysis.  
 
 
As the interaction with SUMO2/3 was not dependent on the SUMOylation status of 
the protein, this could be due to the presence of putative SIM domains in human SALL1. To 
further explore this possibility, we analyzed SALL1 sequence using the GPS-SUMO software to 
identify putative SUMO interaction motifs. The free access software GPS-SUMO is based on a 
new generation group-based prediction system (GPS) algorithm integrated with Particle Swarm 
Optimization approach (Zhao et al. 2014; http://sumosp.biocuckoo.org). The program suggested 
one putative SIM between amino acids 71-75 (VLIVN) with a high probability score (45.98) and 
three other SIMs with lower scores: between amino acids 195-199 (VIEEN) with score 31.52, 
between amino acids 254-258 (ILLLA) with score 30.39 and between amino acids 1252-1256 
(ISVIQ) with score 30.76. (Fig. 29C). Netzer and coworkers previously reported the direct 
interaction between SALL1 and SUMO1 using the yeast-two-hybrid system: the region of 
interaction was located between amino acids 689-1324, in the C-terminal part of the protein 
(Netzer et al., 2002), which is compatible with the ISVIQ site. Taken together, these results 
indicated the presence of at least one sequence SIM in SALL1. Further experiments would be 
required to demonstrate the functionality of this SIM, the possible presence of other SIMs and 
their putative role in SALL1 localization.   
 
 
2. SUMOylation and localization of Drosophila Sall Proteins 
 
Previous work from the laboratory published in 2010 and 2011 reported that 
Drosophila melanogaster Salm protein can be SUMOylated in vitro in the IKEE SUMOylation 
consensus site located between ZF2 and ZF3 (Fig. 36B) (Sánchez et al. 2010; Sánchez et al. 
2011). Furthermore, SUMOylation has a role on Sall function: SUMOylation status of Sall 
proteins modulates the development of wing discs in vivo, affecting vein formation and final size 
of the adult wing (Sánchez et al., 2010). As the SUMOylation assays were previously done in 
vitro, we decided to check the SUMOylation capacity of Salm in Drosophila cultured cells using 
the new technology based on NeutrAvidin chromatography described in Results, Part I. Since 
Salm is not endogenously expressed in none of the available Drosophila cells lines, we 
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performed these experiments by overexpressing Salm. Kc167 and S2R+ cells were transfected 
with pUAST-CFP-HisMycSalm and with pAc5-BirA
opt
-T2A-GFPpuro or pAc5-bioSmt3-T2A-
BirA
opt
-T2A-GFPpuro in presence of pAc-Gal4. Drosophila cells were transfected with different 
amounts of plasmids, treated with the proteasome inhibitor MG132 and collected at different 
times after transfection in order to increase the yield of Salm protein (Fig. 35). Unfortunately, 
cells transfected with pUAST-CFP-HisMycSalm died 3 days after transfection. None of our 
attempts yielded enough amount of Drosophila Salm protein to be able to perform NeutrAvidin 
chromatography (Fig. 35). The overexpression of Salm resulted toxic for the cells and, therefore, 
we decided to perform these experiments in a heterologous system, using mammalian cultured 
cells. 
 
 
Figure 35. Overexpression of Salm in S2R+ cells. A. Overexpression of Salm in presence (+) or 
absence  (-) of bioSmt3. B. Overexpression of Salm in presence or absence of MG132 with or without 
bioSmt3. 
 
 
2.1. SUMOylation of Drosophila Salm in mammalian cells 
 
To avoid the yield limitations faced with the use of Drosophila cells, we used HEK 
293FT cells as a system to investigate the SUMOylation of Drosophila Salm protein. First, we 
checked the level of protein expression after transfecting the cells with CMV-CFP-HisMycSalm 
or with CMV-CFP-HisMycSalm
IKDP
, a Salm SUMOylation mutant where the IKEE (Lys 641) 
consensus site was mutated to IKDP (Fig. 36B; (Sánchez et al., 2010). Once we obtained optimal 
levels of expression (Fig. 36A, Input panel), NeutrAvidin pulldowns were performed. Our results 
showed that Drosophila Salm WT was modified by bioSUMO1 and bioSUMO3 in mammalian 
cells, but that SUMOylation was abolished when the Salm
IKDP
 mutant was expressed (Fig. 36A, 
Elution panel). These experiments confirmed the results previously obtained in vitro (Sánchez et 
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al., 2010) and surprisingly showed that, also in the cellular environment, mutation of a single 
SUMOylation consensus site is enough to abolish Salm SUMOylation. 
 
 
 
Figure 36. SUMOylation of Salm. A. Western blot of pulldowns to check SUMOylation of Salm in 
HEK 293FT cells. Salm fused to CFP is SUMOylated in presence (+) of bioSUMO1 as indicated by the 
asterisk. SUMOylation occurs in IKEE site and the mutation IKPD abolishes Salm modification (Elution, 
lane 4). Anti-actin antibodies were used as a loading control. Molecular weight markers are shown to the 
left. B. Salm schematic representation. In red, the SUMO consensus site mutated in CFP-Salm mutant and 
in blue the predicted SIMs are shown. 
 
 
2.2. Drosophila Salm localizes in nuclear bodies in cultured cells 
 
Despite the low expression of the pUAST-CFP-HisMycSalm construct in Drosophila 
cells, it was still possible to observe the localization of Salm in the transfected cells. pUAST-
CFP-HisMycSalm plasmid was used to transfect S2R+ Drosophila cells in presence of pAc-
Gal4. The fusion protein localized in discrete nuclear domains, as it was shown in vivo in the PG 
(See below Fig. 37). Furthermore, partial colocalization between Salm and endogenous Smt3 
was demonstrated (Fig. 37A-A’’).  
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Since we proved the SUMOylation of Drosophila Salm in mammalian cells, we 
decide to check, as we did with the human homolog SALL1, its colocalization with SUMO 
proteins in human cells. U2OS cells were used to perform immunofluorescence experiments. As 
it can be shown in Fig. 37B-B’’, partial colocalization existed between Salm and endogenous 
SUMO proteins. As described in the previous section, we showed that a mutation of the 
consensus site abolishes SUMOylation of Drosophila Salm
IKPD
. We analyzed whether the 
mutation of IKEE consensus site influenced the subcellular localization of the protein and, 
consequently, the partial colocalization between Salm and SUMO. First, we showed that, as 
previously shown, the aggregation of Salm
IKPD 
 in nuclear bodies was similar to that of the WT 
protein (Fig. 37C; Sánchez et al. 2010). In addition, Salm
IKPD
 still showed partial colocalization 
with SUMO2/3 (Fig. 37C-C’’). Taken together, our results indicate that Salm partial localization 
in SUMO bodies is not affected by its SUMOylation status in U2OS mammalian cells. 
 
 
 
Figure 37. Partial colocalization between Salm and SUMO. Salm-CFP (green) partially colocalized 
with Smt3 (red) in S2R+ D. melanogaster cells (A-A’’). In B-B’’, the partial colocalization between Salm 
and SUMO2/3 in U2OS cells is shown. Yellow arrows indicate colocalization, green arrows indicate 
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domains where only Salm is present and red arrows indicate domains where only SUMO2/3 is present. 
Similar results were observed for Salm mutant (C-C’’). Nuclei were stained with DAPI (blue). Green and 
red channels are shown independently in black and white (A’-C’’). Pictures were taken using a Leica DM 
IRE2 confocal microscope with a 63X objective. 
 
 
These results are similar to what we observed for human SALL1, where the 
interaction with SUMO2/3 is not dependent on the SUMOylation status of the protein and could 
be due to the presence of SIM domains in the sequence. Also in this case, we analyzed the 
Drosophila Salm sequence using the GPS-SUMO software and the program suggested two 
putative SIMs: the first between amino acids 256-260 (IQLIQ) with score 24.94 and another 
between amino acids 172-176 (VEVDV) with lower probability score (19.35) (Fig. 36B). Further 
experiments would be required to demonstrate the presence of this SIM and its putative function 
in Salm localization.   
 
 
3. Analysis of CBX4 as a possible SUMO E3 ligase for SALL1  
 
 Our results demonstrated the SUMOylation of human SALL1 in HEK 293FT cells. As 
SUMOylation might be regulated in vivo by E3 ligases, we were interested on studying which 
ligases could be involved in SALL1 SUMOylation and analyzing their possible interactions in 
vivo. Therefore, our aim of this part of the work was to identify possible E3 ligases for SALL1 
using different approaches. 
 
 
3.1. Identification of human SALL1 partners by BioID 
 
 The “proximity proteomics” BioID methodology in combination with Mass 
Spectrometry was used to identify possible interactors of human SALL1. BioID is a method to 
screen for proximate and interacting proteins in living cells. The method is based on a modified 
form of the biotin ligase, called BirA*, which losses target specificity and is able to add biotin to 
unspecific sequences in close proximity. BirA* is fused to a protein of interest and expressed in 
cell culture, where the efficient biotinylation of endogenous proteins adjacent to, or interacting 
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with, our protein of interest takes place by adding an excess of biotin in the culture medium (Fig. 
38A) (Roux et al. 2012; Dingar et al. 2014).  
Myc-BirA* was fused to the N-terminus part of human SALL1, either the full length 
form (FL) or the truncated form SALL1(826) present in Townes-Brocks patients. Lysates of 
HEK 293FT cells transfected with CMV-Myc-BirA*-SALL1 or CMV-Myc-BirA*-SALL1(826) 
were used to perform pulldown experiments using NeutrAvidin beads. Total protein eluates were 
resolved on a SDS-PAGE and stained with Colloidal Coomassie (Fig. 38B). Bands were excised 
from the gel, subjected to trypsin digestion and, analyzed by Mass Spectrometry. The 
experiments were done in triplicates. In collaboration with the group of Dr. Jesper Olsen at the 
University of Copenhagen, we identified proteins that are possible interactors of human SALL1, 
either the FL or the truncated forms. We identified 2608 proteins from this Mass Spectrometry 
analysis. After our analysis of the ratio of intensities between the SALL1(FL) and the 
SALL1(826) samples (explained in Materials and Methods), we obtained a list of 404 possible 
interactors for SALL1(FL). We focused our attention in those proteins, the other proteins 
interacting with the truncated SALL1(826) will be the object of a different study in the 
laboratory (Appendix V). 
 We performed a bioinformatics analysis of the selected proteins (Fig. 39). GO analysis 
revealed that the putative interactors of SALL1 were involved in different biological processes as 
translation, catabolic process of transcribed mRNA or protein targeting to membrane. The 404 
proteins were localized in different cellular compartments: in the nucleus, they were related to 
the SWI/SNF complex, PML body or as proteins associated to chromatin; The portion of 
proteins present in the cytoplasm were associated to the ribosome, extracellular vesicular 
exosome and collagen. In respect to the molecular function, most of the proteins identified were 
factors involved in gene expression regulation. As shown in Fig. 39, GO categories emerging 
from the analysis were phosphoproteins, chromatin, mRNA, DNA or histone deacetylase binding 
proteins, as well as proteins involved in DNA catalytic activity. Interestingly, the SUMO ligase 
activity is well represented. Among the interactors of SALL1, we identified CBX4, PIAS1, 
PIAS2 and PIAS4, known mammalian SUMO E3 ligases which could be involved in the 
SUMOylation of SALL1 in vivo. 
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Figure 38. The proximity proteomics BioID methodology in combination with Mass Spectrometry. 
A. Schematic representation of the BioID methodology adpted from Roux et al. 2012. B. Gel stained with 
Colloidal Coomassie. Pulldowns of HEK 293FT cells transfected with CMV-Myc-BirA*-SALL1(826) or 
CMV-Myc-BirA*-SALL1(FL) with their respective controls. Molecular weight markers are shown to the 
left. Excised gel fragments used for Mass Spectrometry are numbered. 
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Figure 39. Analysis of SALL1(FL) interactors by Mass Spectrometry. GO analysis for biological 
process, cellular component and molecular function performed using Innate DB. 
 
 
CBX4 is the homolog of Drosophila Pc. Interestingly, the genetic interaction 
between sall genes and Pc was previously reported in Drosophila, as mutations in salm enhanced 
RESULTS PART II 
104 
 
Pc group mutations phenotype during embryogenesis (Casanova 1989; Landecker et al. 1994). 
Therefore, we decided to analyze the possible function of CBX4/Pc as SALL E3 ligase.  
 
 
3.1.1. Validation of the interaction of SALL1 and CBX4 
 
 To validate the Mass Spectrometry data we used Western blot as a complementary 
technique. BirA* was fused to the C-Terminus of CBX4 in a vector containing the CMV 
promoter. CMV-CBX4-BirA* was used to transfect HEK 293FT cells in combination with CMV-
SALL1-2xHA or CMV-SALL1(826)-2xHA, where the FL or the truncated forms of SALL1, 
respectively, were fused to two copies in tandem of the hemagglutinin antigen HA. As negative 
controls, cells transfected separately with the individual plasmids were used. After transfection, 
cell lysates were subjected to pulldown using NeutrAvidin beads and the eluates were analyzed 
by Western blot using anti-HA-antibodies (Fig. 40). CBX4 appeared as interactor of both 
proteins, the FL and the truncated SALL1(826), as is shown in the Elution panel (Fig. 40). Each 
lane of the gel was loaded with the same amount of total proteins, which was confirmed by using 
anti-GAPDH antibodies as control, but the relative amount of SALL1(FL) and SALL1(826) was 
different as is clearly visible in the panel on Input. Despite the presence of more exogenous 
SALL1(826) in cells, CBX4 seemed to bind preferentially to SALL1(FL). These experiments 
confirmed the results from Mass Spectrometry described above. 
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Figure 40. Validation of the binding of CBX4/Pc with SALL1. In the Input panel, the relative 
expression of the SALL1 proteins fused to HA tag is shown. In the elution, SALL1(FL)-HA binds 
preferentially to CBX4-BirA* (lane1) and to DmPc-BirA* (lane 3). Controls are shown in lanes 4-7. 
Anti-GAPDH and anti-biotin antibodies were used as loading control and to show the efficiency of the 
different pulldowns, respectively. Molecular weight markers are shown to the left. 
 
 
3.2. SALL1 and CBX4 interact directly 
 
 Our previous results confirmed the interaction between SALL1 and the E3 ligase 
CBX4. However, due to the nature of the BioID method, this interaction could be direct or 
indirect, being mediated by a third protein. In order to discriminate between these two 
possibilities, we expressed SALL1 and CBX4 in cultured cells and performed copulldown 
experiments. HEK 293FT cells were transfected using CMV-SALL1-GFP and CB6-HA-CBX4 
plasmids. Two days after transfection, cells were lysated and incubated with anti-GFP beads 
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(called GFP-trap; see Materials and Methods) to allow the capture of the SALL1-GFP fusion 
protein. After elution, the material was analyzed by Western blot using anti-HA antibodies. As it 
can be seen in Fig. 41, CBX4 was present in the Elution panel of the pulldown, indicating its 
direct interaction with SALL1-GFP. Those results confirmed the data previously obtained with 
the BioID approach and indicated that the interaction between the two proteins is direct and does 
not require a third party. 
 
  
 
 
 
 
 
 
 
Figure 41. Direct interaction of SALL1 and CBX4 
by co-pulldown. In the Input panel, SALL1 is shown 
by using anti-GFP antibodies in presence (+) or 
absence (-) of CBX4. In the Elution panel, anti-HA 
antibodies were used. Molecular weight markers are 
shown to the left. Asterisk indicates the HA positive 
band.  
 
3.2.1. CBX4 localizes in nuclear bodies not overlapping with SALL1 
 
 PcG proteins are concentrated in nuclear foci called PcG bodies (reviewed by Pirrotta 
& Li 2012). In order to detect the localization of CBX4, we contributed to the characterization of 
the new anti-CBX4 antibodies developed by the company Proteintech. We tested the specificity 
of the antibodies by Western blot in lysates from mammalian cells, where we showed a major 
band that appeared at 75 KDa (isoform A) and a smaller band around 50 KDa that corresponded 
to the isoform B (Fig. 42A). In addition, we tested the localization of CBX4 in U2OS cells by 
immunofluorescence, confirming the presence of CBX4 in nuclear structures similar to the PcG 
bodies (Fig. 42B-B’’). 
 Since the interaction between SALL1 and CBX4 was demonstrated, we decided to test 
whether these proteins colocalized in the cells. CMV-SALL1-YFP plasmid was transfected into 
U2OS cells, where endogenous CBX4 was visualized by immunofluorescence using the anti-
CBX4 antibodies. Surprisingly, our confocal pictures showed that there was not colocalization of 
SALL1 and CBX4 in the nuclear bodies (Fig. 42C-C’’). In view of these results, we thought that 
this interaction could take place, not in the nuclear bodies, but in the nucleoplasm. In order to 
check that, we decided to apply PLA to confirm our hypothesis.  
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Figure 42. Characterization of the anti-CBX4 antibodies (Proteintech). A. Western blot using extracts 
from different cell lines. The major band corresponding to the isoform A of CBX4 was identified at 75 
KDa, as expected (asterisk). The isoform B is indicated by an arrow. Molecular weight markers are 
shown to the left. B-B’. CBX4 localization in U2OS cells detected by the anti-CBX4 antibody using an 
AxioD fluorescent microscope. C-C’’. Confocal pictures of U2OS cells transfected with SALL1-YFP. 
SALL1 domains (green) and Pc bodies (red) do not colocalize. CBX4 (green) did not colocalize neither 
with the PML bodies (red) (D-D’’), nor with speckles (E-E’’) visualized using anti-SC-35 antibodies 
(red). B’-E’’. Green and red channels are shown independently in black and white. Nuclei were stained 
with DAPI (blue). Pictures in C-C’’ were taken using a Leica DM IRE2 confocal microscope with a 63X 
objective. Pictures D-E’’ were taken using a Leica DM IRE2 confocal microscope with a 40X objective. 
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U2OS cells were transfected with CMV-SALL1-YFP and anti-SALL1 and anti-CBX4 
antibodies were used to perform PLA. Our analysis of the number of spots confirmed the 
interaction between SALL1 and CBX4 in the nucleus, when compared to cells transfected with 
the empty vector pcDNA used as negative control (Fig. 43A, B). PLA analysis was done taking 
into account only the cells transfected, which were YFP positive. Controls to test the background 
of different antibodies were done (Fig. 43C, D). It was not possible to use anti-GFP antibodies 
because they generated nonspecific positive spots. In conclusion, our experiments showed the 
direct interaction of SALL1 and the E3 ligase CBX4 in the nucleus, probably in the nucleoplasm, 
given the absence of colocalization in the nuclear bodies. 
 
 
 
Figure 43. PLA assay for SALL1 and CBX4 colocalization. A-D. Confocal pictures of PLA assays 
performed in U2OS cells. Red spots indicate the interaction between the two proteins. A. Cells were 
transfected with SALL1-HA. The presence of red spots indicates the nuclear interaction between SALL1 
and CBX4. B. Cells were transfected with the pCDNA3 empty vector as negative control. C, D. Cells 
were transfected with SALL1-HA and PLA assays were performed using only SALL1 antibodies (C) or 
CBX4 antibodies (E), separately, as negative controls. D. Quantification of PLA signal per cell for the 
described conditions A, B, C and D. Mean of sample A shows significant differences with mean of 
control samples B, C and D as indicated by asterisks. Error bars indicate standard error of the mean. 
Three asterisks indicate p<0.001calculated using One Way ANOVA test analysis.  
 
In addition to the colocalization with SALL1, we analyzed by immunofluorescence 
the colocalization of CBX4 with other nuclear factors, such as PML or SC-35 (Fig. 42D-E’’). 
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We did not observe colocalization of CBX4 neither in PML bodies, nor in speckles, suggesting 
that there was not interaction with these factors in the nuclear bodies. However, we cannot 
discard that the interaction takes place in the nucleoplasm, as we did not proceed with further 
experiments such is the PLA analysis.  
 
 
3.3. Functional analysis of SALL1-CBX4 interaction 
 
 Our PLA experiments proved the interaction between SALL1 and CBX4 in the 
nucleoplasm. We hypothesized that this interaction might influence the SUMOylation status of 
SALL1 in the cells, based on the E3 ligase capacity of CBX4.  
 
 
3.3.1. CBX4 influences the SUMOylation status of SALL1 
 
 As mentioned in the Introduction, the presence of exogenous CBX4 in mammalian 
cells enhances the SUMOylation of CTBP1 (Kagey et al., 2003). In order to analyze the possible 
effect of CBX4 on SALL1 SUMOylation, we transfected HEK 293FT cells with CMV-SALL1-
YFP, together with CAG-bioSUMO1-T2A-BirA
opt
-T2A-GFPpuro or CAG-bioSUMO3-T2A-
BirA
opt
-T2A-GFPpuro in presence or absence of CB6-HA-CBX4. Two days after transfection, 
cells were collected and lysed and pulldowns were performed using the NeutrAvidin beads. Our 
results confirmed the SUMOylation of SALL1 in presence of bioSUMO1 (Fig. 44A). 
Surprisingly, when CBX4 was added to the cells, the SUMOylated form of SALL1 disappeared, 
as it is shown in Fig. 44B, where SALL1-YFP is visible in the Input but it is not detectable in the 
Elution. Using anti-HA antibodies we revealed a strong SUMOylation of CBX4 in the cells (Fig. 
44C). Therefore, we hypothesized that the bioSUMO1 or 3 (data not shown) present in the cells 
were massively incorporated into CBX4, limiting the availability of the SUMOylation machinery 
to be conjugated to SALL1-YFP.  
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Figure 44. SUMOylation assay for SALL1 in presence of CBX4. A. SUMOylation of SALL1-YFP, 
marked by an asterisk, is shown in presence of bioSUMO1. B. The presence of CBX4 (+) impedes the 
SUMOylation of SALL1 (Elution, lane 2). C. Strong SUMOylation of HA-CBX4 in presence of 
bioSUMO1 (Elution, lane 2) indicated by the line and the asterisk. Arrowheads mark the unmodified 
SALL1. Molecular weight markers are shown to the left.  
 
 
As our experiments of SUMOylation in cells were inconclusive, we decided to take 
an alternative approach. In collaboration with Dr. Manuel S. Rodriguez and Dr. Valerie Lang 
(Inbiomed, San Sebastian) in vitro SUMOylation assays were performed. The results showed 
that the SUMOylated form of SALL1 FL in presence of SUMO1 or SUMO2/3 varied when 
different amounts of CBX4 were added to the reaction (Fig. 45). The absence of SUMOs and 
CBX4 were used as negative controls. However, we experienced different technical problems 
during the performance of these experiments, mainly difficulties to express SALL1 in sufficient 
quantities for the experiments due to its large size. In summary, our in vitro results are 
compatible with a role of CBX4 promoting the SUMOylation of SALL1, although the 
experiments would need to be confirmed.  
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Figure 45. In vitro SUMOylation of SALL1 in presence of CBX4. Presence of CBX4 at two different 
quantities (+ and ++) contributed to the SUMOylation of SALL1 in presence of SUMO1 (lane 5 and 6). 
Asterisks indicate the SUMOylated forms of SALL1. Arrow indicates the unmodified SALL1. 
 
 
3.3.2. SALL1 influences the number of PcG bodies 
 
 During the course of the SUMOylation experiments in cultured cells described in the 
previous section, we observed that the number of PcG bodies detected with the CBX4 antibodies 
varied in presence of SALL1. Therefore, we hypothesized that SALL1 has a role on PcG bodies 
formation. In order to prove this, we transfected U2OS cells with CMV-SALL1-YFP, CMV-
SALL1(826)-YFP or CMV-EGFP-β-galactosidase, used as a negative control. PcG bodies were 
detected by immunofluorescence using anti-CBX4 antibodies. Pictures were taken with an 
automated fluorescent microscope and were analyzed using the MetaExpress software. With the 
help of Dr. M. González in the laboratory, we set up a specific module that count the number of 
PcG bodies specifically in the transfected cells. Our results showed that the presence of SALL1-
YFP FL increased significantly the number of PcG bodies in a 27% with respect to the control 
(Fig. 46A). The expression of the truncated form SALL1(826)-YFP also increased the number of 
PcG bodies in a 13% with respect to the control, but this difference was not significant.  
RESULTS PART II 
112 
 
 
 
Figure 46. SALL1 influences the levels of CBX4. A. Representation of 3 independent experiment 
performed in U2OS transfected with 500 g of SALL1-YFP, SALL1(826)-YFP or -galactosidase-GFP 
used as negative control. Number of Pc bodies increased significantly in presence of SALL1-YFP. One 
asterisk indicates p< 0.05, two asterisks p<0.01, calculated using Student’s t test analysis. Error bars 
indicate standard deviation. B. Western blot showing that, in presence of SALL1, the amount of CBX4 
increased. This effect is visible in the Input (lanes 3 and 6) and consequently in the Elution (lane 6). Anti-
GFP antibodies were used to control the relative amount of SALL1 added into the cells and anti-actin 
antibodies were used as loading control. Molecular weight markers are shown to the left. 
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We used Western blot analysis as a complementary technique to analyze whether the 
increase in number of PcG bodies was due to increased levels of CBX4. HEK 293FT cells were 
transfected with CB6-HA-CBX4, CAG-bioSUMO1-T2A-BirA
opt
-T2A-GFPpuro or CAG-
bioSUMO3-T2A-BirA
opt
-T2A-GFPpuro, and different amounts of CMV-SALL1-YFP. We found a 
direct correlation between the amount of CBX4 visible in each lane and the amount of SALL1-
YFP added to the cells (Fig. 46B, Input panel). We detected also an increased amount of 
SUMOylated CBX4 in presence of SALL1 (Fig. 46B, Elution panel). However, the increased 
CBX4 levels were detected also in absence of bioSUMO1, indicating that the correlation 
between SALL1 and CBX4 levels might not depend on the SUMOylation status of these 
proteins. The increase in SUMOylated CBX4 partially reflected the higher levels of CBX4 in the 
input of the pulldown reactions.  
Taken together, our results suggested a reciprocal effect between SALL1 and CBX4: 
on one hand, CBX4 could contribute to SALL1 SUMOylation while, on the other hand, SALL1 
could influence the levels of CBX4 and the formation of PcG bodies.  The functional 
significance of this interaction would deserve further analysis.  
 
 
4. Analysis of Pc as a Possible SUMO E3 Ligase for Sall Proteins in 
Drosophila melanogaster 
 
In the previous section, we described the direct interaction between human SALL1 
and CBX4 in mammalian cells, which could influence the SUMOylation and the levels of these 
proteins, as well as the formation of the Pc bodies. To further investigate these facts, we turned 
to Drosophila as a model system in an attempt to understand the developmental consequences of 
this interaction.  
 
 
4.1. Salm and Pc partially colocalize in vivo 
 
Previous experiments from the laboratory showed that Salm had a highly dynamic 
pattern of expression. During L3 Salm localized in the nucleus in a heterogeneous way (Fig. 
47A-A’). Interestingly, when the larva was about to pupariate, Salm changed its distribution in 
the RG dramatically and decorated a ring around the nucleolus at the end of the L3 instar (Fig. 
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47B-B’). This localization is transient, and Salm localized again throughout the nucleus shortly 
after (Fig. 47C-C’). Through the work of different laboratory members, we discovered that this 
translocation was not a general behavior for other transcription factors such were Osa, HP1 or 
PEP (Jonatan Sanchez, PhD Thesis, 2009). We also discovered that the translocation coincided 
with the highest levels of ecdysone at the end of the L3 stages prior entering into pupariation 
(Soraya Curiel, unpublished results). However, the possible causes and consequences of the 
nucleolar translocation of Salm remain unknown. The rapidity of the translocation allowed us to 
speculate that it might be caused by a posttranslational modification of Salm. 
In the course of our research, we observed a partial colocalization between Pc and 
Salm in the PG during L3 instar (Fig. 48). These two factors colocalize in certain foci in the 
polytene chromosomes of the PG of Drosophila, which could correspond to genes regulated by 
Pc. Interestingly, Pc weakly colocalized with Salm, at the end of L3, in the ring structure around 
the nucleolus (Fig. 48). These results are compatible with the interaction of Salm and Pc at this 
stage of development. 
We also used cultured cells as a model to check the colocalization between Salm and 
Pc. As described before, we used pUAST-CFP-HisMycSalm construct in presence of pAc-Gal4 
to express Salm proteins in S2R+ Drosophila cells. Also in cultured cell, we showed partial 
colocalization between Salm and endogenous Pc (Fig. 48B-B’’).  
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Figure 47. Localization of Salm in the PG during L3 instar. A-D’. Localization of Salm (red) in the 
PG cells before (A), during (B) and after (C) the hormonal peak at the end of the L3 instar. The 
translocation to the nucleolus (ring formation) is visible in B-B’. A’-C’. Red channel is presented in black 
and white independently. Nuclei were stained with DAPI (blue). Pictures were taken with a Leica DM 
IRE2 confocal microscope with a 63X objective.  
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Figure 48. Partial colocalization between Salm and Pc. A-A’’. Salm and Pc partially colocalize in PG 
cells during ring formation (indicated by yellow arrows) at the end of the L3 instar. B-B’’. Salm and Pc 
partially colocalize in S2R+ cells transfected with CFP-Salm (yellow arrow). Green and red channels are 
shown independently in black and white. Nuclei were stained with DAPI (blue). Pictures were taken with 
a Leica DM IRE2 confocal microscope using a 63X objective. 
 
 
4.2. Genetic interaction between salm and Pc in vivo 
 
It was previously shown that SUMOylation has a role on Sall proteins during 
Drosophila wings development (Sánchez et al., 2010). We decided to investigate the nature of 
the Pc/Salm interaction, focusing on a possible role of Pc on Salm SUMOylation, using the adult 
wing as a model to perform the experiments (Barrio and De Celis, 2004). For this, we used the 
line Sal
EPV
-Gal4 as a driver to direct the overexpression or the silencing of different genes in the 
area where sall genes are normally expressed. This corresponds to the area spanning from the 
longitudinal vein LII to the region between veins LIV and LV comprising the intervein regions B 
to D (Fig. 49). 
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Figure 49. Silencing Pc in the wing. A. Drosophila wild type wing where the Sal
EPV
-Gal4 expression 
area is indicated (green). B, C. Pictures of adult wings of genotypes Sal
EPV
-Gal4>UAS-GFP (GFP) and 
Sal
EPV
-Gal4>UAS-Pci (Pci). 
 
 
First we checked the phenotype resulting of knocking down Pc in the wing by 
crossing Sal
EPV
-Gal4 with UAS-Pci. As is show in Fig. 49, downregulation of Pc drastically 
reduced the wing areas B and C, resulting in the fusion of veins LII, LIII and LIV and in a 
significantly smaller wing area when compared to control wings.  
It is known that Pc represses the expression of Ultrabithorax (Ubx) in the wing 
imaginal discs and that, in turn, Ubx transcriptionally represses the expression of salm and salr 
(de Navas et al., 2011; Weatherbee et al., 1998). Therefore, the de-repression of Ubx when 
silencing Pc precluded us to analyze the effect of Pc on Sall proteins at the post-transcriptional 
level. To avoid the transcriptional effect of Ubx on sall genes, we generated transgenic flies that 
silenced Pc and Ubx at the same time, Sal
EPV
-Gal4>UAS-Pci,UAS-Ubxi. Silencing Ubx at the 
same time than Pc slightly but significantly rescued the size of the wings at 18
o
C, where the 
effect of silencing Pc is milder than at 25
o
C (Fig. 50).  
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Figure 50. Silencing Pc in combination with Ubx in the wing. Pictures of adult wings of genotypes 
Sal
EPV
-Gal4>UAS-Pci,UAS-GFP (Pci,GFP) and Sal
EPV
-Gal4>UAS-Pci,UAS-Ubxi (Pci,Ubxi) at 18°C and 
25°C. Below, the graph represents the logarithm of the average area of the wings of each genotype and 
temperature expressed in m2. Error bars indicate standard error of the mean. Three asterisks indicate 
p<0.001, calculated using Student’s t test analysis. 
 
The mild effect of silencing Ubx might reflect a poor efficiency of the UAS-Ubxi 
lines. In order to check the efficiency of silencing Pc and Ubx on salm expression, we 
immunostained wing imaginal discs with anti-Salm, anti-Pc and anti-Ubx antibodies (Fig. 51). 
These stainings were performed by Dr. C. Pérez in the laboratory. As expected, silencing Pc 
increased the levels of Ubx protein in the wing blade (Fig. 51B-B’’’). UAS-Ubxi lines #37823 
and #37825 slightly reduced Ubx intensity (Fig. 52). Surprisingly, Salm expression, although 
reduced, was still visible in the wing blade despite the presence of Ubx. This could maybe be due 
to the long perdurance of the protein. 
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Figure 51. Effect of silencing Pc on Ubx and Salm expression. A, B. Wing discs of genotypes Sal
EPV
-
Gal4>UAS-GFP (SalEPv>GFP) and Sal
EPV
-Gal4>UAS-Pci (SalEPv>Pci) showing Pc (red), Ubx (green) 
and Salm (blue) expression. A’-B’’’. Red, green and blue channels are shown independently in black and 
white. Pictures were taken using a Leica DM IRE2 confocal microscope with a 63X objective. 
 
 
 
 
 
Figure 52. Comparison of different Ubxi lines. A-C. Wing discs of genotypes Sal
EPV
-Gal4>UAS-GFP 
(A-A’’’), SalEPV-Gal4>UAS-Pci,UAS-Ubxi#37823 (B-B’’’), SalEPV-Gal4>UAS-Pci,UAS-Ubxi#37825 (C-
C’’’) showing Pc (red), Ubx (green) and Salm (blue) expression. A’-C’’’. Red, green and blue channels 
are shown independently in black and white. Pictures were taken with a Leica DM IRE2 confocal 
microscope with a 63X objective. 
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4.2.1. Salm rescues the phenotype produced by Pc silencing 
 
To check if Sall proteins could rescue the drastic phenotype generated by knocking 
Pc down, we generated the transgenic lines Sal
EPV
-Gal4>UAS-salm,UAS-Pci,UAS-Ubxi and 
Sal
EPV
-Gal4>UAS-salr,UAS-Pci. As shown in Fig. 53, overexpression of Salm rescued the 
phenotype of Pci. The phenotype of Sal
EPV
-Gal4>UAS-salm,UAS-Pci,UAS-Ubxi wings was 
similar to the phenotype of the wings where salm was overexpressed in a WT background: we 
observed extravein formation in LII and LIII and a reduction in the wing area (Fig. 53), which 
was smaller than the control. 
In the case of Salr, its overexpression did not rescue the phenotype produced by 
silencing Pc to the same extent than Salm, as Sal
EPV
-Gal4>UAS-salr,UAS-Pci wings are similar 
to Sal
EPV
-Gal4>UAS-Pci (Fig. 54). We cannot discard that the UAS-salr transgene was 
expressed at lower levels than UAS-salm, as these transgenes were generated by random 
insertion. Other UAS-salr lines would need to be analyzed in order to make a conclusion on the 
efficacy of Salm versus Salr to rescue the Pci phenotype.   
 
 
4.2.2. Role of SUMOylation on sall-Pc genetic interaction 
 
We hypothesized a possible implication of Pc in the Sall SUMOylation process as an 
E3 ligase. As we mentioned previously, ideally we should distinguish between the role of Pc on 
sall genes transcription and its putative role as E3 ligase. In order to do that, we used different 
transgenes. On one hand, we used the mutated forms of Salm and Salr in their respective 
SUMOylation sites, which makes them independent of endogenous SUMOylation; on the other 
hand, we used Smt3-Sall fusion proteins that mimic the constitutively SUMOylated forms of 
Salm and Salr. In the case of Salm, the Salm
IKPD
 mutant and the Smt3-Salm fusion contributed 
significantly less to the rescue of the Pci phenotype compared to the overexpression of the wild 
type protein (Fig. 53). Interestingly, there was not a significant difference between the 
overexpression of the Salm
IKPD
 mutant and the Smt3-Salm fusion, which indicated a complex 
relationship between Salm and SUMOylation in relation to its function in the wing. 
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Figure 53. Analysis of the role of SUMOylation in salm and Pc genetic interaction. Pictures of adult 
wings of the indicated genotypes. Below, graphical representation of the logarithm of wing areas 
expressed in m2. Error bars indicated standard error of the mean. One asterisk indicates p≤ 0.05, three p≤ 
0.001, calculated using Student’s t test. 
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When we analyzed the set of experiments done with Salr we observed that the double 
mutant Salr
IKEA,IKVA
 and the fusion protein Smt3-Salr rescued the phenotype caused by silencing 
Pc, although to a lesser extent than the Salm counterparts. In this case, it is possible to establish a 
direct correlation among these different transgenes, as all of them were inserted in the same 
genomic region and presumably should have similar levels of expression. Interestingly, in this 
case the mutant form Salr
IKEA,IKVA
 showed a significant higher capacity to rescue Pci phenotype 
compared to Smt3-Salr (Fig. 54). These results were in agreement for a role of SUMOylation in 
inhibiting Salr function, as it was previously suggested (Sanchez et al., 2010). However, they did 
not support for a function for Pc on Sall SUMOylation during wing development. 
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Figure 54. Analysis of the role of SUMOylation in salr and Pc genetic interaction. Pictures of adult 
wings of the indicated genotypes. Below, graphical representation of the logarithm of wing areas 
expressed in m2. Error bars indicated standard error of the mean. Two asterisks indicate p≤ 0.01, three 
asterisks indicate p≤ 0.001, calculated using Student’s t test. 
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4.4.3. Interaction of Pc and the SUMOylation pathway: transheterozygous analysis 
 
To further explore the relationship of Pc with the SUMOylation pathway during 
wing development, we performed a transheterozygous analysis. For this, we used the Pc[3] 
mutant combined in heterozygosity with the E2 enzyme mutants lwr[05486], lwr[4-3] or lwr[5]. 
Pc[3] mutant wings did not varied in size with respect to the control (Fig. 55). However, 
lwr[05486], lwr[4-3] and lwr[5] wings were significantly smaller than the control (Fig. 55). No 
major changes were found in size when combining lwr mutants with Pc[3], these changes being 
in opposite directions with lwr[4-3] or lwr[5]. We also performed transheterozygosity 
experiments with Pc[3] mutant in combination with the Smt3[04493] mutant. Smt3[04493] 
wings size resulted very similar to the control, while the Pc[3],Smt3[04493] transheterozygous 
wings showed a significant reduction in relation to the Pc[3] or Smt3[04493] (Fig. 55). These 
results support an interaction between Pc and smt3, while the interaction with lwr is mild. 
However, we cannot discard a more subtle interaction that the trans-heterozygous analysis is not 
able to detect due to the relative abundance of the proteins that we are analyzing. 
 
 
 
 
 
RESULT PART II 
 
125 
 
 
Figure 55. Analysis of a possible interaction between Pc and the SUMOylation machinery.  
Graphical representation of the logarithm of wing areas expressed in m2. Error bars indicate standard 
error of the mean. Two asterisk indicate p≤ 0.01, three asterisks indicate p≤ 0.001, calculated using 
Student’s t test. Below, pictures of adult wings of the indicated genotypes.  
 
 
We also used the trans-heterozygous analysis to further explore the relationship 
between Pc and sall genes in the wing. For that, we used the Pc[3] mutant combined in 
heterozygosity with Df-5, a deficiency that lacks both salm and salr. As mentioned above, wings 
from Pc[3] mutants did not differ significantly in size with respect to the control (Fig. 56). As 
reported previously, Df-5 wings were smaller than control in a 76-78%, depending on the Df-5 
stock that was used (Fig. 56). However, in combination with Pc[3], the wings significantly 
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recovered their size to a 85-94% of the control (Fig. 56). These results indicated a negative 
interaction of Pc on sall genes, which is in contrast with the possible de-repression of Ubx in the 
Pc[3] background. 
 
Figure 56. Analysis of a possible interaction between Pc and sall genes. Pictures of adult wings of the 
indicated genotypes. Below, graphical representation of the logarithm of wing areas expressed in m2. 
Error bars indicate standard error of the mean. Three asterisks indicate p≤ 0.001, calculated using 
Student’s t test. 
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Post-translational modifications (PTMs) control a wide range of physiological 
processes, contributing to extend the functionality and dynamics of eukaryotic proteomes. UbLs 
are involved in diverse biological and cellular processes. In contrast with Ubiquitination, 
SUMOylation is not necessarily involved in protein degradation. SUMO modulates the function 
of target proteins and is implicated in several biological processes such are DNA replication, 
DNA repair, chromatin remodeling, cell cycle, transcription, translation and stress response. In 
the last 20 years many different approaches were used to identify SUMOylated proteins that are 
important for the maintenance of the cellular equilibrium. 
 
 
1. bioSmt3 methodology to analyze SUMOylation in Drosophila 
 
Drosophila Smt3 is necessary throughout development. Differently from the 
situation in mammals and S. cereviasie, not many screenings have been performed in Drosophila 
to envision a complete scenario of the SUMOylated subproteome. Removing Smt3 from the PG 
blocks development at L3 larval instar and our long-term aim was to identify SUMOylated 
proteins that were involved in steroidogenesis. During this work we developed a new system, 
using a biotin tag at the N-terminal part of Drosophila Smt3, in order to identify SUMOylated 
protein in cell sand in vivo. The method was based on a technology developed in the laboratory 
of Dr. U. Mayor for the identification of ubiquitinated substrates in vivo (Franco et al., 2011). 
The first attempt, performed in cells and in vivo, using pUAST-bioSmt3::BirA did not allow us to 
get enough enrichment in the sample of biotinylated/SUMOylated proteins for a successful Mass 
Spectrometry identification. We think that this lack of SUMOylated material was mainly due to 
three reasons: (i) the relative abundance of SUMO-conjugated proteins is lower than the 
abundance of ubiquitinated ones; (ii) our vector contained a single smt3 gene, while Franco and 
coworkers used a vector with seven repetitions of Ub; and (iii) the fusion protein bioSmt3::BirA 
was not completely processed in the cells, which impeded the isolation of enough material for 
Mass Spectrometry analysis after NeutrAvidin chromatography. Optimization of the technique 
by using the multicistronic vector pAc5-STABLE2-Neo (González et al., 2011) was successful. 
We performed a global screening in S2R+ Drosophila cells, after the demonstration of the 
efficacy of the system on a specific target, Ftz-f1, previously described to be SUMOylated in 
vitro (Talamillo et al., 2013).  
DISCUSSION 
130 
 
The aim behind the development of the bioSmt3 system was to have an approach to 
perform a single-step pulldown under very stringent conditions, taking advantage of the strong 
affinity between biotin and NeutrAvidin. The efficacy of the system was demonstrated in cells 
through the validation of putative SUMOylated targets using exogenous proteins. More 
importantly, validation was also performed in endogenous conditions, revealing the sensitivity of 
the methodology. Using specific antibodies, we demonstrated the SUMOylation of Fax and Lam, 
which were not previously described to be conjugated to SUMO and those could be considered 
as targets for future investigations.  
The in vivo analysis was performed using the anterior part of the larval body, which 
contains the imaginal discs, because it was reported the importance of SUMOylation in 
proliferating tissues during Drosophila development (Kanakousaki and Gibson, 2012). We 
observed a remarkable difference in terms of total number of putative targets when comparing 
the Mass Spectrometry list obtained from S2R+ cells (980) with the list obtained from larvae 
(92). In general, the recovery of material in cells is more direct and simple than the isolation of 
specific larval tissues. Also, in S2R+ cells, we expressed lwr at the same time than bioSmt3 to 
optimize the process of SUMO conjugation. These two aspect might be crucial to increase the 
yield of SUMOylated proteins.  
To explore the functionality of bioSmt3, we analyzed two main aspects: (i) the 
localization of bioSmt3, that was mainly in nuclear bodies both in cells and in vivo as happens 
for the endogenous Smt3, and (ii) the capability to rescue the phenotype caused by removing 
smt3 in the Drosophila PG. The bioSmt3 transgene used in these experiments is insensitive to the 
dsRNA directed against the endogenous smt3, as we used a degenerated nucleotide sequence for 
the transgene (Sánchez et al., 2010). The complete rescue of the phenotype supported the validity 
of our methodology, indicating also that in hs-Gal4>UAS-Smt3i,UAS-bioSmt3-T2A-BirA
opt 
transgenic Drosophila the majority of Smt3 available is the bioSmt3 fusion. Interestingly, 
Tramtrack and Calmodulin appeared in the list of putative SUMOylated targets in vivo: these 
proteins are expressed in the PG and there is an indication of the SUMOylation of Tramtrack in 
the literature (Lehembre et al., 2000). The optimization of the recovery of material from tissues 
would be necessary for the identification the complete SUMOylated subproteome. Also, the 
collection of isolated PGs (or cerebral-PG complexes) will be advisable in order to identify the 
SUMOylated proteins that are implicated in steroidogenesis, reducing in this way the 
background from other tissues. However, we did not obtain results after dissecting 100 PGs per 
genotype when using the genetic combination phm-Gal4>UAS-smt3i,UAS-bioSmt3::BirA. This 
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results might improve by using the multicistronic vectors in presence of Lwr and by increasing 
the number of isolated PGs.   
The GO terms obtained from the lists of proteins derived from the Mass 
Spectrometry experiments was what we expected from a SUMOylated subproteome, based on 
what it was described in other systems. We compared our lists among themselves (cultured cells 
versus in vivo) and with a list obtained from Drosophila embryos. The analysis of SUMOylated 
proteins in early development was performed using two different approaches: a two-step affinity 
purification strategy using His6 and FLAG tags at the N-terminus of Smt3 and, under native 
condition, a single-step anti-FLAG immunopurification (Nie et al., 2009). The overlap between 
our lists and that of Nie et al. was significant, considering that the experiments were done using 
different biological systems. In all the lists, gene expression regulators were overrepresented, 
which was in agreement with the role of SUMOylation as a modulator of the transcriptional 
activity important during development.  
 
 
2. New methodology for the analysis of bioUbL modifications in 
mammalian cells 
 
The modularity of the bioSmt3 vector allowed us to easily switch the promoter and to 
substitute the different modules. The screening performed in HEK 293FT cells using bioSUMO3 
gave us the confirmation of the efficacy of the system. We identified and validated proteins 
conjugated to SUMO3 already described in mammalian cells. Based on that, we generated a 
collection of vectors including most of the UbL modifiers described until now. Importantly, this 
strategy could be very useful and easy to apply to any mammalian model system. First of all, 
almost any protein can be biotinylated in vivo; second, the procedure is simple, as only one-step 
pull down is required under stringent conditions avoiding more complicated biochemical 
procedures; third, the modified proteins can be easily visualized in cells or tissues using 
streptavidin fused to a fluorescent dye; fourth, the vectors can be used either in transient 
transfection or to generate stable cell lines; and fifth, the vectors give the possibility to express 
the corresponding E2 or E3 to enhance the modification of interest. Furthermore, the bioUbL 
methodology is very sensitive and allowed us to identify the modified proteins without using a 
previous heat shock treatment, which is usually done to stress cells and enhance protein 
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modifications. Despite the fact that the bioUbL methodology implies the overexpression of the 
modifiers, and this would be considered as less physiological than the identification of the 
endogenous counterpart using specific antibodies (Becker et al., 2013), the economical cost of 
the experiments is highly reduced. To overcome the caveat of the overexpression, a useful 
application of the bioUbL methodology would be the replacement of the endogenous UbL by the 
corresponding bioUbL, which would have endogenous levels of expression. Taken together, all 
these enumerated advantages place the bioUbL methodology among the first choices for 
researchers interested on UbL modification, based on its high versatility, reliability and 
accessibility to most laboratories. 
 
 
3. SUMOylation of SALL proteins: Role of SUMOylation on SALL proteins 
localization 
 
 
The link of human SALL proteins to the hereditary syndromes TBS and OS, justify 
the interest of studying this family of transcription factors, as well as the possible role that 
SUMOylation might have on these proteins function. In addition, numerous phenotypic studies 
in Drosophila Salm confirm the relevance of this family of proteins during development, as well 
as the role of SUMOylation on their function (Sánchez et al., 2010).  
SALL proteins accumulate in nuclear foci that do not overlap with PML bodies, PcG 
bodies, or with speckles. In order to investigate on the nature of these bodies we checked the 
colocalization with SUMO proteins and we demonstrated that SALL1 and Salm overlap partially 
with bioSUMO1, bioSUMO2 or with the endogenous SUMO2/3 in mammalian cells. This 
partial colocalization differs from the one of the PML bodies, where SUMO is always present 
and could act as scaffold to build the nuclear bodies (reviewed by Nagai et al. 2011).  
Previous results from the laboratory showed that SUMOylation influences Salm 
localization in HEK 293FT mammalian cells. By overexpressing exogenous Smt3, the size of 
Salm nuclear foci changed depending of the SUMOylation status of the protein, while the mutant 
form of Salm resulted insensitive to the presence of Smt3 (Sánchez et al., 2010). In this work we 
did not appreciate changes in the localization of human SALL1 or Drosophila Salm in presence 
of bioSUMOs. These results could be due to the fact that we overexpressed mammalian SUMOs 
instead of Drosophila Smt3: Smt3 is homolog to SUMO2/3 but the existing differences could 
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cause the homologs to act differently (Ureña et al 2015). Another hypothesis could be that, 
similar to what happen in the PcG bodies, the presence of SUMOs influences the size of the PcG 
bodies in opposite ways in human versus Drosophila cells (Gonzalez et al., 2014). The optimal 
condition to analyze Salm localization in presence of Smt3 would implicate the endogenous 
expression of Salm in Drosophila cells. However, there are not available cell lines that express 
endogenous Salm, while the overexpression of Salm is deleterious for the cells. For those 
reasons, we adopted U2OS cells as a model system. Our results showed that the localization of 
either SALL1 or Salm in these cells does not depend on their SUMOylation status, as mutants in 
acceptor lysines do not show apparent differences in localization with their WT counterpart. 
Therefore, our hypothesis is that the localization of SALL1 and Salm does not depend on their 
SUMOylation status, but on the presence of putative SIM motifs in their aminoacidic sequences. 
It would be important to demonstrate this hypothesis with future experiments and to determine 
whether certain factors need to be SUMOylated to be able to interact with SALL1/Salm.  
 
4. E3 ligases involved in SALL SUMOylation  
 
E3 ligases are enzymes that promote SUMOylation and can show specificity for their 
substrates. Since our long term aim is to understand the role of SUMOylation on SALL function, 
we focused on the identification of specific SUMO E3 ligases. Some lines of evidences directed 
our interest to the analysis of CBX4/Pc ligases. First, we identified CBX4 as an interactor of 
SALL1 through the BioID screen; second, we observed a partial colocalization of Salm and Pc in 
the PG cells. Biochemical evidences suggested that the interaction between SALL1 and CBX4 is 
direct, not requiring a third party. In addition, our results indicated that CBX4 could enhance 
SALL1 SUMOylation in vitro. The fact that SALL1 and CBX4 did not colocalize in the nuclear 
PcG bodies and the PLA confirmation of the interaction between these two transcription factors, 
supports the idea that these factors interact in the nucleoplasm. Interestingly, our experiments 
revealed an unexpected role of SALL1 on the regulation of CBX4: in presence of SALL1 we 
reported an increase in the SUMOylation of CBX4, as well as an increase in the number of PcG 
bodies. Assuming the relationship between these two proteins, our data could suggest and 
hypothetical E3 ligase activity for both proteins (Fig. 57). The increase in the number of PcG 
bodies in presence of SALL1 could also reveal a role for this transcription factor in the function 
of CBX4/Pc, as the PcG bodies are involved in the transcriptional repression of CBX4/Pc target 
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loci. The existence of modulators of the Pc function is an active area of research at the moment, 
and it would be very pertinent to confirm the role of SALL1 on this function. The role of SALL1 
could be based on the stabilization of CBX4/Pc protein or on changes in the affinity of CBX4/Pc 
for its target DNA or interacting proteins. In any of these cases, it would be relevant to perform 
further investigation to elucidate the cross-relationship between SALL and CBX4/Pc proteins. 
 
 
Figure 57. Schematically representation of the hypothetical function of SALL1 and CBX4. CBX4, 
as E3 ligase, could be involved in SALL1 SUMOylation. Our data suggest that, in turn, SALL1 could be 
involved in CBX4 SUMOylation and stabilization. 
 
 
4.1. Analysis of the relationship between Drosophila Salm and Pc 
 
Drosophila Salm and Pc, differently from their mammalian counterparts, show 
partial colocalization in Drosophila cultured cells and, more importantly, in steroidogenic 
tissues: Salm and Pc colocalize in the PG at the end of the L3 instar, when the level of ecdysone 
is high at the onset of pupariation. Then, Salm translocates to the nucleolus for a short lapse of 
time, being this a particular behavior not reported for other known transcription factor as Osa, 
HP1 or PEP. The direct interaction and the colocalization of SALL and Pc proteins would 
suggest a functional relationship between these factors. To explore this possibility, we turned to 
Drosophila, more specifically to the Drosophila wing as a model system. However, the 
transcriptional relationship between Salm and Pc hinder the analysis of the role of Pc on Salm at 
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the post-translational level: Pc represses the expression of Ubx in the wing, being this in turn a 
transcriptional repressor of salm. To overcome this difficulty, we performed several genetic 
experiments, including overexpression of Salm and Salr, either the WT or SUMO-modified and 
mutant forms, in a background where Pc and Ubx were silenced, as well as a transheterozygous 
analysis between mutants of Pc, the SUMOylation machinery and sall. From this battery of 
experiments, we could extract the following conclusions. First, the wings that overexpress WT 
salm in a Pci background are significantly smaller than wings that overexpress it in a WT 
background, indicating that the presence of Pc is relevant for the phenotype. Second, the 
overexpression of the constitutively SUMOylated or mutant forms of Salm rescues the Pci 
phenotype to a lesser extent than the WT counterpart, supporting the idea that the SUMOylation 
status if the protein is relevant for the rescue of the Pci phenotype. In this respect, it is puzzling 
that the constitutively SUMOylated and the mutant form of Salm behave in a similar way, 
despite the fact that they are modified in opposite ways in relation to SUMO. Fourth, the mutant 
form of Salr has a higher capacity to rescue the Pci phenotype than the constitutively 
SUMOylated and the WT forms. This result is in agreement to the previously reported 
enhancement of Salr activity when its SUMOylation is impeded (Sánchez et al., 2010). However, 
the mutation of the SUMOylation site should be irrelevant in a background where the putative 
E3 ligase is mutated. Fifth, our transheterozygous analysis shows a mild genetic interaction 
between Pc and the SUMOylation machinery during wing development. And sixth, Pc interacts 
genetically with sall genes in our heterozygous analysis in the wing. However, this interaction is 
counterintuitive, keeping in mind that the reduction of Pc significantly rescues the phenotype 
caused by the reduction of sall genes. 
Taken together, these results indicate an interaction between Sall factors and Pc in 
the wing, although we cannot conclude whether this interaction is post-translational or not. We 
corroborated a previous observation in which SUMOylation influences the role of Sall proteins 
in the wing in opposite directions, underlying a major effect of SUMOylation on Salr versus 
Salm. Whether this difference depends on Pc is not clear and would deserve further studies.  
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I. The bioSmt3 system, coupled with Mass Spectrometry is an efficient tool to identify 
SUMOylated proteins in cells and in vivo in Drosophila. 
 
II. Use of multicistronic vector pAc5-STABLE2-Neo in bioSmt3 system is necessary for 
efficiency of methodology in cells and in vivo. 
 
III. The sensitivity of the bioSmt3 system allows the detection of the SUMOylation of 
endogenous proteins. 
 
IV. The bioUbL system is suitable for the study of UbL post-translational modifications in 
mammalian cells, as demonstrated with the bioSUMO3 and bioUFM1 studies. 
 
V. SALL proteins are SUMOylated in mammalian cells. Human SALL1 SUMOylation 
resides in lysines K571, K592, K982 and/or K1086, while Drosophila Salm 
SUMOylation resides in lysine K641. 
 
VI. SALL proteins localize in nuclear domains and partially colocalize with bioSUMO and 
endogenous SUMO.  
 
VII. SALL1 interacts directly with SUMO2/3 in the nucleus. 
 
VIII. CBX4 was identified as a putative interactor of human SALL1 in the BioID screening. 
 
IX. SALL1 and CBX4 proteins interact directly, possibly in the nucleoplasm. 
 
X. CBX4 could be implicated in SALL1 SUMOylation, while SALL1 could influence 
CBX4 SUMOylation and stability.  
 
XI. The expression of SALL1 increases the number of PcG bodies in U2OS cells. 
 
XII. Drosophila Salm and Pc colocalize in vivo in the PG cells, at the end of the third instar 
larva, during the hormonal peak. 
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XIII. Drosophila salm and Pc interact genetically during wing development. However, we 
could not demonstrate a post-translational role for Pc on Sall proteins in the wing.  
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APPENDIX I. List of proteins conjugated by bioSmt3 detected in S2R+ Drosophila cells. 
Protein names Gene names FBID KEY 
ANNOTATION 
SYMBOL 
Number 
of 
Proteins Peptides PEP 
Average 
Intensity 
bioSmt3/Ctrl 
 
lwr FBgn0010602 CG3018 1 16 0 4,20E+04 
U1 small nuclear ribonucleoprotein 70 kDa snRNP-U1-70K FBgn0016978 CG8749 1 24 3,184E-100 2,43E+03 
Otefin Ote FBgn0266420 CG5581 1 23 0 2,13E+03 
 
sip2 FBgn0031878 CG9188 6 37 0 2,13E+03 
 
CG4806 FBgn0260456 CG4806 3 38 0 2,10E+03 
 
Map60 FBgn0010342 CG1825 2 24 0 2,05E+03 
RuvB-like helicase 1 pont FBgn0040078 CG4003 1 20 0 1,61E+03 
 
CG9300 FBgn0036886 CG9300 1 25 0 1,53E+03 
T-complex protein 1 subunit gamma Cctgamma FBgn0015019 CG8977 2 33 0 1,51E+03 
 
CG7839 FBgn0036124 CG7839 3 50 0 1,41E+03 
 
Sym FBgn0037371 CG2097 1 42 0 1,39E+03 
 
CG11123 FBgn0033169 CG11123 1 27 0 1,19E+03 
Eukaryotic translation initiation factor 2 subunit 3 Su(var)3-9 FBgn0263755 CG43664 5 23 3,1E-212 1,17E+03 
Cytoplasmic dynein 1 intermediate chain sw FBgn0003654 CG18000 27 17 7,639E-195 1,15E+03 
 
CG4564 FBgn0263993 CG43736 2 23 0 1,14E+03 
 
Vap-33A FBgn0029687 CG5014 4 9 8,284E-95 1,13E+03 
 
Incenp FBgn0260991 CG12165 3 30 0 1,11E+03 
 
Tpr2 FBgn0032586 CG4599 3 22 0 1,09E+03 
H/ACA ribonucleoprotein complex subunit 4 Nop60B FBgn0259937 CG3333 5 19 2,3926E-92 1,06E+03 
Eukaryotic translation initiation factor 3 subunit J Adam FBgn0027619 CG12131 1 15 2,646E-151 1,02E+03 
 
Uba2 FBgn0029113 CG7528 3 19 5,801E-141 9,77E+02 
Lysine-specific demethylase NO66 CG2982 FBgn0266570 CG2982 2 25 4,173E-143 9,02E+02 
 
Zinc finger protein CG2199 CG2199 FBgn0035213 CG2199 3 21 0 8,93E+02 
 
prod FBgn0014269 CG18608 2 18 0 8,68E+02 
DNA topoisomerase 2 Top2 FBgn0003732 CG10223 2 55 4,033E-303 8,56E+02 
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Serine/threonine-protein phosphatase 4 regulatory subunit 2 PPP4R2r FBgn0030208 CG2890 7 28 0 8,08E+02 
 
kuk FBgn0038476 CG5175 2 23 0 7,98E+02 
Bifunctional glutamate/proline--tRNA ligase Aats-glupro FBgn0005674 CG5394 3 113 0 7,90E+02 
Lamin Dm0 Lam FBgn0002525 CG6944 1 61 0 7,86E+02 
 
qkr58E-1 FBgn0022986 CG3613 2 22 0 7,83E+02 
 
eIF4AIII FBgn0037573 CG7483 2 17 1,387E-138 7,73E+02 
H/ACA ribonucleoprotein complex subunit 2-like protein NHP2 FBgn0029148 CG5258 1 8 2,4096E-26 7,66E+02 
 
smt3 FBgn0264922 CG4494 1 12 0 7,35E+02 
40S ribosomal protein S3 RpS3 FBgn0002622 CG6779 3 17 9,954E-50 7,16E+02 
Eukaryotic translation initiation factor 2 subunit 1 eIF-2alpha FBgn0261609 CG9946 1 15 2,6329E-57 6,44E+02 
 
CG10496 FBgn0034631 CG10496 1 15 9,341E-156 6,26E+02 
 
Spp FBgn0031260 CG11840 3 4 2,9596E-12 6,10E+02 
Ran-binding protein 16 Ranbp16 FBgn0053180 CG33180 1 21 1,132E-103 5,96E+02 
Transcription termination factor 2 lds FBgn0002542 CG2684 2 34 6,548E-126 5,77E+02 
Dynein heavy chain, cytoplasmic Dhc64C FBgn0261797 CG7507 3 81 0 5,73E+02 
Kinesin-like protein Klp10A Klp10A FBgn0030268 CG1453 2 24 1,195E-302 5,68E+02 
Nuclear cap-binding protein subunit 1 Cbp80 FBgn0022942 CG7035 2 18 2,2023E-92 5,45E+02 
Proliferating cell nuclear antigen PCNA FBgn0005655 CG9193 2 9 1,2798E-68 5,43E+02 
 
CG10627 FBgn0036298 CG10627 1 16 6,722E-104 5,22E+02 
 
 CG11376 FBgn0031216 CG11376 1 2 0,0010894 5,07E+02 
 
blanks FBgn0035608 CG10630 2 17 3,23E-128 5,06E+02 
 
nop5 FBgn0026196 CG10206 4 19 2,009E-256 4,75E+02 
Cytochrome b5 Cyt-b5 FBgn0264294 CG2140 4 2 1,3557E-39 4,73E+02 
 
ebd1 FBgn0035153 CG3371 1 24 7,946E-209 4,60E+02 
 
Saf-B FBgn0039229 CG6995 4 31 1,281E-304 4,46E+02 
 
tum FBgn0086356 CG13345 3 17 2,966E-254 4,43E+02 
40S ribosomal protein SA sta FBgn0003517 CG14792 3 10 1,238E-202 4,42E+02 
Ubiquitin specific protease 14 Usp14 FBgn0032216 CG5384 1 16 3,698E-130 4,34E+02 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 
kDa subunit Ost48 FBgn0014868 CG9022 1 12 4,399E-160 4,28E+02 
 
pav FBgn0011692 CG1258 4 22 6,075E-241 4,28E+02 
 
Hpr1 FBgn0037382 CG2031 1 25 8,151E-252 4,27E+02 
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CG17494 FBgn0040011 CG17494 3 28 6,181E-193 4,21E+02 
Nascent polypeptide-associated complex subunit alpha Nacalpha FBgn0086904 CG8759 1 7 3,873E-114 4,13E+02 
RRP15-like protein CG3817 FBgn0038275 CG3817 2 11 1,787E-111 4,02E+02 
 
CG10373 FBgn0032704 CG10373 4 5 0 3,87E+02 
 
Bruce FBgn0266717 CG6303 4 41 2,035E-245 3,73E+02 
 
Hlc FBgn0001565 CG1666 2 17 1,962E-85 3,68E+02 
Replication factor C subunit 1 Gnf1 FBgn0004913 CG1119 1 23 8,553E-195 3,63E+02 
 
Su(var)2-10 FBgn0003612 CG8068 11 10 1,88E-114 3,55E+02 
Eukaryotic peptide chain release factor subunit 1 eRF1 FBgn0036974 CG5605 2 9 1,114E-192 3,53E+02 
 
Rtnl1 FBgn0053113 CG33113 9 17 6,158E-246 3,53E+02 
 
Dlic FBgn0030276 CG1938 2 16 4,484E-98 3,51E+02 
60S ribosomal protein L4 RpL4 FBgn0003279 CG5502 2 14 7,4005E-69 3,49E+02 
Protein suppressor of variegation 3-7 Su(var)3-7 FBgn0003598 CG8599 4 16 4,623E-271 3,48E+02 
 
CG4289 FBgn0037020 CG4289 1 9 3,941E-124 3,35E+02 
 
ADD1 FBgn0026573 CG8290 4 20 1,03E-128 3,33E+02 
 
nudC FBgn0021768 CG9710 1 16 2,68E-189 3,30E+02 
 
CG7897 FBgn0266580 CG7897 3 42 3,872E-231 3,22E+02 
Transcription factor kayak, isoforms D/sro kay FBgn0001297 CG33956 2 11 4,004E-218 3,21E+02 
 
Protein tramtrack, beta isoform ttk FBgn0003870 CG1856 2 14 9,476E-267 3,18E+02 
 
DIP1 FBgn0024807 CG17686 15 4 1,077E-75 2,98E+02 
 
CG15816 FBgn0261570 CG42684 1 2 8,7724E-05 2,97E+02 
60S acidic ribosomal protein P0 RpLP0 FBgn0000100 CG7490 1 11 1,136E-126 2,93E+02 
 
MAN1 FBgn0034962 CG3167 2 17 2,6934E-92 2,93E+02 
 
 CG13773 FBgn0042092 CG13773 1 8 2,0311E-30 2,92E+02 
 
DMAP1 FBgn0034537 CG11132 1 19 5,375E-102 2,91E+02 
 
PpD3 FBgn0005777 CG8402 1 20 7,598E-121 2,91E+02 
 
Nup98-96 FBgn0039120 CG10198 3 28 3,242E-196 2,88E+02 
Ubiquitin carboxyl-terminal hydrolase 7 Usp7 FBgn0030366 CG1490 1 30 4,247E-287 2,84E+02 
SH3 domain-binding glutamic acid-rich protein homolog Sh3beta FBgn0035772 CG8582 1 12 1,515E-162 2,77E+02 
Myeloid leukemia factor Mlf FBgn0034051 CG8295 9 7 3,378E-122 2,76E+02 
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Chromodomain-helicase-DNA-binding protein Mi-2 homolog Mi-2 FBgn0262519 CG8103 16 38 9,767E-165 2,62E+02 
 
 CG7946 FBgn0039743 CG7946 1 15 5,7526E-91 2,59E+02 
Protein slender lobes sle FBgn0037810 CG12819 3 30 0 2,58E+02 
 
mei-38 FBgn0260986 CG14781 3 6 1,0991E-91 2,56E+02 
Hsp90 co-chaperone Cdc37 Cdc37 FBgn0011573 CG12019 3 12 3,892E-185 2,56E+02 
Myosin heavy chain, non-muscle zip FBgn0265434 CG15792 4 89 0 2,53E+02 
 
crp FBgn0001994 CG7664 3 16 6,89E-132 2,51E+02 
Probable elongation factor 1-beta Ef1beta FBgn0028737 CG6341 1 10 1,8374E-58 2,44E+02 
E3 ubiquitin-protein ligase hyd hyd FBgn0002431 CG9484 2 45 0 2,44E+02 
 
E(var)3-9 FBgn0260243 CG11971 8 13 1,685E-196 2,43E+02 
 
CG1815 FBgn0039863 CG1815 4 24 6,914E-170 2,40E+02 
 
Dref FBgn0015664 CG5838 3 14 3,7015E-81 2,38E+02 
Chromosomal serine/threonine-protein kinase JIL-1 JIL-1 FBgn0020412 CG6297 3 17 7,452E-207 2,37E+02 
Septin-1 Sep1 FBgn0011710 CG1403 2 8 1,806E-129 2,36E+02 
T-complex protein 1 subunit alpha T-cp1 FBgn0003676 CG5374 2 17 1,477E-119 2,32E+02 
 
 CG17068 FBgn0031098 CG17068 1 13 5,365E-223 2,26E+02 
26S protease regulatory subunit 4 Rpt2 FBgn0015282 CG5289 1 13 1,8506E-76 2,23E+02 
 
Mrp4 FBgn0263316 CG14709 11 23 3,3474E-98 2,22E+02 
Dosage compensation regulator mle FBgn0002774 CG11680 24 30 4,912E-206 2,22E+02 
Transcription factor AP-1 Jra FBgn0001291 CG2275 1 7 1,5698E-37 2,21E+02 
 
Mtor FBgn0013756 CG8274 4 69 0 2,20E+02 
 
smid FBgn0016983 CG8571 5 17 2,6708E-98 2,18E+02 
 
stwl FBgn0003459 CG3836 2 23 8,033E-212 2,15E+02 
 
Uba1 FBgn0023143 CG1782 1 31 0 2,15E+02 
60S acidic ribosomal protein P2 RpLP2 FBgn0003274 CG4918 2 3 1,6568E-08 2,11E+02 
 
CG1024 FBgn0027514 CG1024 3 12 4,358E-98 2,11E+02 
 
CG3287 FBgn0265003 CG44154 2 14 3,164E-239 2,07E+02 
 
Rpn1 FBgn0028695 CG7762 1 19 3,4961E-54 2,04E+02 
 
CG9123 FBgn0030629 CG9123 25 11 2,2589E-52 2,03E+02 
Probable arginine--tRNA ligase, cytoplasmic Aats-arg FBgn0027093 CG9020 1 21 3,2894E-68 1,98E+02 
 
Su(var)2-HP2 FBgn0026427 CG12864 3 26 3,66E-140 1,96E+02 
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Zinc finger protein hangover hang FBgn0026575 CG32575 4 19 9,062E-178 1,95E+02 
 
coil FBgn0033265 CG8710 4 18 9,1873E-79 1,94E+02 
Actin-42A Act42A FBgn0000043 CG12051 1 18 0 1,93E+02 
 
CG11092 FBgn0027537 CG11092 4 21 2,301E-123 1,92E+02 
 
CG12304 FBgn0036515 CG12304 4 9 2,918E-24 1,92E+02 
Zinc finger protein ush ush FBgn0003963 CG2762 2 12 2,2434E-90 1,88E+02 
Kinesin heavy chain Khc FBgn0001308 CG7765 2 28 1,692E-178 1,87E+02 
 
CG13730 FBgn0052176 CG32176 2 9 1,1504E-91 1,84E+02 
 
Pcf11 FBgn0264962 CG10228 3 25 1,035E-132 1,84E+02 
Phosphatidylinositol-binding clathrin assembly protein LAP lap FBgn0086372 CG2520 4 10 3,051E-100 1,82E+02 
 
CG7261 FBgn0027509 CG7261 2 18 5,9973E-72 1,82E+02 
 CG1316 FBgn0035526 CG1316 1 7 3,4675E-32 1,82E+02 
 
 
 mrt FBgn0039507 CG3361 2 17 2,502E-137 1,81E+02 
F-box-like/WD repeat-containing protein ebi ebi FBgn0263933 CG4063 3 10 1,463E-256 1,80E+02 
 
Bifunctional protein BirA birA 
  
1 27 0 1,79E+02 
26S proteasome non-ATPase regulatory subunit 1 Rpn2 FBgn0028692 CG11888 2 20 7,528E-114 1,76E+02 
T-complex protein 1 subunit delta CG5525 FBgn0032444 CG5525 1 10 5,299E-65 1,74E+02 
Cleavage and polyadenylation specificity factor subunit 1 Cpsf160 FBgn0024698 CG10110 2 18 9,2798E-64 1,74E+02 
 
CG7262 FBgn0038274 CG7262 1 19 1,628E-123 1,71E+02 
Centrosome-associated zinc finger protein CP190 Cp190 FBgn0000283 CG6384 1 19 1,25E-252 1,71E+02 
Casein kinase I isoform alpha CkIalpha FBgn0015024 CG2028 3 9 2,3894E-22 1,71E+02 
 
CG1416 FBgn0032961 CG1416 2 9 7,5123E-97 1,70E+02 
Polycomb protein PHO pho FBgn0002521 CG17743 1 6 1,5549E-16 1,69E+02 
Putative fatty acyl-CoA reductase CG8306 CG8306 FBgn0034142 CG8306 2 10 1,1121E-66 1,68E+02 
Surfeit locus protein 6 homolog Surf6 FBgn0038746 CG4510 1 8 2,8026E-15 1,67E+02 
Enhancer of mRNA-decapping protein 4 homolog Ge-1 FBgn0032340 CG6181 1 27 6,6692E-78 1,65E+02 
 
CG2064 FBgn0033205 CG2064 5 11 1,8442E-37 1,63E+02 
 
CG7265 FBgn0038272 CG7265 1 9 2,888E-185 1,62E+02 
 
cg FBgn0000289 CG8367 13 12 4,1E-48 1,61E+02 
Serine-arginine protein 55 B52 FBgn0004587 CG10851 9 7 1,8171E-37 1,61E+02 
APPENDICES  
148 
 
Longitudinals lacking protein, isoforms F/I/K/T lola FBgn0005630 CG12052 1 9 1,104E-194 1,58E+02 
 
tho2 FBgn0031390 CG31671 3 27 1,049E-264 1,57E+02 
 
CG17090 FBgn0035142 CG17090 4 15 8,6649E-76 1,56E+02 
 
Apc FBgn0015589 CG1451 5 5 3,893E-14 1,55E+02 
Heterogeneous nuclear ribonucleoprotein 27C Hrb27C FBgn0004838 CG10377 10 5 1,074E-128 1,54E+02 
 
unc-45 FBgn0010812 CG2708 2 18 8,1125E-89 1,53E+02 
 
zf30C FBgn0270924 CG3998 2 12 7,6031E-44 1,52E+02 
 
wol FBgn0261020 CG7870 1 6 5,3243E-20 1,51E+02 
 
BtbVII FBgn0263108 CG43365 3 5 1,3566E-14 1,51E+02 
 
Bipolar kinesin KRP-130 Klp61F FBgn0004378 CG9191 4 31 1,26E-114 1,50E+02 
 
CG11107 FBgn0033160 CG11107 1 13 9,9659E-83 1,47E+02 
 
CG7033 FBgn0030086 CG7033 2 31 0 1,45E+02 
 
Rs1 FBgn0021995 CG2173 2 15 7,5499E-86 1,44E+02 
Cofilin/actin-depolymerizing factor homolog tsr FBgn0011726 CG4254 1 11 2,048E-169 1,43E+02 
Elongation factor 1-gamma Ef1gamma FBgn0029176 CG11901 1 13 7,22E-204 1,42E+02 
 
msps FBgn0027948 CG5000 5 38 1,789E-103 1,41E+02 
 
Nup358 FBgn0039302 CG11856 3 39 5,295E-205 1,41E+02 
F-actin-capping protein subunit beta cpb FBgn0011570 CG17158 1 8 1,1E-53 1,38E+02 
Protein extra bases kra FBgn0250753 CG2922 1 10 4,8781E-51 1,37E+02 
 
east FBgn0261954 CG4399 4 19 0 1,35E+02 
 
p53 FBgn0039044 CG33336 5 7 1,0992E-21 1,35E+02 
Protein held out wings how FBgn0264491 CG10293 6 8 2,2933E-27 1,34E+02 
Hsc70-interacting protein 2 HIP FBgn0260484 CG32789 4 9 6,4516E-66 1,33E+02 
 
mod(mdg4) FBgn0002781 CG32491 1 10 1,737E-142 1,32E+02 
Clathrin heavy chain Chc FBgn0000319 CG9012 1 24 9,279E-102 1,30E+02 
 
Df31 FBgn0022893 CG2207 1 15 3,013E-262 1,28E+02 
 
CG8569  FBgn0033752 CG8569 1 10 8,7411E-27 1,27E+02 
 
VhaM8.9 FBgn0037671 CG8444 1 7 1,304E-24 1,27E+02 
 
bon FBgn0023097 CG5206 3 12 1,7611E-86 1,27E+02 
THO complex subunit 5 thoc5 FBgn0034939 CG2980 1 7 2,0078E-68 1,26E+02 
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Lysine-specific demethylase lid lid FBgn0031759 CG9088 1 20 2,618E-106 1,25E+02 
 
CG12567 FBgn0039958 CG12567 8 6 1,1117E-25 1,25E+02 
Ribonucleoside-diphosphate reductase large subunit RnrL FBgn0011703 CG5371 1 16 3,105E-119 1,24E+02 
 
GATA-binding factor A pnr FBgn0003117 CG3978 4 5 1,6737E-73 1,23E+02 
 
Aats-asp FBgn0002069 CG3821 2 14 0 1,21E+02 
DNA replication licensing factor Mcm5 Mcm5 FBgn0017577 CG4082 1 14 4,0481E-42 1,19E+02 
 
 Cpsf73 FBgn0261065 CG7698 1 13 5,1989E-63 1,19E+02 
Protein odr-4 homolog CG10616 FBgn0036286 CG10616 3 6 3,5303E-96 1,19E+02 
 
MESR4 FBgn0034240 CG4903 4 14 5,3546E-80 1,18E+02 
Polynucleotide 5-hydroxyl-kinase NOL9 CG8414 FBgn0034073 CG8414 1 15 2,015E-171 1,18E+02 
 
Aats-thr FBgn0027081 CG5353 4 18 1,6456E-70 1,17E+02 
 
homer FBgn0025777 CG11324 5 11 1,4405E-32 1,17E+02 
 
CG8331 FBgn0033906 CG8331 5 2 4,1636E-06 1,17E+02 
Protein painting of fourth Pof FBgn0035047 CG3691 1 8 7,7358E-30 1,16E+02 
Eukaryotic translation initiation factor 4E eIF-4E FBgn0015218 CG4035 4 6 5,2967E-27 1,16E+02 
 
CG13096 FBgn0032050 CG13096 2 12 7,0451E-50 1,15E+02 
 
mbm FBgn0086912 CG11604 1 5 2,6948E-26 1,13E+02 
Nuclear pore complex protein Nup214 Nup214 FBgn0010660 CG3820 1 19 1,452E-102 1,12E+02 
 
CG5482 FBgn0034368 CG5482 1 9 1,5915E-27 1,12E+02 
 
l(2)35Df FBgn0001986 CG4152 1 19 3,0464E-53 1,12E+02 
 
Spindly FBgn0031549 CG15415 2 14 4,5584E-49 1,11E+02 
 
Rpn6 FBgn0028689 CG10149 2 10 4,6638E-44 1,08E+02 
 
CG4769 FBgn0035600 CG4769 1 3 2,2799E-08 1,08E+02 
 
tou FBgn0033636 CG10897 4 25 1,75E-100 1,07E+02 
DNA ligase 1 DNA-ligI FBgn0262619 CG5602 1 11 2,7478E-71 1,06E+02 
 
CG12288 FBgn0032620 CG12288 2 6 7,2799E-94 1,06E+02 
Nuclear export mediator factor NEMF homolog Clbn FBgn0259152 CG11847 3 14 3,0599E-43 1,06E+02 
 
Lhr FBgn0034217 CG18468 3 9 7,5046E-43 1,05E+02 
 
Sin FBgn0028402 CG10582 5 12 2,7274E-47 1,03E+02 
 
Sin3A FBgn0022764 CG8815 12 19 2,2528E-90 1,03E+02 
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Rpt1 FBgn0028687 CG1341 2 14 1,9657E-69 1,02E+02 
 
Elf FBgn0020443 CG6382 2 13 1,7252E-57 1,02E+02 
 
Sec61alpha FBgn0086357 CG9539 2 3 3,6456E-07 1,02E+02 
DNA topoisomerase 1 Top1 FBgn0004924 CG6146 5 12 1,0715E-62 1,01E+02 
 
MSBP FBgn0030703 CG9066 1 9 9,2967E-64 1,01E+02 
 
FK506-binding protein 59 FKBP59 FBgn0029174 CG4535 1 7 3,2859E-19 1,00E+02 
60S ribosomal protein L22 RpL22 FBgn0015288 CG7434 1 11 3,149E-102 9,98E+01 
 
D19A FBgn0022935 CG10269 4 13 1,524E-113 9,92E+01 
 
Nup133 FBgn0039004 CG6958 11 14 1,1733E-74 9,77E+01 
 
cher FBgn0014141 CG3937 11 47 4,499E-161 9,74E+01 
 
CG7246 FBgn0030081 CG7246 6 12 4,0355E-35 9,64E+01 
60S ribosomal protein L14 RpL14 FBgn0017579 CG6253 3 4 1,2078E-12 9,63E+01 
ATP-dependent RNA helicase WM6 Hel25E FBgn0014189 CG7269 2 10 6,1568E-29 9,58E+01 
 
Nup107 FBgn0027868 CG6743 12 14 2,0001E-56 9,49E+01 
 
 CG8436 FBgn0037670 CG8436 1 7 1,9162E-59 9,45E+01 
Adenylyl cyclase-associated protein capt FBgn0261458 CG33979 3 6 1,3898E-69 9,40E+01 
 
Gdi FBgn0004868 CG4422 2 12 6,8992E-40 9,40E+01 
 
CG12301 FBgn0036514 CG12301 9 10 7,8819E-64 9,33E+01 
Integrator complex subunit 3 homolog IntS3 FBgn0262117 CG17665 2 10 2,2802E-25 9,32E+01 
Sterile alpha and TIR motif-containing protein 1 Ect4 FBgn0262579 CG43119 6 16 9,352E-188 9,24E+01 
 
mdy FBgn0004797 CG31991 1 18 3,3899E-90 9,18E+01 
 
ste24a FBgn0034176 CG9000 1 6 1,7359E-41 9,12E+01 
Protein FAM50 homolog CG12259 FBgn0039557 CG12259 1 5 6,4654E-23 9,10E+01 
 
row FBgn0033998 CG8092 3 15 4,8755E-59 9,03E+01 
Eukaryotic translation initiation factor 3 subunit M Tango7 FBgn0033902 CG8309 1 6 2,1204E-35 8,96E+01 
Chromatin-remodeling complex ATPase chain Iswi Iswi FBgn0011604 CG8625 2 14 6,5658E-42 8,91E+01 
Transcription factor GAGA Trl FBgn0013263 CG33261 14 4 1,6193E-37 8,88E+01 
 
CG8258 FBgn0033342 CG8258 1 24 1,358E-145 8,82E+01 
Protein suppressor of hairy wing su(Hw) FBgn0003567 CG8573 1 9 2,1586E-51 8,81E+01 
 
crol FBgn0020309 CG14938 5 12 6,0847E-42 8,79E+01 
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Dp1 FBgn0027835 CG5170 4 35 6,532E-140 8,71E+01 
 
CG5787 FBgn0032454 CG5787 1 11 6,7342E-44 8,69E+01 
 CG8858 FBgn0033698 CG8858 1 22 2,6756E-93 8,61E+01 
Eukaryotic translation initiation factor 3 subunit  eIF3-S10 FBgn0037249 CG9805 2 29 5,138E-100 8,45E+01 
 
CG8552 FBgn0031990 CG8552 2 12 1,748E-174 8,40E+01 
 
Nup75 FBgn0034310 CG5733 8 12 1,1914E-32 8,34E+01 
 
Past1 FBgn0016693 CG6148 5 14 3,6651E-33 8,31E+01 
 
ade5 FBgn0020513 CG3989 4 6 4,0633E-16 8,16E+01 
Annexin;Annexin-B10 AnxB10 FBgn0000084 CG9579 7 12 2,2905E-42 8,14E+01 
 
pod1 FBgn0029903 CG4532 4 11 4,5864E-67 8,00E+01 
Protein dopey-1 homolog CG15099 FBgn0034400 CG15099 1 24 6,41E-114 7,97E+01 
 
Aats-val FBgn0027079 CG4062 2 13 2,2689E-50 7,82E+01 
 
dgt1 FBgn0039710 CG18041 1 6 6,518E-56 7,74E+01 
Serendipity locus protein delta Sry-delta FBgn0003512 CG17958 1 5 2,3912E-14 7,68E+01 
GTP-binding protein CG1354 CG1354 FBgn0030151 CG1354 4 8 1,9782E-26 7,66E+01 
 
Rpn5 FBgn0028690 CG1100 1 15 1,8891E-43 7,62E+01 
Eukaryotic translation initiation factor 3 subunit C eIF3-S8 FBgn0034258 CG4954 1 17 4,9692E-52 7,61E+01 
Ribonucleoprotein RB97D Rb97D FBgn0004903 CG6354 5 7 3,4768E-17 7,39E+01 
 
CG10462 FBgn0032815 CG10462 4 11 3,4916E-88 7,26E+01 
 
CG12608 FBgn0030630 CG12608 10 9 2,5773E-67 7,21E+01 
Probable glutamine--tRNA ligase Aats-gln FBgn0027090 CG10506 1 12 3,1384E-56 7,14E+01 
 
alt FBgn0038535 CG18212 3 17 2,392E-182 7,10E+01 
 
ATPCL FBgn0020236 CG8322 4 13 1,9241E-80 7,09E+01 
Alanine--tRNA ligase, cytoplasmic Aats-ala FBgn0027094 CG13391 5 12 4,9086E-88 7,09E+01 
 
CG9740 FBgn0037669 CG9740 1 4 1,1813E-11 7,09E+01 
 
Chro FBgn0044324 CG10712 3 10 1,0915E-90 7,07E+01 
 
CG3071 FBgn0023527 CG3071 2 7 1,842E-15 7,05E+01 
 
CG1832 FBgn0032979 CG1832 3 3 6,0169E-35 7,05E+01 
 
CG3815 FBgn0029861 CG3815 1 9 1,002E-62 7,04E+01 
 
 CG2662 FBgn0024993 CG2662 2 6 7,9515E-28 7,03E+01 
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UPF0505 protein CG8202 CG8202 FBgn0037622 CG8202 2 10 1,5519E-27 6,94E+01 
 
CG6686 FBgn0032388 CG6686 4 10 2,9787E-37 6,91E+01 
La protein homolog La FBgn0011638 CG10922 3 10 3,8733E-34 6,86E+01 
 
CG12325 FBgn0033557 CG12325 1 7 2,3527E-22 6,81E+01 
 
 CG3163 FBgn0034961 CG3163 1 8 8,2945E-22 6,77E+01 
FACT complex subunit Ssrp1 Ssrp FBgn0010278 CG4817 22 13 6,7142E-44 6,75E+01 
Tropomyosin-1, isoforms 9A/A/B Tm1 FBgn0003721 CG4898 15 7 5,3456E-39 6,73E+01 
 
Aats-tyr FBgn0027080 CG4561 1 10 4,3312E-29 6,69E+01 
 
CG6241 FBgn0037792 CG6241 1 9 1,2879E-50 6,68E+01 
Catalase Cat FBgn0000261 CG6871 1 9 2,4232E-81 6,65E+01 
Eukaryotic initiation factor 4A eIF-4a FBgn0001942 CG9075 4 7 1,8081E-86 6,63E+01 
 
REG FBgn0029133 CG1591 1 6 7,6905E-15 6,62E+01 
 
CG1703 FBgn0030321 CG1703 22 18 1,3279E-51 6,59E+01 
NAD-dependent protein deacetylase Sirt2 Sirt2 FBgn0038788 CG5085 2 5 6,975E-284 6,56E+01 
Calcium-transporting ATPase sarcoplasmic/endoplasmic reticulum 
type Ca-P60A FBgn0263006 CG3725 3 16 4,4201E-81 6,54E+01 
Annexin-B9;Annexin AnxB9 FBgn0000083 CG5730 5 7 2,3651E-18 6,53E+01 
Probable nucleolar GTP-binding protein 1 CG8801 FBgn0028473 CG8801 3 10 4,9015E-29 6,48E+01 
 
CG7927 FBgn0027549 CG7927 1 9 9,7244E-22 6,48E+01 
Copia protein copia\GIP FBgn0013437 - 4 4 4,8911E-17 6,47E+01 
 
bl FBgn0000193 
 
10 6 4,0393E-23 6,41E+01 
 
CG10802 FBgn0029664 CG10802 1 5 9,7147E-27 6,41E+01 
 
CG5728 FBgn0039182 CG5728 1 16 1,6156E-56 6,36E+01 
 
Cct5 FBgn0010621 CG8439 3 12 1,964E-36 6,32E+01 
 
mor FBgn0002783 CG18740 3 12 1,2364E-62 6,30E+01 
Uncharacterized protein CG4951 CG4951 FBgn0039563 CG4951 2 5 3,661E-101 6,30E+01 
 
CG33217 FBgn0053217 CG33217 2 8 8,7422E-20 6,25E+01 
 
Broad-complex core protein  br FBgn0283451 CG11491 10 5 7,8657E-87 6,25E+01 
 
39 kDa FK506-binding nuclear protein FK506-bp1 FBgn0013269 CG6226 1 6 1,0072E-25 6,24E+01 
Regucalcin regucalcin FBgn0030362 CG1803 3 12 1,673E-46 6,21E+01 
 
CG11723 FBgn0031391 CG11723 1 4 1,2163E-13 6,13E+01 
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CG13887 FBgn0035165 CG13887 1 4 9,0423E-10 6,10E+01 
60S ribosomal protein L5 RpL5 FBgn0064225 CG17489 4 8 7,4577E-20 6,08E+01 
 
Nap1 FBgn0015268 CG5330 2 5 1,8767E-25 6,05E+01 
 
CG4239 FBgn0030745 CG4239 3 2 5,3651E-14 6,04E+01 
 
pzg FBgn0259785 CG7752 1 13 1,185E-122 5,92E+01 
Heat shock protein 27 Hsp27 FBgn0001226 CG4466 1 4 2,2022E-14 5,88E+01 
 
Rrp6 FBgn0038269 CG7292 3 15 4,5928E-50 5,86E+01 
 
CG9797 FBgn0037621 CG9797 1 5 5,1533E-32 5,84E+01 
RNA-binding protein 4F Rnp4F FBgn0014024 CG3312 4 11 5,412E-149 5,82E+01 
Eukaryotic translation initiation factor 3 subunit E Int6 FBgn0025582 CG9677 2 6 1,16E-26 5,80E+01 
Caspase-8 Dredd FBgn0020381 CG7486 4 7 3,835E-108 5,80E+01 
 
CG5589 FBgn0036754 CG5589 3 7 6,8411E-50 5,78E+01 
 
nsl1 FBgn0262527 CG4699 9 7 3,3417E-64 5,77E+01 
Nuclear factor NF-kappa-B p110 subunit Rel FBgn0014018 CG11992 2 13 6,4436E-29 5,77E+01 
 
IntS4 FBgn0026679 CG12113 1 10 3,3139E-33 5,75E+01 
 
Aats-ile FBgn0027086 CG11471 1 23 8,98E-100 5,70E+01 
60S acidic ribosomal protein P1 RpLP1 FBgn0002593 CG4087 1 3 1,6872E-52 5,70E+01 
 
CG12768 FBgn0037206 CG12768 2 5 4,6713E-13 5,69E+01 
 
CG13895 FBgn0035158 CG13895 2 3 1,344E-109 5,68E+01 
RNA-binding protein 8A tsu FBgn0033378 CG8781 2 5 3,4688E-14 5,66E+01 
 
CG4729 FBgn0036623 CG4729 3 6 1,0821E-13 5,65E+01 
 
Bub3 FBgn0025457 CG7581 4 5 8,7179E-25 5,62E+01 
40S ribosomal protein S17 RpS17 FBgn0005533 CG3922 1 6 6,4722E-17 5,61E+01 
Negative elongation factor A Nelf-A FBgn0038872 CG5874 1 10 9,5939E-67 5,55E+01 
 
 
Pyruvate kinase PyK FBgn0267385 CG7070 2 15 1,376E-100 5,53E+01 
 
NTPase FBgn0024947 CG3059 4 9 2,4818E-53 5,53E+01 
Heat shock factor protein Hsf FBgn0001222 CG5748 11 12 2,0765E-88 5,52E+01 
 
Cortactin FBgn0025865 CG3637 2 28 4,166E-245 5,48E+01 
Nuclear pore complex protein Nup160 homolog Nup160 FBgn0262647 CG4738 1 9 1,2611E-58 5,48E+01 
 
CG1888 FBgn0033421 CG1888 1 8 1,9312E-28 5,41E+01 
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D19B FBgn0022699 CG10270 2 12 2,3551E-75 5,34E+01 
 
shrb FBgn0086656 CG8055 1 5 5,5149E-27 5,33E+01 
 
CG14442 FBgn0029893 CG14442 3 8 2,7195E-34 5,25E+01 
THO complex subunit 6 thoc6 FBgn0036263 CG5632 1 5 3,6359E-15 5,19E+01 
Kinesin light chain Klc FBgn0010235 CG5433 1 8 1,6176E-23 5,17E+01 
RNA-binding protein squid sqd FBgn0263396 CG16901 3 4 1,0296E-29 5,13E+01 
 
cindr FBgn0027598 CG31012 5 20 0 5,09E+01 
 
Pol32 FBgn0283467 CG3975 17 6 1,144E-16 5,09E+01 
 
Desat1 FBgn0086687 CG5887 8 4 4,102E-100 5,08E+01 
Lysyl-tRNA synthetase Aats-lys FBgn0027084 CG12141 3 17 1,1773E-47 5,04E+01 
 
CG7824 FBgn0039711 CG7824 4 4 2,8581E-23 5,02E+01 
 
Sec63 FBgn0035771 CG8583 1 9 1,2809E-21 4,97E+01 
Actin-57B Act57B FBgn0000044 CG10067 11 15 6,803E-213 4,97E+01 
 
bocks FBgn0037719 CG9424 2 5 7,6709E-18 4,92E+01 
 
Fmr1 FBgn0028734 CG6203 6 12 3,876E-141 4,91E+01 
 
CG18178 FBgn0036035 CG18178 1 5 2,3493E-28 4,89E+01 
 
CG9799 FBgn0038146 CG9799 2 10 2,3812E-26 4,88E+01 
 
CG5554 FBgn0034914 CG5554 1 4 6,3678E-09 4,87E+01 
Ribosome biogenesis protein BRX1 homolog CG11583 FBgn0035524 CG11583 1 7 1,6633E-56 4,87E+01 
 
CG7696 FBgn0051224 CG31224 3 10 2,954E-71 4,86E+01 
 
CG15100 FBgn0034401 CG15100 2 11 8,1929E-71 4,85E+01 
 
CG1371 FBgn0033482 CG1371 5 19 1,9799E-65 4,80E+01 
 
Nucleosomal histone kinase 1 ball FBgn0027889 CG6386 2 5 1,1675E-10 4,80E+01 
Guanine nucleotide-binding protein-like 3 homolog Ns1 FBgn0038473 CG3983 2 9 9,8367E-37 4,78E+01 
Probable elongation factor 1-delta eEF1delta FBgn0032198 CG4912 2 8 1,699E-102 4,74E+01 
RuvB-like helicase 2 rept FBgn0040075 CG9750 1 7 1,8192E-24 4,73E+01 
 
Zif FBgn0037446 CG10267 1 6 1,5933E-22 4,73E+01 
Embryonic polarity protein dorsal dl FBgn0260632 CG6667 4 8 3,3726E-28 4,71E+01 
 
CG8771 FBgn0033766 CG8771 2 9 8,851E-37 4,71E+01 
60S ribosomal protein L28 RpL28 FBgn0035422 CG12740 4 3 7,4883E-09 4,67E+01 
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Cnx99A FBgn0015622 CG11958 9 11 1,8558E-36 4,65E+01 
 
RpL23A FBgn0026372 CG7977 5 6 2,6935E-25 4,62E+01 
Transitional endoplasmic reticulum ATPase TER94 TER94 FBgn0261014 CG2331 5 33 5,072E-247 4,61E+01 
 
CG17337 FBgn0259979 CG17337 2 6 1,2089E-13 4,57E+01 
Ran GTPase-activating protein RanGAP FBgn0003346 CG9999 5 6 1,8637E-24 4,57E+01 
Ubiquitin-60S ribosomal protein L40; Ubi-p63E FBgn0003943 CG11624 20 6 2,609E-138 4,56E+01 
 
Zn72D FBgn0263603 CG5215 4 10 6,0223E-51 4,56E+01 
 
CG10107 FBgn0035713 CG10107 2 7 3,8274E-78 4,50E+01 
Casein kinase II subunit alpha CkIIalpha FBgn0264492 CG17520 2 6 1,4964E-39 4,49E+01 
 
CG8939 FBgn0030720 CG8939 1 6 6,7406E-50 4,49E+01 
 
CG14712 FBgn0037924 CG14712 1 13 1,9497E-52 4,43E+01 
 
CG5168 FBgn0032246 CG5168 1 4 1,2957E-14 4,43E+01 
Methionine aminopeptidase und FBgn0025117 CG4008 2 3 1,6816E-07 4,40E+01 
Box A-binding factor srp FBgn0003507 CG3992 5 3 2,1392E-26 4,38E+01 
Cysteine and histidine-rich domain-containing protein CHORD FBgn0029503 CG6198 1 5 1,3584E-31 4,36E+01 
Host cell factor;HCF N-terminal chain;HCF C-terminal chain Hcf FBgn0039904 CG1710 3 29 0 4,35E+01 
Eukaryotic translation initiation factor 2 subunit 2 eIF-2beta FBgn0004926 CG4153 2 5 5,2308E-16 4,31E+01 
 
 
 CG10333 FBgn0032690 CG10333 2 6 5,0023E-30 4,28E+01 
ATPase ASNA1 homolog CG1598 FBgn0033191 CG1598 2 4 2,8224E-48 4,27E+01 
Protein purity of essence poe FBgn0011230 CG14472 2 25 6,5749E-55 4,25E+01 
Protein peanut pnut FBgn0013726 CG8705 1 4 3,0153E-17 4,25E+01 
 
BEAF-32 FBgn0015602 CG10159 3 4 7,53E-13 4,24E+01 
Nucleoporin GLE1 CG14749 FBgn0033316 CG14749 1 11 1,2738E-34 4,20E+01 
 
pch2 FBgn0051453 CG31453 1 5 3,5016E-25 4,19E+01 
 
deltaCOP FBgn0028969 CG14813 4 6 8,9364E-23 4,13E+01 
ATP-dependent RNA helicase p62 Rm62 FBgn0003261 CG10279 8 12 1,3816E-48 4,08E+01 
Regulator of chromosome condensation Rcc1 FBgn0002638 CG10480 1 9 2,164E-36 4,08E+01 
 
Mes2 FBgn0037207 CG11100 3 4 5,1456E-23 4,08E+01 
V-type proton ATPase subunit B Vha55 FBgn0005671 CG17369 2 6 2,8671E-27 4,07E+01 
 
CG1647 FBgn0039602 CG1647 4 6 8,3242E-41 4,04E+01 
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Transcription initiation factor TFIID subunit 9 e(y)1 FBgn0000617 CG6474 2 6 1,9597E-12 4,03E+01 
 
CG4554 FBgn0034734 CG4554 2 11 3,0483E-32 4,02E+01 
 
CG5885 FBgn0025700 CG5885 1 2 4,8388E-26 3,95E+01 
 
mip40 FBgn0034430 CG15119 1 5 9,2009E-44 3,95E+01 
 
msk FBgn0026252 CG7935 4 17 1,379E-101 3,94E+01 
 
CG9798 FBgn0051522 CG31522 1 2 3,2806E-17 3,93E+01 
 
CG3756 FBgn0031657 CG3756 1 7 2,0443E-27 3,92E+01 
Probable ATP-dependent RNA helicase pitchoune pit FBgn0266581 CG6375 1 9 1,4075E-26 3,90E+01 
Protein MON2 homolog mon2 FBgn0031985 CG8683 1 9 8,3299E-22 3,88E+01 
 
iPLA2-VIA FBgn0036053 CG6718 4 10 3,6085E-23 3,86E+01 
Ribosome biogenesis protein BOP1 homolog CG5033 FBgn0028744 CG5033 2 7 4,1864E-35 3,86E+01 
 
htt FBgn0027655 CG9995 7 11 6,1514E-34 3,86E+01 
Probable dynactin subunit 2 Dmn FBgn0021825 CG8269 1 7 1,8268E-31 3,85E+01 
 
CG3209 FBgn0034971 CG3209 3 3 7,1359E-10 3,83E+01 
 
Phosphoglycerate kinase Pgk FBgn0250906 CG3127 1 9 1,5616E-17 3,83E+01 
 
lost FBgn0263594 CG14648 3 8 5,3454E-60 3,81E+01 
 
Rbp2 FBgn0262734 CG4429 6 6 4,8577E-12 3,76E+01 
 
αCOP FBgn0025725 CG7961 2 22 1,7334E-88 3,70E+01 
 
Gcn5 FBgn0020388 CG4107 2 8 4,004E-24 3,67E+01 
Eukaryotic translation initiation factor 3 subunit B eIF3-S9 FBgn0034237 CG4878 2 10 6,019E-34 3,65E+01 
 
CG13367 FBgn0025634 CG13367 3 2 8,1586E-07 3,62E+01 
Elongation factor 2 EF2 FBgn0000559 CG2238 3 32 7,305E-133 3,62E+01 
Ribonucleoside-diphosphate reductase subunit M2 RnrS FBgn0011704 CG8975 1 5 1,9895E-27 3,57E+01 
 
mre11 FBgn0020270 CG16928 17 5 2,7424E-27 3,54E+01 
 
CG11138 FBgn0030400 CG11138 4 4 6,854E-10 3,53E+01 
Replication protein A 70 kDa DNA-binding subunit RpA-70 FBgn0010173 CG9633 1 11 5,765E-34 3,51E+01 
Serrate RNA effector molecule homolog Ars2 FBgn0033062 CG7843 2 13 4,0409E-31 3,49E+01 
DNA damage-binding protein 1 pic FBgn0260962 CG7769 1 8 6,3373E-21 3,49E+01 
 
CG10139 FBgn0033951 CG10139 1 4 4,569E-10 3,47E+01 
C-terminal-binding protein CtBP FBgn0020496 CG7583 4 5 6,2051E-13 3,43E+01 
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Tcp-1zeta FBgn0027329 CG8231 1 18 2,272E-119 3,32E+01 
Glyceraldehyde-3-phosphate dehydrogenase 1 Gapdh1 FBgn0001091 CG12055 3 4 1,3026E-11 3,31E+01 
 
Vps35 FBgn0034708 CG5625 4 9 1,5119E-58 3,30E+01 
Lamin-B receptor LBR FBgn0034657 CG17952 2 10 7,7992E-51 3,27E+01 
GPI mannosyltransferase 3 CG12006 FBgn0035464 CG12006 2 4 1,2456E-08 3,24E+01 
Transcriptional regulator ATRX homolog XNP FBgn0039338 CG4548 3 8 4,2561E-25 3,24E+01 
tRNA (cytosine(34)-C(5))-methyltransferase CG6133 FBgn0026079 CG6133 1 14 2,7277E-47 3,22E+01 
 
gfzf FBgn0250732 CG33546 3 5 1,0193E-20 3,22E+01 
 
Tcp-1eta FBgn0037632 CG8351 1 14 3,925E-125 3,21E+01 
Importin subunit alpha Pen FBgn0267727 CG4799 1 9 9,8293E-44 3,20E+01 
 
cib FBgn0026084 CG4944 3 4 7,5372E-18 3,19E+01 
WD repeat-containing protein 55 homolog CG14722 FBgn0037943 CG14722 1 5 2,8855E-32 3,19E+01 
 
CG1908 FBgn0030274 CG1908 3 7 8,0181E-43 3,18E+01 
Transcription factor grauzone grau FBgn0001133 CG33133 2 4 1,0356E-09 3,18E+01 
Adenylosuccinate synthetase CG17273 FBgn0027493 CG17273 2 4 3,8356E-10 3,18E+01 
 
Tudor-SN FBgn0035121 CG7008 2 16 2,0945E-64 3,15E+01 
 
Strn-Mlck FBgn0265045 CG44162 8 2 0,0017194 3,15E+01 
 
CG6418 FBgn0036104 CG6418 1 9 3,313E-63 3,14E+01 
5-3 exoribonuclease 2 homolog Rat1 FBgn0031868 CG10354 2 7 1,7183E-44 3,13E+01 
Uncharacterized protein CG1785 CG1785 FBgn0030061 CG1785 1 5 2,9405E-45 3,12E+01 
Protein hu-li tai shao hts FBgn0263391 CG43443 6 20 0 3,12E+01 
 
CG8478 FBgn0037746 CG8478 4 7 5,1732E-39 3,11E+01 
Histone H2B His2B FBgn0001198 - 1 3 4,4606E-09 3,10E+01 
 
CG7668 FBgn0036929 CG7668 4 5 9,1307E-18 3,04E+01 
 
CG4004 FBgn0030418 CG4004 4 2 1,4009E-06 3,02E+01 
 
 CG10465 FBgn0033017 CG10465 1 5 5,2442E-20 3,00E+01 
 
Rpt5 FBgn0028684 CG10370 2 7 7,5902E-25 2,96E+01 
Zinc finger protein 1 zfh1 FBgn0004606 CG1322 2 5 1,9058E-69 2,96E+01 
Elongation factor 1-alpha 1 Ef1alpha48D FBgn0000556 CG8280 5 16 0 2,95E+01 
Nuclear pore complex protein Nup88 mbo FBgn0026207 CG6819 1 7 1,4685E-26 2,93E+01 
Failed axon connections fax FBgn0014163 CG4609 6 15 1,674E-204 2,90E+01 
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Serine hydroxymethyltransferase CG3011 FBgn0029823 CG3011 6 7 8,7928E-13 2,89E+01 
 
Fim FBgn0024238 CG8649 7 23 0 2,89E+01 
 
ClC-b FBgn0033755 CG8594 1 5 1,0191E-12 2,88E+01 
 
casp FBgn0034068 CG8400 2 6 4,0346E-22 2,88E+01 
Oxysterol-binding protein Osbp FBgn0020626 CG6708 2 8 2,7126E-29 2,87E+01 
DNA polymerase alpha catalytic subunit DNApol-alpha180 FBgn0259113 CG6349 1 7 4,3779E-52 2,87E+01 
 
CG4557 FBgn0029912 CG4557 2 9 1,0897E-39 2,85E+01 
60S ribosomal protein L13 RpL13 FBgn0011272 CG4651 1 2 8,2245E-05 2,85E+01 
 
 
 Ku80 FBgn0041627 CG18801 25 4 1,0805E-28 2,83E+01 
Signal peptidase complex subunit 2 Spase25 FBgn0030306 CG1751 4 4 1,7397E-09 2,81E+01 
Nucleosome-remodeling factor subunit NURF301 E(bx) FBgn0000541 CG32346 6 14 3,1228E-48 2,81E+01 
60S ribosomal protein L3 RpL3 FBgn0020910 CG4863 7 6 1,2494E-26 2,80E+01 
 
OstStt3 FBgn0011336 CG7748 2 3 2,0015E-05 2,78E+01 
 
CG12010 FBgn0035443 CG12010 2 7 7,8334E-19 2,76E+01 
 
CG8950 FBgn0034186 CG8950 1 5 2,6287E-15 2,74E+01 
Ribosomal RNA processing protein 1 homolog Nnp-1 FBgn0022069 CG12396 1 7 2,3744E-32 2,72E+01 
 
rin FBgn0015778 CG9412 2 8 6,6106E-39 2,71E+01 
 
CG6370 FBgn0034277 CG6370 1 12 5,9713E-60 2,71E+01 
 
CG30403 FBgn0050403 CG30403 3 5 1,5528E-31 2,70E+01 
Protein ultraspiracle usp FBgn0003964 CG4380 1 3 4,477E-06 2,69E+01 
 
Nop56 FBgn0038964 CG13849 3 5 6,0792E-15 2,67E+01 
Coatomer subunit gamma γCOP FBgn0028968 CG1528 4 10 6,6728E-28 2,62E+01 
 
l(1)1Bi FBgn0001341 CG6189 5 4 1,7827E-10 2,61E+01 
 
Pdi FBgn0014002 CG6988 3 5 2,8491E-15 2,57E+01 
Transcription initiation factor IIA subunit 1 TfIIA-L FBgn0011289 CG5930 5 5 8,8005E-33 2,56E+01 
MPN domain-containing protein CG4751 CG4751 FBgn0032348 CG4751 1 6 4,2918E-14 2,54E+01 
 
CG17259 FBgn0031497 CG17259 2 6 1,8888E-27 2,53E+01 
Protein ref(2)P ref(2)P FBgn0003231 CG10360 1 7 4,3737E-34 2,53E+01 
 
Nup154 FBgn0021761 CG4579 5 10 9,8499E-35 2,49E+01 
DNA replication licensing factor Mcm6 Mcm6 FBgn0025815 CG4039 2 7 2,6545E-29 2,48E+01 
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FACT complex subunit spt16 dre4 FBgn0002183 CG1828 2 13 2,7551E-54 2,46E+01 
 
CG3838 FBgn0032130 CG3838 2 2 2,2222E-06 2,45E+01 
 
Gint3 FBgn0034372 CG5469 1 4 4,1399E-07 2,44E+01 
 
yps FBgn0022959 CG5654 2 4 8,9237E-44 2,42E+01 
Heat shock 70 kDa protein cognate 4 Hsc70-4 FBgn0266599 CG4264 2 42 0 2,42E+01 
 
polybromo FBgn0039227 CG11375 3 10 9,9483E-20 2,38E+01 
 psq FBgn0263102 CG2368 8 3 7,6262E-27 2,37E+01 
Probable UDP-glucose 4-epimerase Gale FBgn0035147 CG12030 2 6 4,6362E-13 2,36E+01 
 
MBD-R2 FBgn0038016 CG10042 2 8 3,6483E-37 2,35E+01 
Vinculin Vinc FBgn0004397 CG3299 2 13 5,5242E-47 2,34E+01 
DNA-directed RNA polymerase I subunit RPA1 RpI1 FBgn0019938 CG10122 1 7 2,0374E-35 2,32E+01 
 
tacc FBgn0026620 CG9765 10 8 5,3324E-25 2,31E+01 
 
CG12360 FBgn0283439 CG46281 2 7 1,916E-28 2,31E+01 
Serine/threonine-protein phosphatase PP2A 65 kDa regulatory 
subunit Pp2A-29B FBgn0260439 CG17291 3 7 6,1621E-52 2,30E+01 
 
Hmu FBgn0015737 CG3373 11 3 4,5024E-13 2,30E+01 
 
CG9894 FBgn0031453 CG9894 1 4 9,614E-50 2,29E+01 
 
CG4199 FBgn0025628 CG4199 3 8 1,944E-38 2,29E+01 
Zinc finger CCCH domain-containing protein 15 homolog CG8635 FBgn0033317 CG8635 1 3 2,0026E-08 2,29E+01 
 
Akap200 FBgn0027932 CG13388 3 23 0 2,27E+01 
 
Su(fu) FBgn0005355 CG6054 2 5 3,4165E-15 2,27E+01 
 
CG9203 FBgn0267977 CG9203 2 5 2,4276E-12 2,27E+01 
 
E(Pc) FBgn0000581 CG7776 3 8 2,0919E-44 2,24E+01 
 
l(3)mbt FBgn0002441 CG5954 2 5 4,3159E-29 2,22E+01 
DNA ligase lig3 FBgn0038035 CG17227 2 7 3,2537E-19 2,21E+01 
26S proteasome non-ATPase regulatory subunit 4 Rpn10 FBgn0015283 CG7619 1 3 5,0124E-14 2,20E+01 
 
 CG11943 FBgn0031078 CG11943 9 16 2,0135E-38 2,19E+01 
 
Bap60 FBgn0025463 CG4303 1 6 4,1482E-29 2,18E+01 
Dehydrogenase/reductase SDR family protein 7-like CG7601 FBgn0027583 CG7601 1 4 1,3911E-54 2,17E+01 
Caprin homolog Capr FBgn0042134 CG18811 2 12 1,8499E-44 2,17E+01 
Protein groucho gro FBgn0001139 CG8384 3 5 3,6994E-18 2,16E+01 
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Sec31 FBgn0033339 CG8266 4 7 1,4715E-80 2,16E+01 
 
CG14438 FBgn0029899 CG14438 1 8 2,8725E-19 2,13E+01 
Trithorax group protein osa 
 osa FBgn0261885 CG7467 4 7 1,251E-17 2,13E+01 
Probable ubiquitin carboxyl-terminal hydrolase FAF faf FBgn0005632 CG1945 3 14 3,4768E-28 2,12E+01 
 
CG1910 FBgn0022349 CG1910 19 15 3,44E-172 2,10E+01 
Helicase domino dom FBgn0020306 CG9696 10 9 1,9208E-28 2,10E+01 
 
 CG6905 FBgn0265574 CG6905 1 4 5,7828E-13 2,07E+01 
 
Droj2 FBgn0038145 CG8863 1 2 8,9974E-06 2,07E+01 
 
eIF4G FBgn0023213 CG10811 3 17 3,3454E-74 2,05E+01 
 
IntS8 FBgn0025830 CG5859 3 7 7,9424E-21 2,04E+01 
 
kis FBgn0266557 CG3696 5 5 4,1886E-11 2,03E+01 
 
CG8929 FBgn0034504 CG8929 2 4 1,3481E-10 2,01E+01 
 
vig2 FBgn0046214 CG11844 5 4 1,1424E-10 2,01E+01 
 
Hsc70Cb FBgn0026418 CG6603 2 19 9,891E-115 1,99E+01 
 
 CG9839 FBgn0037633 CG9839 1 5 2,2452E-14 1,99E+01 
 
CG17129 FBgn0035151 CG17129 3 6 2,0446E-23 1,99E+01 
 
CG13097 FBgn0032051 CG13097 1 5 2,4625E-30 1,97E+01 
Polycomb protein Scm Scm FBgn0003334 CG9495 1 6 6,4305E-21 1,97E+01 
 
swm FBgn0002044 CG10084 3 8 7,2262E-28 1,94E+01 
 
CG1399 FBgn0033212 CG1399 6 9 6,8963E-31 1,94E+01 
 
chinmo FBgn0086758 CG31666 3 4 1,3145E-16 1,93E+01 
 
CG2247 FBgn0030320 CG2247 1 3 1,5929E-06 1,93E+01 
 
Eb1 FBgn0027066 CG3265 6 3 2,4826E-07 1,92E+01 
Calreticulin CG9429 FBgn0005585 CG9429 3 4 3,666E-21 1,92E+01 
Zinc finger protein on ecdysone puffs Pep FBgn0004401 CG6143 5 14 6,753E-198 1,89E+01 
Histone-lysine N-methyltransferase eggless egg FBgn0086908 CG12196 1 5 1,0817E-23 1,88E+01 
 
CG9715 FBgn0036668 CG9715 3 6 6,3693E-16 1,88E+01 
 
CG10576 FBgn0035630 CG10576 3 7 2,3507E-21 1,88E+01 
 
CG8273 FBgn0037716 CG8273 3 4 2,1171E-11 1,86E+01 
Chromosomal protein D1 D1 FBgn0000412 CG9745 2 3 1,9211E-08 1,85E+01 
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  CG42360 FBgn0259742 CG42360 2 5 2,7155E-23 1,85E+01 
Nucleolar complex protein 2 homolog CG9246 FBgn0032925 CG9246 1 4 8,3323E-35 1,85E+01 
 
IntS9 FBgn0036570 CG5222 1 5 1,0918E-28 1,84E+01 
 
CG4030 FBgn0034585 CG4030 1 2 0,00049702 1,84E+01 
Actin-binding protein anillin scra FBgn0261385 CG2092 3 10 2,2276E-31 1,84E+01 
Probable uridine-cytidine kinase CG6364 FBgn0263398 CG6364 5 4 6,5644E-09 1,84E+01 
Sodium/potassium-transporting ATPase subunit alpha Atpα FBgn0002921 CG5670 16 14 8,8351E-54 1,83E+01 
 
eIF-4B FBgn0020660 CG10837 4 4 3,7285E-15 1,83E+01 
Lethal(2)neighbour of tid protein;Lethal(2)neighbour of tid protein 
2 l(2)not FBgn0011297 CG4084 4 2 8,366E-06 1,80E+01 
FAM203 family protein CG6073 CG6073 FBgn0039417 CG6073 1 4 2,1028E-23 1,79E+01 
 
Cenp-C FBgn0266916 CG31258 3 8 1,5139E-17 1,79E+01 
Enolase Eno FBgn0000579 CG17654 3 5 1,1E-21 1,78E+01 
Phosphatidate cytidylyltransferase CdsA FBgn0010350 CG7962 4 3 1,0826E-23 1,77E+01 
 
Mad1 FBgn0026326 CG2072 2 6 1,8586E-13 1,76E+01 
 
par-6 FBgn0026192 CG5884 1 6 2,4899E-21 1,75E+01 
Probable RNA-binding protein CG14230 CG14230 FBgn0031062 CG14230 1 6 3,0953E-27 1,74E+01 
Transcription factor Ken ken FBgn0011236 CG5575 1 4 1,1542E-31 1,74E+01 
 
CG6838 FBgn0037182 CG6838 2 5 2,0451E-20 1,73E+01 
 
Mpp6 FBgn0032921 CG9250 1 3 6,3969E-16 1,73E+01 
Serine/threonine-protein kinase polo polo FBgn0003124 CG12306 3 5 1,5782E-12 1,73E+01 
Exportin-1 emb FBgn0020497 CG13387 2 7 1,4127E-17 1,72E+01 
Probable histone-binding protein Caf1 Caf1 FBgn0263979 CG4236 3 3 1,8796E-13 1,72E+01 
 
BubR1 FBgn0263855 CG7838 3 6 4,0908E-22 1,70E+01 
 
CG8545 FBgn0033741 CG8545 2 6 4,2866E-16 1,67E+01 
40S ribosomal protein S3a RpS3A FBgn0017545 CG2168 6 5 1,5606E-17 1,67E+01 
 
CG2023 FBgn0037383 CG2023 1 5 2,4685E-17 1,67E+01 
 
CG7902 FBgn0004862 CG7902 2 5 2,3825E-12 1,67E+01 
 
Pre-mRNA-processing factor 39 CG1646 FBgn0039600 CG1646 4 5 2,0287E-14 1,66E+01 
 
 CG11875 FBgn0039301 CG11875 1 3 1,4024E-08 1,65E+01 
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Transcription factor HNF-4 homolog Hnf4 FBgn0004914 CG9310 7 5 5,5063E-22 1,65E+01 
 
CG31156 FBgn0051156 CG31156 1 3 5,5514E-07 1,65E+01 
Formin-like protein CG32138 CG32138 FBgn0267795 CG32138 5 7 4,1687E-16 1,63E+01 
 
 CG12129 FBgn0033475 CG12129 1 3 1,0674E-06 1,63E+01 
 
mip130 FBgn0023509 CG3480 2 6 4,0441E-20 1,62E+01 
 
Girdin FBgn0035411 CG12734 2 5 3,3534E-12 1,61E+01 
 
CG2065 FBgn0033204 CG2065 1 5 2,6533E-25 1,60E+01 
Molybdenum cofactor synthesis protein cinnamon cin FBgn0000316 CG2945 5 3 3,1747E-10 1,60E+01 
 
tex FBgn0037569 CG9615 2 3 1,4961E-13 1,60E+01 
60S ribosomal protein L15;Ribosomal protein L15 RpL15 FBgn0028697 CG17420 2 2 1,08E-12 1,59E+01 
 
Psa FBgn0261243 CG1009 7 6 1,1705E-12 1,58E+01 
 
XRCC1 FBgn0026751 CG4208 2 4 1,3203E-09 1,57E+01 
Probable small nuclear ribonucleoprotein Sm D2 SmD2 FBgn0261789 CG1249 1 2 1,69E-26 1,55E+01 
  Strica FBgn0033051 CG7863 1 5 4,0753E-15 1,55E+01 
Protein lin-54 homolog mip120 FBgn0033846 CG6061 5 6 2,1873E-19 1,54E+01 
AP-2 complex subunit alpha alpha-Adaptin FBgn0264855 CG4260 3 7 5,494E-18 1,53E+01 
Protein strawberry notch sno FBgn0265630 CG44436 4 7 2,5732E-20 1,52E+01 
 
p47 FBgn0033179 CG11139 1 4 3,8118E-33 1,52E+01 
 
γSnap1 FBgn0028552 CG3988 3 3 4,5751E-06 1,51E+01 
Ubiquitin-like modifier-activating enzyme 5 CG1749 FBgn0030305 CG1749 1 3 5,1342E-07 1,48E+01 
 
CG13625 FBgn0039210 CG13625 1 3 3,9093E-25 1,47E+01 
Bystin bys FBgn0010292 CG1430 1 5 1,5452E-12 1,47E+01 
 
Cand1 FBgn0027568 CG5366 4 9 3,5418E-18 1,46E+01 
E3 ubiquitin-protein ligase Bre1 Bre1 FBgn0086694 CG10542 1 7 1,1692E-17 1,46E+01 
 
CG10907 FBgn0036207 CG10907 1 3 7,5772E-08 1,45E+01 
 Cul-4 FBgn0033260 CG8711 2 5 1,9626E-10 1,45E+01 
 
CG3995 FBgn0038472 CG3995 2 3 2,4679E-07 1,44E+01 
Adenosylhomocysteinase Ahcy13 FBgn0014455 CG11654 1 2 7,9698E-06 1,42E+01 
 
defl FBgn0036038 CG18176 2 5 1,5043E-14 1,42E+01 
 
Karybeta3 FBgn0087013 CG1059 3 7 1,6487E-30 1,41E+01 
Bifunctional methylenetetrahydrofolate Nmdmc FBgn0010222 CG18466 2 3 1,8966E-08 1,40E+01 
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dehydrogenase/cyclohydrolase, mitochondrial 
Coatomer subunit beta betaCop FBgn0008635 CG6223 1 9 5,7741E-25 1,39E+01 
 
CG3229 FBgn0053123 CG33123 2 7 2,5837E-16 1,39E+01 
DNA-binding protein modulo mod FBgn0002780 CG2050 2 17 8,947E-131 1,39E+01 
 
CG14805 FBgn0023514 CG14805 3 2 4,4112E-05 1,39E+01 
 
CG6962 FBgn0037958 CG6962 1 4 6,8214E-46 1,39E+01 
Hepatocyte growth factor-regulated tyrosine kinase substrate Hrs FBgn0031450 CG2903 5 5 1,6083E-27 1,37E+01 
 
Rpt3 FBgn0028686 CG16916 4 2 2,0464E-07 1,37E+01 
 
RpS15 FBgn0034138 CG8332 2 3 8,5689E-14 1,37E+01 
 
Nc73EF FBgn0010352 CG11661 4 6 2,2403E-23 1,37E+01 
 
Srp72 FBgn0038810 CG5434 3 4 5,5323E-18 1,36E+01 
 
Sc2 FBgn0035471 CG10849 3 3 7,0758E-09 1,34E+01 
 
 CG8108 FBgn0027567 CG8108 2 5 7,2578E-15 1,34E+01 
Putative mitochondrial inner membrane protein CG6455 FBgn0019960 CG6455 1 2 2,9195E-07 1,34E+01 
40S ribosomal protein S10b RpS10b FBgn0261593 CG14206 5 3 5,1871E-09 1,32E+01 
 
TepIV FBgn0041180 CG10363 17 5 2,1123E-10 1,31E+01 
 
Dek FBgn0026533 CG5935 6 4 2,8816E-20 1,31E+01 
 
CTCF FBgn0035769 CG8591 2 4 5,2374E-10 1,30E+01 
Conserved oligomeric Golgi complex subunit 2 ldlCp FBgn0026634 CG6177 1 4 4,5601E-13 1,27E+01 
 
 
 RhoGAP18B FBgn0261461 CG42274 5 3 1,7968E-42 1,27E+01 
 
 CG7757 FBgn0036915 CG7757 2 4 9,8889E-09 1,27E+01 
 
G9a FBgn0040372 CG2995 2 9 7,7039E-21 1,26E+01 
 
CG1550 FBgn0033225 CG1550 1 4 4,3693E-12 1,26E+01 
HEAT repeat-containing protein 1 homolog l(2)k09022 FBgn0086451 CG10805 1 6 4,7609E-29 1,25E+01 
Aprataxin and PNK-like factor CG6171 FBgn0026737 CG6171 3 2 4,0577E-12 1,25E+01 
Actin-5C Act5C FBgn0000042 CG4027 1 18 0 1,24E+01 
Eukaryotic translation initiation factor 5A eIF-5A FBgn0034967 CG3186 1 2 8,4935E-05 1,24E+01 
 
Brf FBgn0038499 CG31256 3 3 3,8809E-07 1,23E+01 
 
l(3)72Dn FBgn0263605 CG5018 2 5 2,5151E-09 1,23E+01 
Protein penguin pen FBgn0015527 CG1685 1 7 9,6853E-15 1,22E+01 
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Aats-his FBgn0027087 CG6335 2 3 1,3574E-06 1,21E+01 
 
D12 FBgn0027490 CG13400 3 5 1,4518E-15 1,21E+01 
 
CG14005 FBgn0031739 CG14005 1 4 9,1957E-09 1,20E+01 
 
CG3335 FBgn0036018 CG3335 2 6 1,6122E-16 1,20E+01 
 
Hop FBgn0024352 CG2720 4 11 4,7E-34 1,20E+01 
 
 CG2051 FBgn0037376 CG2051 2 4 3,2977E-13 1,19E+01 
 
CG5953 FBgn0032587 CG5953 3 4 2,1903E-19 1,19E+01 
40S ribosomal protein S18 RpS18 FBgn0010411 CG8900 3 3 8,4857E-08 1,19E+01 
Probable 26S proteasome non-ATPase regulatory subunit 3 Rpn3 FBgn0261396 CG42641 3 4 1,3683E-06 1,18E+01 
 
CG8735 FBgn0033309 CG8735 1 3 4,8657E-07 1,18E+01 
Protein NASP homolog CG8223 FBgn0037624 CG8223 1 7 4,2907E-42 1,18E+01 
 
CG10425 FBgn0039304 CG10425 1 3 3,7475E-09 1,18E+01 
G2/mitotic-specific cyclin-B CycB FBgn0000405 CG3510 4 2 6,0827E-05 1,18E+01 
 
CG12909 FBgn0033507 CG12909 5 3 8,6074E-09 1,17E+01 
Mediator of RNA polymerase II transcription subunit 1 MED1 FBgn0037109 CG7162 5 4 1,0682E-42 1,17E+01 
Heat shock protein 68 Hsp68 FBgn0001230 CG5436 1 9 1,563E-135 1,17E+01 
 
Protein arginine N-methyltransferase 5 csul FBgn0015925 CG3730 3 4 2,013E-10 1,16E+01 
 
CG12702 FBgn0031070 CG12702 2 5 4,3392E-25 1,16E+01 
 
CG8209 FBgn0035830 CG8209 2 4 2,2384E-10 1,15E+01 
Tubulin beta-3 chain betaTub60D FBgn0003888 CG3401 1 8 5,6514E-38 1,14E+01 
Probable tRNA (guanine(26)-N(2))-dimethyltransferase CG6388 FBgn0032430 CG6388 1 5 1,1346E-12 1,13E+01 
 
CG12065 FBgn0030052 CG12065 2 10 9,0732E-79 1,13E+01 
Structural maintenance of chromosomes protein SMC2 FBgn0027783 CG10212 3 7 1,5989E-19 1,12E+01 
 
PMCA FBgn0259214 CG42314 8 7 5,9153E-24 1,12E+01 
 
 CG6841 FBgn0036828 CG6841 2 5 1,1744E-17 1,11E+01 
 
Patr-1 FBgn0266053 CG5208 3 5 8,4314E-29 1,11E+01 
Inositol-3-phosphate synthase Inos FBgn0025885 CG11143 1 9 1,826E-34 1,11E+01 
Tyrosine-protein kinase PR2 Ack-like FBgn0263998 CG43741 2 4 1,6984E-11 1,10E+01 
 
EndoGI FBgn0028515 CG4930 1 4 4,8847E-14 1,10E+01 
 
Nup50 FBgn0033264 CG2158 1 10 8,471E-40 1,09E+01 
14-3-3 protein epsilon 14-3-3epsilon FBgn0020238 CG31196 6 9 3,7559E-24 1,09E+01 
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Heat shock protein 26 Hsp26 FBgn0001225 CG4183 1 2 0,00022892 1,09E+01 
Histone H1 CG33801 FBgn0053801 CG33801 7 3 4,5395E-20 1,09E+01 
Probable elongator complex protein 2 Elp2 FBgn0033540 CG11887 1 5 1,9324E-14 1,09E+01 
 
mxc FBgn0260789 CG12124 2 3 3,6173E-06 1,08E+01 
 
CG7556 FBgn0030990 CG7556 1 4 7,4328E-13 1,08E+01 
 
CG12576 FBgn0031190 CG12576 2 3 7,5219E-13 1,08E+01 
Transcription initiation factor TFIID subunit 1 Taf1 FBgn0010355 CG17603 5 5 1,0866E-09 1,08E+01 
 
CG14696 FBgn0037853 CG14696 3 3 1,628E-07 1,07E+01 
 
slik FBgn0035001 CG4527 8 10 4,941E-31 1,07E+01 
Transcription factor Dp Dp FBgn0011763 CG4654 3 3 3,6236E-10 1,07E+01 
Probable transaldolase;Transaldolase tal FBgn0087003 - 2 2 0,0012336 1,06E+01 
 
CG2260 FBgn0030000 CG2260 1 2 1,6677E-10 1,06E+01 
 
 CG9727 FBgn0037445 CG9727 1 3 8,7966E-08 1,06E+01 
 
jigr1 FBgn0039350 CG17383 1 3 1,2166E-08 1,06E+01 
 
Graf FBgn0030685 CG8948 2 3 8,562E-07 1,05E+01 
 
kcc FBgn0261794 CG5594 4 4 6,9651E-08 1,05E+01 
Oxysterol-binding protein CG1513 FBgn0033463 CG1513 4 3 3,3063E-05 1,04E+01 
 
CG10289 FBgn0035688 CG10289 2 9 3,0747E-28 1,03E+01 
 
Aats-trp FBgn0010803 CG9735 3 4 3,1472E-10 1,03E+01 
 
nito FBgn0027548 CG2910 2 4 3,7003E-15 1,02E+01 
Mediator of RNA polymerase II transcription subunit 13 skd FBgn0003415 CG9936 3 4 9,7255E-21 1,02E+01 
 
kst FBgn0004167 CG12008 8 38 1,154E-108 1,02E+01 
Guanine nucleotide-binding protein subunit beta-like protein Rack1 FBgn0020618 CG7111 1 2 0,0001196 1,02E+01 
Tubulin alpha-3 chain; alphaTub84D FBgn0003885 CG2512 15 13 2,88E-118 1,01E+01 
Protein asunder asun FBgn0020407 CG6814 1 2 0,000529 1,00E+01 
Signal recognition particle receptor subunit alpha homolog Gtp-bp FBgn0010391 CG2522 2 3 1,6557E-05 1,00E+01 
Protein enabled ena FBgn0000578 CG15112 4 3 9,782E-07 1,00E+01 
 
HP5 FBgn0030301 CG1745 3 2 1,0396E-05 9,99E+00 
LIN1-like protein CG5198 FBgn0032250 CG5198 2 3 2,3194E-06 9,91E+00 
 
nocte FBgn0261710 CG17255 2 19 1,63E-164 9,88E+00 
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COP9 signalosome complex subunit 4 CSN4 FBgn0027054 CG8725 2 3 1,8513E-19 9,85E+00 
 
CG11883 FBgn0033538 CG11883 3 4 7,6784E-20 9,85E+00 
Nucleolar protein 14 homolog l(3)07882 FBgn0010926 CG5824 1 5 6,1635E-11 9,84E+00 
 
CG9153 FBgn0035207 CG9153 3 4 1,1647E-07 9,83E+00 
Synaptobrevin Syb FBgn0003660 CG12210 5 2 3,5783E-11 9,79E+00 
 
Sec22 FBgn0260855 CG7359 1 2 1,3734E-12 9,77E+00 
 
Nopp140 FBgn0037137 CG7421 1 6 5,1408E-29 9,75E+00 
 
dalao FBgn0030093 CG7055 2 2 5,6266E-09 9,71E+00 
 
Nat1 FBgn0031020 CG12202 1 5 2,2006E-20 9,66E+00 
Heat shock protein 83 Hsp83 FBgn0001233 CG1242 1 39 0 9,63E+00 
 
CG9684 FBgn0037583 CG9684 2 5 1,1596E-13 9,55E+00 
Poly [ADP-ribose] polymerase Parp FBgn0010247 CG40411 3 4 1,8115E-11 9,54E+00 
 
CG34422 FBgn0085451 CG34422 2 4 1,0603E-28 9,45E+00 
40S ribosomal protein S4 RpS4 FBgn0011284 CG11276 1 2 0,00017634 9,41E+00 
Probable N6-adenosine-methyltransferase MT-A70-like protein CG5933 FBgn0039139 CG5933 1 4 1,8564E-11 9,36E+00 
Cytosolic Fe-S cluster assembly factor NUBP1 homolog CG17904 FBgn0032597 CG17904 1 2 9,398E-09 9,33E+00 
AP-3 complex subunit delta g FBgn0001087 CG10986 4 3 4,559E-07 9,31E+00 
 
wdb FBgn0027492 CG5643 1 5 8,1968E-12 9,31E+00 
 
ens FBgn0264693 CG14998 8 5 6,4857E-20 9,29E+00 
Regulator of telomere elongation helicase 1 homolog CG4078 FBgn0029798 CG4078 4 5 1,4287E-13 9,29E+00 
 
CG7956 FBgn0038890 CG7956 6 3 6,1782E-07 9,22E+00 
Uncharacterized protein CG7065 CG7065 FBgn0030091 CG7065 1 5 3,9676E-17 9,21E+00 
 
Oga FBgn0038870 CG5871 2 6 1,0544E-13 9,14E+00 
Dynamin shi FBgn0003392 CG18102 7 3 7,2388E-18 9,09E+00 
 
 CG7845 FBgn0033059 CG7845 1 2 2,4103E-07 9,06E+00 
Rho GTPase-activating protein 92B RhoGAP92B FBgn0038747 CG4755 2 6 2,2969E-13 9,05E+00 
 
CG6195 FBgn0038723 CG6195 1 2 0,00048434 8,90E+00 
DNA-directed RNA polymerase II subunit RPB1 RpII215 FBgn0003277 CG1554 6 7 3,0028E-21 8,85E+00 
Peptidyl-prolyl cis-trans isomerase Cyp1 FBgn0004432 CG9916 3 2 5,2118E-14 8,80E+00 
 
CG4282 FBgn0034114 CG4282 1 3 7,4118E-19 8,77E+00 
Acyl-CoA synthetase family member 4 homolog U26 FBgn0027780 CG13401 2 3 1,4921E-07 8,76E+00 
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vlc FBgn0259978 CG8390 3 3 1,1748E-05 8,66E+00 
 
MEP-1 FBgn0035357 CG1244 3 4 4,0407E-14 8,66E+00 
 
mr FBgn0002791 CG3060 2 5 2,0388E-22 8,64E+00 
 
CG15107 FBgn0041702 CG15107 1 2 5,0835E-05 8,60E+00 
 
Molybdopterin synthase catalytic subunit Mocs2 FBgn0039280 CG10238 1 2 8,6736E-10 8,53E+00 
 
Arc1 FBgn0033926 CG12505 2 2 1,6828E-19 8,49E+00 
 
coro FBgn0265935 CG9446 1 4 6,128E-09 8,45E+00 
Polycomb protein l(1)G0020 l(1)G0020 FBgn0027330 CG1994 2 3 2,2192E-07 8,31E+00 
 
 CG10565 FBgn0037051 CG10565 1 4 2,635E-20 8,26E+00 
 
Vps20 FBgn0034744 CG4071 2 3 9,386E-08 8,18E+00 
 
CG9641 FBgn0031483 CG9641 2 2 5,6191E-05 8,08E+00 
14-3-3 protein zeta 14-3-3zeta FBgn0004907 CG17870 4 7 1,294E-61 8,07E+00 
 
CG14814 FBgn0023515 CG14814 5 2 1,0112E-06 7,94E+00 
Apoptosis inhibitor 5 homolog Aac11 FBgn0027885 CG6582 1 3 7,8433E-13 7,93E+00 
Heterogeneous nuclear ribonucleoprotein 87F Hrb87F FBgn0004237 CG12749 3 3 3,797E-15 7,91E+00 
40S ribosomal protein S14 RpS14a FBgn0004403 CG1524 1 2 0,0000459 7,84E+00 
 
Ranbp9 FBgn0037894 CG5252 2 3 3,9421E-08 7,82E+00 
 
CG12042 FBgn0033206 CG12042 1 2 7,7458E-05 7,80E+00 
Nucleolar protein 6 Mat89Ba FBgn0261286 CG12785 1 4 4,2974E-08 7,78E+00 
 
egl FBgn0000562 CG4051 3 4 7,4028E-16 7,77E+00 
Probable actin-related protein 2/3 complex subunit 2 Arpc2 FBgn0032859 CG10954 1 5 6,4548E-10 7,73E+00 
Putative oxidoreductase GLYR1 homolog CG4747 FBgn0043456 CG4747 1 7 3,3759E-31 7,68E+00 
Kinesin-like protein subito sub FBgn0003545 CG12298 25 3 7,6579E-08 7,57E+00 
 
CG14480 FBgn0034242 CG14480 1 3 1,5388E-08 7,56E+00 
DNA-directed RNA polymerase I subunit RPA2 RpI135 FBgn0003278 CG4033 1 5 4,9236E-24 7,53E+00 
 
Dg FBgn0034072 CG18250 5 2 8,4586E-05 7,52E+00 
 
Aats-asn FBgn0086443 CG10687 1 3 4,4768E-07 7,52E+00 
U3 small nucleolar RNA-associated protein 18 homolog wcd FBgn0262560 CG7989 1 4 7,0096E-11 7,51E+00 
Pescadillo homolog CG4364 FBgn0032138 CG4364 1 2 5,1574E-05 7,49E+00 
Centrosomin cnn FBgn0013765 CG4832 6 7 9,5739E-20 7,48E+00 
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Polycomb protein Sfmbt Sfmbt FBgn0032475 CG16975 3 3 4,0994E-07 7,48E+00 
 
 Tap42 FBgn0051852 CG31852 1 3 4,1915E-06 7,42E+00 
 
CG9330 FBgn0036888 CG9330 2 10 1,1122E-21 7,41E+00 
Large subunit GTPase 1 homolog Ns3 FBgn0266284 CG14788 1 3 2,7396E-08 7,39E+00 
Tubulin beta-1 chain betaTub56D FBgn0003887 CG9277 10 11 1,0635E-56 7,37E+00 
 
Klp3A FBgn0011606 CG8590 1 2 0,00041233 7,37E+00 
 
KP78a FBgn0026064 CG6715 2 2 8,8687E-10 7,35E+00 
 
Gp93 FBgn0039562 CG5520 2 11 1,9047E-29 7,35E+00 
 
vig FBgn0024183 CG4170 1 2 1,0987E-20 7,30E+00 
CLIP-associating protein chb FBgn0021760 CG32435 1 6 1,1051E-13 7,29E+00 
 
CG3605 FBgn0031493 CG3605 1 2 2,0635E-05 7,23E+00 
205 kDa microtubule-associated protein Map205 FBgn0002645 CG1483 4 32 0 7,23E+00 
 
Trax FBgn0038327 CG5063 3 2 0,00050649 7,18E+00 
Signal recognition particle 68 kDa protein Srp68 FBgn0035947 CG5064 1 2 0,00022222 7,07E+00 
 
CG4936 FBgn0038768 CG4936 1 2 2,2786E-09 7,06E+00 
Protein rigor mortis rig FBgn0250850 CG30149 1 4 1,0598E-07 7,04E+00 
 
CG4294 FBgn0034742 CG4294 2 3 3,3647E-10 7,01E+00 
Histone deacetylase Rpd3;Histone deacetylase Rpd3 FBgn0015805 CG7471 2 6 1,3073E-24 6,97E+00 
 
Unr FBgn0263352 CG7015 4 2 0,00018081 6,90E+00 
 
Pak3 FBgn0044826 CG14895 4 4 5,6715E-29 6,90E+00 
THO complex protein 7 thoc7 FBgn0035110 CG17143 2 2 2,8859E-05 6,88E+00 
Probable protein phosphatase CG10417 CG10417 FBgn0033021 CG10417 2 4 1,8058E-47 6,87E+00 
 
Txl FBgn0035631 CG5495 2 3 1,5733E-06 6,80E+00 
Moesin/ezrin/radixin homolog 1 Moe FBgn0011661 CG10701 7 20 2,8224E-52 6,80E+00 
 
Hex-A FBgn0001186 CG3001 8 2 7,8878E-06 6,76E+00 
 
CG9305 FBgn0032512 CG9305 2 2 1,0447E-07 6,74E+00 
Protein daughter of sevenless dos FBgn0016794 CG1044 3 4 3,0732E-21 6,74E+00 
 
Pax FBgn0041789 CG31794 9 4 3,7686E-34 6,73E+00 
 
CG4849 FBgn0039566 CG4849 2 4 1,3194E-10 6,67E+00 
 
dgt5 FBgn0033740 CG8828 1 2 1,6425E-05 6,63E+00 
 CG9590 FBgn0038360 CG9590 3 3 1,7286E-07 6,58E+00 
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mus201 FBgn0002887 CG10890 7 4 1,5516E-07 6,53E+00 
GTP-binding protein 128up 128up FBgn0010339 CG8340 1 2 6,2098E-07 6,51E+00 
 
CG12050 FBgn0032915 CG12050 2 3 1,1891E-12 6,50E+00 
 CG3308 FBgn0038877 CG3308 2 3 1,6417E-08 6,47E+00 
 
Rcd1 FBgn0033897 CG8233 4 3 8,0595E-09 6,46E+00 
 
oys FBgn0033476 CG18445 2 2 4,5583E-08 6,46E+00 
Probable prefoldin subunit 2 l(3)01239 FBgn0010741 CG6302 1 3 2,3246E-08 6,46E+00 
 
CG7878 FBgn0037549 CG7878 1 2 1,7827E-05 6,44E+00 
Inorganic pyrophosphatase Nurf-38 FBgn0016687 CG4634 4 2 4,1714E-05 6,42E+00 
 
MTA1-like FBgn0027951 CG2244 7 3 7,8562E-06 6,42E+00 
 
CG7275 FBgn0036500 CG7275 3 2 2,389E-16 6,40E+00 
 
Atac2 FBgn0032691 CG10414 1 2 2,6653E-06 6,34E+00 
Phosphoglycerate mutase Pglym78 FBgn0014869 CG1721 7 3 5,7981E-09 6,30E+00 
 
CG8036 FBgn0037607 CG8036 5 12 1,8533E-30 6,29E+00 
Sex determination protein fruitless fru FBgn0004652 CG14307 14 2 1,4872E-33 6,29E+00 
Cap-specific mRNA (nucleoside-2-O-)-methyltransferase 1 CG6379 FBgn0029693 CG6379 1 3 7,5101E-06 6,25E+00 
Mediator of RNA polymerase II transcription subunit 6 MED6 FBgn0024330 CG9473 2 3 2,9311E-06 6,22E+00 
ATP synthase subunit alpha, mitochondrial blw FBgn0011211 CG3612 1 12 1,2215E-38 6,16E+00 
Transcription elongation factor SPT5 Spt5 FBgn0040273 CG7626 2 3 8,8986E-14 6,14E+00 
 
CG9754 FBgn0034617 CG9754 1 5 1,3745E-12 6,13E+00 
 
Hel89B FBgn0022787 CG4261 6 5 4,6684E-11 6,11E+00 
 
CG14544 FBgn0039407 CG14544 1 2 6,7968E-06 6,04E+00 
 
CG5854 FBgn0039130 CG5854 2 2 2,0825E-06 6,02E+00 
 
l(2)37Cb FBgn0086444 CG10689 1 2 0,00038795 5,93E+00 
Protein 4.1 homolog cora FBgn0010434 CG11949 7 7 1,2578E-28 5,92E+00 
 
sti FBgn0002466 CG10522 2 13 2,212E-32 5,83E+00 
 tral FBgn0041775 CG10686 1 3 6,0234E-10 5,83E+00 
 
CG7627 FBgn0032026 CG7627 3 6 4,2516E-29 5,82E+00 
 
Snx6 FBgn0032005 CG8282 1 2 8,8826E-05 5,82E+00 
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eIF5B FBgn0026259 CG10840 4 9 6,694E-99 5,82E+00 
Probable cleavage and polyadenylation  Cpsf100 FBgn0027873 CG1957 2 3 1,6126E-11 5,81E+00 
Probable histone-lysine N-methyltransferase Mes-4 Mes-4 FBgn0039559 CG4976 1 4 1,3245E-16 5,78E+00 
Polyadenylate-binding protein pAbp FBgn0265297 CG5119 1 15 7,823E-99 5,76E+00 
 
 CG5745 FBgn0038855 CG5745 1 6 2,9997E-13 5,75E+00 
Protein teashirt tsh FBgn0003866 CG1374 2 2 2,9095E-05 5,73E+00 
 
CG10973 FBgn0036306 CG10973 2 4 3,9876E-08 5,72E+00 
 
Ns2 FBgn0034243 CG6501 1 2 0,00049013 5,71E+00 
 
CG6316 FBgn0052075 CG32075 1 2 8,4951E-05 5,66E+00 
Protein BCL9 homolog lgs FBgn0039907 CG2041 1 2 3,3399E-05 5,64E+00 
 
Tom70 FBgn0032397 CG6756 2 2 0,00046882 5,58E+00 
 
nej FBgn0261617 CG15319 2 2 0,00013938 5,54E+00 
 
GM130 FBgn0034697 CG11061 5 5 2,2752E-09 5,54E+00 
Protein FAM188A homolog CG7332 FBgn0030973 CG7332 1 14 1,7968E-59 5,53E+00 
ATP-dependent RNA helicase bel bel FBgn0263231 CG9748 1 6 3,8013E-13 5,53E+00 
Enhancer of mRNA-decapping protein 3 Edc3 FBgn0036735 CG6311 2 2 3,2638E-09 5,48E+00 
 
Phb2 FBgn0010551 CG15081 3 2 0,00012446 5,47E+00 
 
Cul-2 FBgn0032956 CG1512 1 5 8,9244E-19 5,42E+00 
 
CG1291 FBgn0035401 CG1291 2 2 4,326E-06 5,41E+00 
Septin-2 Sep2 FBgn0014029 CG4173 1 3 1,7172E-14 5,41E+00 
 
CG17233 FBgn0036958 CG17233 4 2 0,00061821 5,39E+00 
DNA replication licensing factor Mcm2 Mcm2 FBgn0014861 CG7538 1 4 3,7738E-09 5,38E+00 
 
wda FBgn0039067 CG4448 1 3 1,3944E-06 5,37E+00 
La-related protein larp FBgn0261618 CG42551 6 15 3,1112E-36 5,36E+00 
 
 
 CaBP1 FBgn0025678 CG5809 1 2 0,0013801 5,36E+00 
Pyruvate carboxylase PCB FBgn0027580 CG1516 4 51 0 5,32E+00 
Protein lingerer lig FBgn0020279 CG8715 5 4 4,9734E-21 5,31E+00 
Probable U3 small nucleolar RNA-associated protein 11 CG1789 FBgn0030063 CG1789 1 3 6,1838E-06 5,22E+00 
1-acylglycerophosphocholine O-acyltransferase  CG32699 FBgn0052699 CG32699 2 3 5,2326E-07 5,20E+00 
 
 CG13663 FBgn0039291 CG13663 2 2 0,00022037 5,19E+00 
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kin17 FBgn0024887 CG5649 3 2 0,0011071 5,15E+00 
 
omd FBgn0038168 CG9591 1 3 8,7505E-08 5,14E+00 
Spectrin alpha chain alpha-Spec FBgn0250789 CG1977 1 53 7,122E-292 5,13E+00 
 
Saf6 FBgn0031281 CG3883 2 3 0,00001329 5,10E+00 
Putative U5 small nuclear ribonucleoprotein 200 kDa helicase CG5931 FBgn0263599 CG5931 1 10 1,6748E-23 5,07E+00 
Zinc finger protein-like 1 homolog CG5382 FBgn0038950 CG5382 2 2 8,8777E-05 5,06E+00 
 
Rpt4 FBgn0028685 CG3455 4 2 0,00000475 5,01E+00 
 
Eip63E FBgn0005640 CG10579 9 2 4,1024E-05 5,01E+00 
 
Acn FBgn0263198 CG10473 2 3 8,3235E-31 5,00E+00 
Protein ROP Rop FBgn0004574 CG15811 1 6 4,7536E-24 4,99E+00 
 
IntS1 FBgn0034964 CG3173 2 2 2,4714E-05 4,96E+00 
 
CG30122 FBgn0050122 CG30122 6 7 1,7356E-38 4,94E+00 
 
CG2807 FBgn0031266 CG2807 2 5 4,7362E-13 4,92E+00 
Probable prefoldin subunit 6 CG7770 FBgn0036918 CG7770 1 2 3,0458E-05 4,92E+00 
26S protease regulatory subunit 8 Rpt6 FBgn0020369 CG1489 1 2 5,3352E-05 4,89E+00 
 
CG1309 FBgn0035519 CG1309 1 2 2,9301E-06 4,88E+00 
 
 CG8944 FBgn0030680 CG8944 2 2 3,9391E-05 4,85E+00 
GTP-binding nuclear protein Ran Ran FBgn0020255 CG1404 2 3 8,1544E-07 4,85E+00 
Polycomb group protein Psc Psc FBgn0005624 CG3886 3 3 1,5289E-08 4,83E+00 
DNA-binding protein Ets97D Ets97D FBgn0004510 CG6338 1 2 7,1028E-06 4,82E+00 
 
Fatp FBgn0267828 CG46149 4 3 3,7178E-05 4,80E+00 
 
CG2396 FBgn0050349 CG30349 2 3 5,406E-07 4,79E+00 
Membrane-associated protein Hem Hem FBgn0011771 CG5837 1 3 2,6826E-05 4,76E+00 
 
CG11120 FBgn0039250 CG11120 2 3 5,8452E-11 4,74E+00 
 
CG3523 FBgn0283427 CG3523 4 37 6,14E-112 4,74E+00 
 
CG7967 FBgn0035251 CG7967 2 2 0,00027699 4,69E+00 
F-actin-capping protein subunit alpha cpa FBgn0034577 CG10540 1 2 1,1561E-05 4,62E+00 
Myb protein Myb FBgn0002914 CG9045 2 2 0,00046109 4,61E+00 
Putative ATP-dependent RNA helicase me31b me31B FBgn0004419 CG4916 2 2 7,2284E-07 4,59E+00 
 
sds22 FBgn0028992 CG5851 2 2 0,00033349 4,51E+00 
 
CG3847 FBgn0029867 CG3847 2 2 0,00030094 4,45E+00 
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Myosin-IB Myo61F FBgn0010246 CG9155 4 3 2,0889E-10 4,45E+00 
 
CG11208 FBgn0034488 CG11208 1 3 6,8296E-15 4,45E+00 
UDP-glucose 6-dehydrogenase sgl FBgn0261445 CG10072 1 2 0,00033116 4,44E+00 
 
Snm1 FBgn0037338 CG10018 1 2 2,0713E-06 4,42E+00 
 
GATAd FBgn0032223 CG5034 3 4 3,2608E-08 4,40E+00 
 
CG41099 FBgn0039955 CG41099 6 4 8,9337E-21 4,34E+00 
Exportin-2 Cas FBgn0022213 CG13281 1 4 1,2009E-07 4,23E+00 
 
uex FBgn0262124 CG42595 1 2 0,00018537 4,22E+00 
 
hyx FBgn0037657 CG11990 1 2 2,8688E-05 4,20E+00 
Dipeptidyl peptidase 3 DppIII FBgn0037580 CG7415 4 12 5,8768E-33 4,14E+00 
PTB domain-containing adapter protein ced-6 ced-6 FBgn0029092 CG11804 3 2 0,00019944 4,14E+00 
 
Rip11 FBgn0027335 CG6606 1 2 5,0986E-23 4,13E+00 
 
Mms19 FBgn0037301 CG12005 2 2 7,9848E-05 4,13E+00 
Actin-related protein 2 Arp2 FBgn0011742 CG9901 3 2 8,1413E-05 4,11E+00 
Ubiquitin carboxyl-terminal hydrolase CG8494 FBgn0033916 CG8494 2 2 0,00002034 4,11E+00 
 
Nup62 FBgn0034118 CG6251 1 2 1,2061E-07 4,11E+00 
 
Zpr1 FBgn0030096 CG9060 1 3 8,156E-07 4,10E+00 
40S ribosomal protein S6 RpS6 FBgn0261592 CG10944 6 2 5,6836E-05 4,06E+00 
Protein Mo25 Mo25 FBgn0017572 CG4083 1 2 0,00039779 4,05E+00 
UPF0483 protein CG5412 CG5412 FBgn0038806 CG5412 1 4 4,4521E-11 4,03E+00 
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APPENDIX II. List of proteins conjugated by bioSmt3 detected in vivo in Drosophila melanogaster. 
Protein names Gene names FBID KEY 
ANNOTATION 
SYMBOL 
Number 
of 
proteins Peptides PEP 
Average 
intensity 
bioSmt3/Ctrl 
Bifunctional glutamate/proline--tRNA ligase Aats-glupro FBgn0005674 CG5394 2 116 0 1,09E+04 
14-3-3 protein zeta;14-3-3 protein epsilon 14-3-3ζ FBgn0004907 CG17870 7 3 1,1347E-08 8,28E+02 
Histone H3.3;Histone H3 His3.3A FBgn0014857 CG5825 3 5 1,517E-28 8,09E+02 
 
Uba2 FBgn0029113 CG7528 1 27 0 6,92E+02 
Histone H2B His2B FBgn0001198 - 1 2 5,4159E-19 3,50E+02 
Histone H4 His4 FBgn0001200 - 1 13 1,3768E-52 3,06E+02 
 
lwr FBgn0010602 CG3018 1 4 5,9244E-13 3,05E+02 
ATP synthase subunit beta, mitochondrial ATPsynβ FBgn0010217 CG11154 3 9 4,9509E-81 2,40E+02 
Heat shock 70 kDa protein cognate 4 Hsc70-4 FBgn0266599 CG4264 1 14 1,229E-188 1,59E+02 
Transitional endoplasmic reticulum ATPase TER94 TER94 FBgn0261014 CG2331 4 6 4,0583E-15 1,05E+02 
Tubulin beta-2 chain βTub85D FBgn0003889 CG9359 1 16 5,9309E-69 1,00E+02 
 
smt3 FBgn0264922 CG4494 1 6 3,971E-174 9,81E+01 
Heat shock 70 kDa protein cognate 1 Hsc70-1 FBgn0001216 CG8937 2 7 1,3002E-72 8,09E+01 
 
Mdh2 FBgn0262559 CG7998 1 3 1,4716E-25 6,94E+01 
Tubulin beta-1 chain βTub56D FBgn0003887 CG9277 6 16 9,9335E-74 6,08E+01 
Heat shock protein 68 Hsp68 FBgn0001230 CG5436 7 5 2,976E-152 4,74E+01 
Heat shock 70 kDa protein cognate 3 Hsc70-3 FBgn0001218 CG4147 1 4 7,2801E-25 4,57E+01 
Larval serum protein 1 alpha chain Lsp1α FBgn0002562 CG2559 1 5 1,0979E-10 4,55E+01 
40S ribosomal protein S17 RpS17 FBgn0005533 CG3922 1 3 3,1723E-22 4,45E+01 
Tubulin alpha-3 chain;Tubulin alpha-1 chain αTub84D FBgn0003885 CG2512 3 14 7,021E-99 4,33E+01 
 
CG30069 FBgn0050069 CG30069 1 7 7,5049E-57 4,32E+01 
ATP synthase subunit alpha, mitochondrial blw FBgn0011211 CG3612 1 12 7,3051E-33 3,87E+01 
RNA-binding protein 8A tsu FBgn0033378 CG8781 1 3 2,7578E-16 3,72E+01 
Actin-5C;Actin-42A Act5C FBgn0000042 CG4027 2 26 0 3,69E+01 
Histone H2A;Histone H2A.v CG33856 FBgn0053856 CG33856 3 2 1,4155E-05 3,43E+01 
 
CG4564 FBgn0263993 CG43736 3 8 1,3289E-42 3,36E+01 
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CG7839 FBgn0036124 CG7839 1 3 3,5721E-40 2,94E+01 
 
alt FBgn0038535 CG18212 2 4 5,7898E-36 2,71E+01 
Protein FAM188A homolog CG7332 FBgn0030973 CG7332 1 2 5,5693E-05 2,69E+01 
Heat shock protein 83 Hsp83 FBgn0001233 CG1242 1 6 2,585E-100 2,68E+01 
Tubulin beta-3 chain βTub60D FBgn0003888 CG3401 1 10 3,2615E-38 2,65E+01 
 
CG30403 FBgn0050403 CG30403 1 5 1,2592E-87 2,61E+01 
Host cell factor Hcf FBgn0039904 CG1710 2 12 3,0878E-56 2,39E+01 
60S ribosomal protein L13 RpL13 FBgn0011272 CG4651 1 5 9,0502E-16 2,35E+01 
Pyruvate kinase PyK FBgn0267385 CG7070 2 3 3,2931E-35 2,34E+01 
 
Sec61α FBgn0086357 CG9539 1 3 8,2835E-06 2,24E+01 
Protein CDV3 homolog CG3760 FBgn0022343 CG3760 2 3 7,2015E-13 2,15E+01 
60S ribosomal protein L10a-2 RpL10Ab FBgn0036213 CG7283 2 2 0,00093223 2,10E+01 
Ubiquitin-60S ribosomal protein L40 RpL40 FBgn0003941 CG2960 5 5 9,4484E-84 1,92E+01 
 
CG9300 FBgn0036886 CG9300 1 6 2,4685E-23 1,79E+01 
 
CG8036 FBgn0037607 CG8036 2 3 2,2429E-05 1,66E+01 
Isocitrate dehydrogenase [NADP] Idh FBgn0001248 CG7176 5 3 6,4078E-07 1,62E+01 
Clathrin heavy chain Chc FBgn0000319 CG9012 1 4 2,5377E-07 1,61E+01 
Troponin I wupA FBgn0004028 CG7178 11 2 5,8274E-09 1,54E+01 
Tubulin alpha-2 chain αTub85E FBgn0003886 CG9476 1 11 1,9357E-83 1,51E+01 
TBC1 domain family member CG11727 Evi5 FBgn0262740 CG11727 4 2 0,0037161 1,50E+01 
Elongation factor 2 Ef2b FBgn0000559 CG2238 3 4 1,7847E-07 1,47E+01 
 
Graf FBgn0030685 CG8948 1 3 5,4938E-05 1,45E+01 
 
eIF4G FBgn0023213 CG10811 2 5 8,0907E-25 1,45E+01 
Calmodulin Cam FBgn0000253 CG8472 1 2 1,4888E-09 1,41E+01 
60S ribosomal protein L14 RpL14 FBgn0017579 CG6253 1 2 2,677E-07 1,41E+01 
ATP-dependent RNA helicase WM6 Hel25E FBgn0014189 CG7269 1 2 0,00011907 1,13E+01 
Glutathione S-transferase 1-1 GstD1 FBgn0001149 CG10045 1 3 9,1522E-07 1,07E+01 
26S protease regulatory subunit 4 Rpt2 FBgn0015282 CG5289 1 2 1,0979E-05 1,07E+01 
 
Titin sls FBgn0086906 CG1915 5 8 5,885E-23 1,05E+01 
 
Rtnl1 FBgn0053113 CG33113 7 3 1,0917E-07 9,65E+00 
 
Rab11 FBgn0015790 CG5771 1 2 0,00020589 9,36E+00 
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CG31321 FBgn0051321 CG31321 1 4 2,8144E-08 8,77E+00 
Nuclear cap-binding protein subunit 1 Cbp80 FBgn0022942 CG7035 2 2 0,0014937 8,76E+00 
 
Ku80 FBgn0041627 CG18801 1 5 1,7108E-62 8,71E+00 
40S ribosomal protein S3 RpS3 FBgn0002622 CG6779 1 3 8,3258E-16 8,50E+00 
 
Hml FBgn0029167 CG7002 1 2 0,00054236 7,88E+00 
40S ribosomal protein SA sta FBgn0003517 CG14792 2 3 5,3159E-22 7,88E+00 
 
CG9090 FBgn0034497 CG9090 1 2 0,0014859 7,58E+00 
Cofilin/actin-depolymerizing factor homolog tsr FBgn0011726 CG4254 1 2 4,256E-07 7,49E+00 
Protein tramtrack, beta isoform ttk FBgn0003870 CG1856 1 2 2,017E-08 7,47E+00 
Apolipophorins;Apolipophorin-2;Apolipophorin-1 Rfabg FBgn0087002 CG11064 1 11 4,432E-139 7,46E+00 
GTP-binding nuclear protein Ran Ran FBgn0020255 CG1404 2 2 0,0000135 7,45E+00 
 
CG2118 FBgn0039877 CG2118 2 6 8,0517E-32 7,42E+00 
Glyceraldehyde-3-phosphate dehydrogenase 1 Gapdh1 FBgn0001091 CG12055 1 6 2,9902E-23 7,28E+00 
Glyceraldehyde-3-phosphate dehydrogenase 2 Gapdh2 FBgn0001092 CG8893 2 7 2,8103E-28 7,21E+00 
Actin-57B Act57B FBgn0000044 CG10067 6 21 1,547E-265 7,16E+00 
 
Mpcp FBgn0026409 CG4994 1 5 1,3156E-08 6,69E+00 
Protein hu-li tai shao hts FBgn0263391 CG43443 4 9 3,4994E-70 6,44E+00 
 
Vap-33A FBgn0029687 CG5014 3 2 0,00015283 6,40E+00 
Fructose-bisphosphate aldolase Ald FBgn0000064 CG6058 4 20 4,909E-191 6,32E+00 
Alcohol dehydrogenase Adh FBgn0000055 CG3481 1 2 6,1211E-11 6,26E+00 
26S proteasome non-ATPase regulatory subunit 14 Rpn11 FBgn0028694 CG18174 1 2 0,00068868 6,23E+00 
 
 CG8552 FBgn0031990 CG8552 1 21 0 5,62E+00 
Arginine kinase Argk FBgn0000116 CG32031 6 6 9,577E-23 5,42E+00 
 
regucalcin FBgn0030362 CG1803 2 9 3,3548E-43 5,24E+00 
Fat-body protein 1 Fbp1 FBgn0000639 CG17285 2 3 2,086E-11 5,04E+00 
 
ATPCL FBgn0020236 CG8322 2 3 9,0326E-14 4,99E+00 
Peroxiredoxin 1 Jafrac1 FBgn0040309 CG1633 1 2 2,0866E-09 4,96E+00 
Protein Im not dead yet Indy FBgn0036816 CG3979 3 2 3,118E-06 4,91E+00 
Larval serum protein 1 beta chain Lsp1beta FBgn0002563 CG4178 1 10 8,1206E-33 4,84E+00 
 
fon FBgn0032773 CG15825 2 2 5,1244E-18 4,79E+00 
Larval cuticle protein 4 Lcp4 FBgn0002535 CG2044 1 2 2,5507E-14 4,29E+00 
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Elongation factor 1-alpha 1 Ef1α48D FBgn0000556 CG8280 3 13 7,4592E-46 4,15E+00 
 
TM9SF4 FBgn0028541 CG7364 1 2 1,7581E-06 4,05E+00 
Eukaryotic translation initiation factor 3 subunit J Adam FBgn0027619 CG12131 1 16 0 4,05E+00 
Heat shock protein 27 Hsp27 FBgn0001226 CG4466 1 2 0,0012542 4,01E+00 
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APPENDIX III. List of proteins conjugated by bioSUMO3 detected in HEK 293FT mammalian cells. 
Protein names Gene names 
Protein 
IDs Score 
Ran GTPase-activating protein 1  RanGAP1 P46060 467,01 
SUMO-activating enzyme subunit 2  UBA2 Q9UBT2 108,99 
Small ubiquitin-related modifier 3  SUMO3 P55854 68,42 
Polyubiquitin-B  UBB P0CG47 40,54 
Heat shock cognate 71 kDa protein  HSPA8 P11142 132,43 
Heat shock 70 kDa protein 1A/1B HSPA1A P08107 154,37 
DNA topoisomerase 1 TOP1 P11387 91,82 
78 kDa glucose-regulated protein HSPA5 P11021 79,57 
General transcription factor II-I  GTF2I P78347 85,58 
Transcriptional regulator Kaiso ZBTB33 Q86T24 33,57 
Transcription intermediary factor 1-beta TRIM28 Q13263 69,57 
RNA-binding protein 25 RBM25 P49756 52,42 
NAD-dependent deacetylase sirtuin-1 SIRT1 Q96EB6 58,17 
Poly [ADP-ribose] polymerase 1 PARP1 P09874 55,94 
E3 ubiquitin-protein ligase TRIM33 TRIM33 Q9UPN9 98,32 
Transcription intermediary factor 1-alpha TRIM24 O15164 60,58 
 
DNA topoisomerase 2-alpha TOP2A P11388 42,20 
Polyubiquitin-C  UBC P0CG48 59,99 
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APPENDIX IV. List of proteins conjugated by bioUFM1 detected in HEK 293FT mammalian cells. 
Protein names Gene names Protein IDs 
 
Proteins Peptides PEP 
average 
ratio 
UFM1/ctrl 
Protein odr-4 homolog ODR4 Q5SWX8 1 2 6,47E-18 3,39E+03 
Phosphoribosylformylglycinamidine synthase PFAS O15067 1 2 2,72E-04 9,25E+02 
Brain acid soluble protein 1 BASP1 P80723 1 2 1,42E-25 4,97E+02 
Sorting nexin-1 SNX1 Q13596 1 2 2,69E-05 1,07E+02 
La-related protein 1 LARP1 Q6PKG0 1 2 2,66E-04 7,57E+01 
Band 4.1-like protein 2 EPB41L2 O43491 1 2 3,69E-06 6,25E+01 
Afadin MLLT4 P55196 1 2 4,48E-06 5,84E+01 
Calmodulin-like protein 3 CALML3 P27482 1 2 8,41E-22 5,58E+01 
Leucine-rich repeat-containing protein 15 LRRC15 Q8TF66 1 2 4,20E-06 5,18E+01 
Cytosol aminopeptidase LAP3 P28838 1 2 1,95E-04 3,85E+01 
4F2 cell-surface antigen heavy chain SLC3A2 P08195 1 2 6,46E-09 3,85E+01 
Heterogeneous nuclear ribonucleoprotein A0 HNRNPA0 Q13151 1 2 1,02E-14 3,77E+01 
Cofilin-1;Cofilin-2 CFL1;CFL2 P23528 2 2 7,32E-06 3,06E+01 
Kinesin-like protein KIF11 KIF11 P52732 1 2 1,14E-05 2,95E+01 
Hemoglobin subunit alpha HBA1 P69905 1 2 5,29E-06 2,89E+01 
 
Nucleoprotein TPR TPR P12270 1 2 1,70E-05 2,54E+01 
DNA replication licensing factor MCM3 MCM3 P25205 1 2 1,95E-05 2,54E+01 
       
Protein FAM91A1 FAM91A1 Q658Y4 1 2 4,27E-13 1,92E+01 
Nuclear migration protein nudC NUDC Q9Y266 1 2 6,71E-05 1,91E+01 
Inosine-5-monophosphate dehydrogenase 2 IMPDH2 P12268 1 2 6,01E-04 1,48E+01 
Thioredoxin-related transmembrane protein 2 TMX2 Q9Y320 1 2 2,88E-05 1,30E+01 
Exportin-1 XPO1 O14980 1 2 4,07E-06 1,30E+01 
Serine/arginine repetitive matrix protein 2 SRRM2 Q9UQ35 1 2 3,14E-06 1,27E+01 
Vigilin HDLBP Q00341 1 2 6,81E-28 1,18E+01 
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Voltage-dependent anion-selective channel protein 3 VDAC3 Q9Y277 1 2 1,29E-117 1,08E+01 
Transportin-1 TNPO1 Q92973 1 2 2,25E-06 1,03E+01 
Gamma-adducin ADD3 Q9UEY8 1 2 2,97E-06 1,03E+01 
Lysozyme C LYZ P61626 1 2 2,84E-07 9,15E+00 
ELAV-like protein 1 ELAVL1 Q15717 1 2 1,47E-06 9,15E+00 
Methionine--tRNA ligase, cytoplasmic MARS P56192 1 2 8,52E-05 8,78E+00 
Serine/threonine-protein phosphatase 4 regulatory 
subunit 3A SMEK1;SMEK2 Q6IN85 2 2 7,75E-05 8,31E+00 
ADP-ribosylation factor 5 ARF5 P84085 4 2 1,06E-06 8,06E+00 
Phosphate carrier protein, mitochondrial SLC25A3 Q00325 1 2 2,15E-05 7,92E+00 
60S ribosomal protein L24 RPL24 P83731 1 2 1,66E-03 7,54E+00 
40S ribosomal protein S16 RPS16 P62249 1 2 2,20E-05 7,32E+00 
Calnexin CANX P27824 1 2 4,35E-07 7,31E+00 
Coatomer subunit gamma-1 COPG1 Q9Y678 2 2 2,38E-05 7,25E+00 
Drebrin DBN1 Q16643 1 2 4,16E-20 6,92E+00 
26S proteasome non-ATPase regulatory subunit 3 PSMD3 O43242 1 2 7,82E-08 6,87E+00 
Double-stranded RNA-specific adenosine deaminase ADAR P55265 1 2 6,35E-05 6,78E+00 
Eukaryotic translation initiation factor 5A-1-like EIF5AL1 Q6IS14 3 2 1,28E-49 6,69E+00 
Epidermal growth factor receptor substrate 15-like 1 EPS15L1 Q9UBC2 1 2 1,63E-11 6,61E+00 
Proteasome subunit alpha type-7;Proteasome subunit 
alpha type-7-like PSMA7;PSMA8 O14818 2 2 6,68E-06 6,42E+00 
Probable ATP-dependent RNA helicase DDX10 DDX10 Q13206 1 2 2,20E-05 6,15E+00 
Isocitrate dehydrogenase [NADP] cytoplasmic IDH1 O75874 1 2 3,58E-05 6,08E+00 
Treacle protein TCOF1 Q13428 1 2 3,19E-04 6,01E+00 
CAD protein;Glutamine-dependent carbamoyl-phosphate 
synthase;Aspartate carbamoyltransferase;Dihydroorotase CAD P27708 1 2 6,60E-10 5,94E+00 
Nucleobindin-1 NUCB1 Q02818 1 2 3,57E-06 5,62E+00 
Kinesin-like protein KIF20B KIF20B Q96Q89 1 2 7,52E-05 5,42E+00 
Serpin H1 SERPINH1 P50454 1 2 6,64E-06 5,34E+00 
Histone H1.2;Histone H1.4;Histone H1.3;Histone 
H1t;Histone H1.1 HIST1H1C;HIST1H1E;HIST1H1D;HIST1H1T;HIST1H1A P16403 5 2 7,49E-06 5,23E+00 
Centromere/kinetochore protein zw10 homolog ZW10 O43264 1 2 2,78E-25 4,91E+00 
Complement component 1 Q subcomponent-binding 
protein, mitochondrial C1QBP Q07021 1 2 7,14E-06 4,87E+00 
Heterogeneous nuclear ribonucleoprotein D0 HNRNPD Q14103 1 2 1,30E-07 4,86E+00 
Envoplakin EVPL Q92817 1 2 8,03E-04 4,68E+00 
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Lactoylglutathione lyase GLO1 Q04760 1 2 1,41E-04 4,65E+00 
26S proteasome non-ATPase regulatory subunit 2 PSMD2 Q13200 1 2 6,73E-05 4,52E+00 
40S ribosomal protein S14 RPS14 P62263 1 2 6,92E-06 4,44E+00 
40S ribosomal protein S6 RPS6 P62753 1 2 3,61E-05 4,04E+00 
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APPENDIX V. List of proteins identified with bioID approach as possible interactors of SALL1. 
Protein names Gene names Protein ID Proteins Peptides PEP 
Average Intensity 
SALL1/SALL1(826) 
Kinesin-like protein KIF1B KIF1B O60333 4 2 9,5362E-05 3,88E+04 
Cathepsin D CTSD P07339 4 7 8,129E-38 1,19E+03 
Peptidyl-prolyl cis-trans isomerase FKBP5 FKBP5 Q13451 5 4 1,5793E-09 1,02E+03 
Keratin, type II cytoskeletal 6B KRT6B P04259 2 53 0 8,66E+02 
Histone H2A;Histone H2A.V H2AFV C9J386 2 3 2,7209E-09 6,02E+02 
Dachshund homolog 1 DACH1 Q9UI36 11 12 4,415E-121 5,83E+02 
Leucine-rich repeat-containing protein 15 LRRC15 Q8TF66 2 7 1,5525E-35 5,32E+02 
Zinc finger protein 384 ZNF384 Q8TF68 8 8 1,497E-106 4,49E+02 
Protein MCM10 homolog MCM10 Q7L590 4 22 1,355E-175 4,38E+02 
Apolipoprotein D APOD P05090 3 5 2,8192E-11 4,27E+02 
Desmoglein-4 DSG4 Q86SJ6 2 3 1,6612E-09 4,05E+02 
Ubinuclein-2 UBN2 Q6ZU65 2 12 1,9919E-47 3,77E+02 
Nucleus accumbens-associated protein 1 NACC1 Q96RE7 1 11 1,911E-99 3,53E+02 
Protein-glutamine gamma-glutamyltransferase E TGM3 Q08188 2 16 1,018E-180 3,44E+02 
Histone H1.4 HIST1H1E P10412 5 5 4,5078E-11 3,14E+02 
Protein Wiz WIZ O95785 4 9 4,9244E-38 2,87E+02 
AT-rich interactive domain-containing protein 3A ARID3A Q99856 2 10 4,2258E-50 2,84E+02 
Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 ATP2A1 O14983 4 4 7,5366E-14 2,78E+02 
Skin-specific protein 32 XP32 Q5T750 1 2 0,00080305 2,76E+02 
Lysine-specific demethylase 3A KDM3A Q9Y4C1 6 21 3,1627E-78 2,20E+02 
Transducin-like enhancer protein 4 TLE4 Q04727 19 12 1,5576E-50 2,19E+02 
C-terminal-binding protein 2 CTBP2 P56545 4 10 1,5047E-43 2,17E+02 
Acetyl-CoA carboxylase 1;Biotin carboxylase ACACA Q13085 2 128 0 2,07E+02 
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Structural maintenance of chromosomes flexible hinge domain-containing 
protein 1 SMCHD1 A6NHR9 3 11 6,4485E-27 1,87E+02 
Zinc finger protein castor homolog 1 CASZ1 Q86V15 2 7 1,2946E-45 1,80E+02 
Transcription factor AP-2-delta TFAP2D;TFAP2A Q7Z6R9 2 2 1,9675E-06 1,72E+02 
Corneodesmosin CDSN Q15517 3 3 3,3512E-21 1,61E+02 
POU domain, class 2, transcription factor 1 POU2F1 P14859 22 8 1,4256E-94 1,57E+02 
Ig gamma-2 chain C region IGHG2 P01859 3 3 3,8306E-08 1,53E+02 
E3 SUMO-protein ligase PIAS1 PIAS1 O75925 2 4 9,6473E-24 1,45E+02 
Homeobox protein Hox-D13 HOXD13 P35453 1 8 1,1056E-52 1,43E+02 
BCL-6 corepressor BCOR Q6W2J9 6 33 3,357E-146 1,39E+02 
V-set and immunoglobulin domain-containing protein 8 VSIG8 Q5VU13 1 2 1,5847E-08 1,21E+02 
40S ribosomal protein S9 RPS9 P46781 5 6 4,0826E-11 1,14E+02 
ESF1 homolog ESF1 Q9H501 1 7 1,1791E-50 1,12E+02 
Protein-glutamine gamma-glutamyltransferase K TGM1 P22735 4 11 1,9266E-30 1,10E+02 
Forkhead box protein C1 FOXC1 Q12948 2 4 5,3817E-22 1,08E+02 
Ig lambda-3 chain C regions;I IGLC3 P0CG06 6 2 1,3058E-12 1,02E+02 
DNA-binding protein SATB2 SATB2 Q9UPW6 3 4 8,2554E-12 1,02E+02 
Friend leukemia integration 1 transcription factor FLI1 Q01543 2 11 1,076E-132 9,78E+01 
Transducin-like enhancer protein 1 TLE1 Q04724 4 12 1,4586E-46 9,60E+01 
Galectin-3 LGALS3 P17931 2 3 7,0034E-20 9,29E+01 
Chromosome-associated kinesin KIF4A KIF4A O95239 12 19 2,4676E-45 8,87E+01 
Homeobox protein CDX-2 CDX2 Q99626 2 2 8,0103E-31 8,77E+01 
40S ribosomal protein S28 RPS28 P62857 1 2 1,673E-08 8,28E+01 
Fatty acid-binding protein, heart FABP3 P05413 1 3 6,5531E-15 8,05E+01 
Cyclin-T1 CCNT1 O60563 2 13 1,023E-167 7,92E+01 
Peroxiredoxin-6 PRDX6 P30041 1 6 8,284E-15 7,84E+01 
Interferon regulatory factor 2-binding protein-like IRF2BPL Q9H1B7 1 7 1,045E-20 7,70E+01 
Plakophilin-3 PKP3 Q9Y446 2 7 5,7508E-16 7,62E+01 
Thioredoxin-related transmembrane protein 1 TMX1 Q9H3N1 2 3 7,0416E-14 7,23E+01 
Malate dehydrogenase, cytoplasmic MDH1 P40925 6 3 2,6177E-08 6,42E+01 
Nucleoside diphosphate kinase B NME2 P22392 10 2 5,6259E-07 6,41E+01 
Keratinocyte proline-rich protein KPRP Q5T749 1 4 7,8177E-09 6,29E+01 
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Cleavage stimulation factor subunit 3 CSTF3 Q12996 4 4 8,0477E-13 6,28E+01 
Ig gamma-1 chain C region IGHG1 P01857 1 2 3,1256E-05 6,01E+01 
Caspase-14 CASP14 P31944 1 9 3,1991E-53 5,86E+01 
Serpin B5 SERPINB5 P36952 4 4 7,3893E-13 5,83E+01 
Cytosol aminopeptidase LAP3 P28838 4 6 6,288E-14 5,82E+01 
Leucine--tRNA ligase, cytoplasmic LARS Q9P2J5 7 11 1,3825E-44 5,81E+01 
Cat eye syndrome critical region protein 5 CECR5 Q9BXW7 3 2 9,9269E-09 5,80E+01 
F-box only protein 50 NCCRP1 Q6ZVX7 1 3 1,2251E-16 5,80E+01 
40S ribosomal protein S14 RPS14 P62263 3 3 3,5785E-10 5,70E+01 
Death domain-associated protein 6 DAXX Q9UER7 5 2 7,4154E-07 5,70E+01 
Pre-B-cell leukemia transcription factor 2 PBX2 P40425 11 5 3,265E-54 5,65E+01 
Homeobox protein Hox-C13 HOXC13 P31276 2 2 4,3226E-09 5,21E+01 
60S ribosomal protein L8 RPL8 P62917 7 2 8,1968E-07 5,20E+01 
60S ribosomal protein L18 RPL18 Q07020 8 4 2,1107E-10 5,14E+01 
Zymogen granule protein 16 homolog B ZG16B Q96DA0 1 3 1,4426E-15 5,08E+01 
Crooked neck-like protein 1 CRNKL1 Q9BZJ0 4 8 3,5121E-24 5,01E+01 
60S ribosomal protein L11 RPL11 P62913 4 3 2,191E-31 4,82E+01 
E3 SUMO-protein ligase PIAS2 PIAS2 O75928 5 4 3,7579E-20 4,81E+01 
Calmodulin-like protein 5 CALML5 Q9NZT1 1 5 3,053E-15 4,74E+01 
40S ribosomal protein S7 RPS7 P62081 2 3 3,9494E-06 4,62E+01 
PHD finger protein 21A PHF21A Q96BD5 11 10 8,495E-133 4,61E+01 
40S ribosomal protein S20 RPS20 P60866 5 2 4,8928E-06 4,61E+01 
Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial MCCC1 Q96RQ3 8 13 1,228E-130 4,59E+01 
Transcription initiation factor TFIID subunit 6 TAF6 P49848 12 13 8,349E-99 4,56E+01 
Methyltransferase-like protein 14 METTL14 Q9HCE5 2 5 1,0942E-15 4,51E+01 
Adenosylhomocysteinase AHCY P23526 2 7 1,0809E-41 4,51E+01 
Zinc finger protein 609 ZNF609 O15014 2 3 2,2067E-06 4,47E+01 
THO complex subunit 4 ALYREF Q86V81 2 2 0,00001296 4,37E+01 
40S ribosomal protein S2 RPS2 P15880 7 2 9,1017E-29 4,35E+01 
40S ribosomal protein S11 RPS11 P62280 1 3 1,9971E-05 4,25E+01 
Copine-3 CPNE3 O75131 17 11 6,6063E-49 4,25E+01 
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HMG box transcription factor BBX BBX Q8WY36 6 13 7,4857E-45 4,19E+01 
Integrator complex subunit 12 INTS12 Q96CB8 7 14 4,825E-158 4,17E+01 
Myoglobin MB P02144 7 2 1,1818E-08 4,17E+01 
N-alpha-acetyltransferase 15 NAA15 Q9BXJ9 8 7 1,7813E-13 4,10E+01 
Homeobox protein Nkx-2.5 NKX2-5 P52952 4 4 4,5053E-22 4,06E+01 
Homeobox protein Nkx-2.1 NKX2-1 P43699 3 4 1,9355E-32 4,02E+01 
60S ribosomal protein L22 RPL22 P35268 1 2 1,174E-06 4,01E+01 
Ligand-dependent corepressor LCOR Q96JN0 2 5 1,2389E-19 3,94E+01 
Putative uncharacterized protein C11orf80 C11orf80 B4DXL1 9 2 0,0011845 3,90E+01 
Dual specificity protein phosphatase 14 DUSP14 O95147 1 3 2,6351E-06 3,88E+01 
Arachidonate 12-lipoxygenase, 12R-type ALOX12B O75342 1 3 3,1405E-06 3,87E+01 
Inosine-5-monophosphate dehydrogenase 2 IMPDH2 P12268 4 7 5,033E-29 3,86E+01 
Vacuolar protein sorting-associated protein VTA1 homolog VTA1 Q9NP79 3 4 1,96E-41 3,80E+01 
40S ribosomal protein S26 RPS26 P62854 3 2 1,5923E-11 3,78E+01 
KH domain-containing, RNA-binding, signal transduction-associated 
protein 1 KHDRBS1 Q07666 12 5 6,9157E-16 3,77E+01 
Homeobox protein Nkx-2.3 NKX2-3 Q8TAU0 1 4 8,6809E-14 3,75E+01 
Serpin B4 SERPINB4 P48594 4 11 1,448E-162 3,73E+01 
Prickle-like protein 3 PRICKLE3 O43900 7 6 1,7849E-20 3,73E+01 
40S ribosomal protein S8 RPS8 P62241 2 4 5,2393E-22 3,65E+01 
Coatomer subunit alpha;Xenin;Proxenin COPA P53621 2 4 2,2889E-10 3,64E+01 
Zinc finger and BTB domain-containing protein 9 ZBTB9 Q96C00 1 5 1,2993E-33 3,62E+01 
Transcription factor Sp1 SP1 P08047 2 2 9,886E-187 3,61E+01 
Thioredoxin TXN P10599 2 4 1,6354E-13 3,54E+01 
40S ribosomal protein S15a RPS15A P62244 1 2 0,0021831 3,52E+01 
Transcription factor jun-B JUNB P17275 1 4 1,9348E-18 3,42E+01 
ADP/ATP translocase 3;ADP/ATP translocase 1 SLC25A6;SLC25A4 P12236 3 9 4,4843E-30 3,36E+01 
40S ribosomal protein S16 RPS16 P62249 2 3 6,3781E-10 3,25E+01 
Homeobox protein cut-like 1;Protein CASP CUX1 P39880 11 14 9,1898E-56 3,25E+01 
Catalase CAT P04040 1 15 4,2647E-72 3,23E+01 
Insulin receptor substrate 4 IRS4 O14654 1 7 7,5377E-33 3,20E+01 
Collagen alpha-2(I) chain COL1A2 P08123 2 3 5,0324E-06 3,18E+01 
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1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-1 PLCD1 P51178 7 4 2,7128E-12 3,04E+01 
GTP-binding nuclear protein Ran RAN P62826 5 4 3,2953E-08 3,04E+01 
Proteasome subunit alpha type-3 PSMA3 P25788 4 2 0,00024178 3,03E+01 
ADP-ribosylation factor 3 ARF3 P61204 15 4 7,3427E-10 3,02E+01 
Translationally-controlled tumor protein TPT1 P13693 5 3 7,0254E-07 3,02E+01 
RNA-binding protein FUS FUS P35637 5 6 2,6746E-41 2,99E+01 
Forkhead box protein P1 FOXP1 Q9H334 12 2 9,2828E-09 2,98E+01 
Gamma-enolase;Enolase ENO2 P09104 7 3 4,1445E-12 2,95E+01 
60S ribosomal protein L10 RPL10 P27635 5 3 1,82E-07 2,93E+01 
60S ribosomal protein L19 RPL19 P84098 1 2 0,00082641 2,91E+01 
Phospholipase D3 PLD3 Q8IV08 2 2 9,7906E-06 2,80E+01 
Hephaestin-like protein 1 HEPHL1 Q6MZM0 1 4 1,1443E-10 2,78E+01 
60S ribosomal protein L27 RPL27 P61353 1 3 3,6023E-05 2,74E+01 
Stathmin-2;Stathmin STMN2 Q93045 4 2 1,7274E-05 2,73E+01 
60S ribosomal protein L14 RPL14 P50914 3 2 1,0132E-07 2,73E+01 
E3 SUMO-protein ligase PIAS4 PIAS4 Q8N2W9 1 4 5,1596E-12 2,73E+01 
G patch domain-containing protein 11 GPATCH11 Q8N954 2 3 3,8929E-06 2,72E+01 
Bloom syndrome protein BLM P54132 4 7 6,5826E-20 2,71E+01 
Zinc finger and BTB domain-containing protein 21 ZBTB21 Q9ULJ3 2 13 2,874E-103 2,70E+01 
Forkhead box protein J3 FOXJ3 Q9UPW0 20 2 3,8174E-06 2,69E+01 
Histone H3.3 H3F3A P84243 6 6 6,9418E-14 2,69E+01 
Histone H2A.Z H2AFZ P0C0S5 5 3 1,6451E-08 2,68E+01 
Far upstream element-binding protein 1 FUBP1 Q96AE4 7 9 1,0119E-23 2,65E+01 
40S ribosomal protein S24 RPS24 P62847 5 2 1,6015E-06 2,63E+01 
14-3-3 protein sigma SFN P31947 6 13 7,1541E-86 2,63E+01 
Nuclear pore complex protein Nup155 NUP155 O75694 4 2 4,7227E-09 2,62E+01 
60S ribosomal protein L7 RPL7 P18124 4 2 4,7478E-07 2,55E+01 
Acidic leucine-rich nuclear phosphoprotein 32 family member A ANP32A P39687 7 2 3,4089E-05 2,54E+01 
Secretory carrier-associated membrane protein 3 SCAMP3 O14828 2 2 1,4883E-13 2,52E+01 
Homeobox protein DLX-3 DLX3 O60479 2 3 1,1737E-10 2,50E+01 
40S ribosomal protein S6 RPS6 P62753 3 2 0,0016369 2,46E+01 
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Homeobox protein SIX4 SIX4 Q9UIU6 3 8 1,5481E-58 2,45E+01 
Proteasome activator complex subunit 3 PSME3 P61289 4 3 2,9958E-21 2,44E+01 
Histone H1.5 HIST1H1B P16401 1 3 9,9713E-08 2,41E+01 
60S ribosomal protein L15;Ribosomal protein L15 RPL15 P61313 4 2 3,3452E-05 2,41E+01 
Triosephosphate isomerase TPI1 P60174 3 14 1,058E-229 2,37E+01 
Zinc finger protein 536 ZNF536 O15090 22 3 8,3185E-07 2,35E+01 
Zinc finger protein 362 ZNF362 Q5T0B9 2 9 1,633E-135 2,33E+01 
14-3-3 protein gamma;14-3-3 protein gamma, N-terminally processed YWHAG P61981 3 4 9,1E-27 2,33E+01 
ELM2 and SANT domain-containing protein 1 ELMSAN1 Q6PJG2 2 3 2,2582E-06 2,31E+01 
RNA-binding protein 6 RBM6 P78332 7 5 7,2129E-12 2,31E+01 
Ig kappa chain C region IGKC P01834 1 3 4,8714E-79 2,28E+01 
Beta-catenin-like protein 1 CTNNBL1 Q8WYA6 3 3 6,5412E-06 2,26E+01 
C-terminal-binding protein 1 CTBP1 Q13363 9 6 2,814E-15 2,24E+01 
Prelamin-A/C;Lamin-A/C LMNA P02545 10 16 2,5144E-68 2,23E+01 
YY1-associated protein 1 YY1AP1 Q9H869 15 10 9,0788E-55 2,21E+01 
Lysozyme C LYZ P61626 2 3 1,0693E-10 2,18E+01 
Motor neuron and pancreas homeobox protein 1 MNX1 P50219 4 2 6,1139E-14 2,13E+01 
Homeobox protein DLX-2;Homeobox protein DLX-5 DLX2;DLX5 Q07687 3 3 2,8865E-22 2,06E+01 
Trifunctional enzyme subunit alpha, mitochondrial;Long-chain enoyl-
CoA hydratase;Long chain 3-hydroxyacyl-CoA dehydrogenase HADHA P40939 2 2 0,0035944 2,02E+01 
5-3 exoribonuclease 2 XRN2 Q9H0D6 3 3 8,4675E-07 1,99E+01 
Polymerase delta-interacting protein 3 POLDIP3 Q9BY77 7 12 1,8262E-58 1,96E+01 
Nuclear receptor subfamily 2 group C member 1 NR2C1 P13056 3 6 2,8869E-42 1,93E+01 
Cip1-interacting zinc finger protein CIZ1 Q9ULV3 10 9 9,0782E-58 1,91E+01 
DNA replication licensing factor MCM7 MCM7 P33993 6 4 2,4309E-14 1,90E+01 
Serpin B3 SERPINB3 P29508 2 14 5,473E-187 1,88E+01 
Homeobox protein aristaless-like 4 ALX4 Q9H161 1 3 4,177E-18 1,84E+01 
UPF0544 protein C5orf45 C5orf45 Q6NTE8 15 4 3,4331E-26 1,84E+01 
60S ribosomal protein L12 RPL12 P30050 2 2 2,5126E-13 1,83E+01 
Protein S100-A9 S100A9 P06702 1 5 1,5321E-81 1,81E+01 
Protein lin-9 homolog LIN9 Q5TKA1 5 2 0,00004325 1,80E+01 
14-3-3 protein zeta/delta YWHAZ P63104 11 8 1,1472E-80 1,80E+01 
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SWI/SNF complex subunit SMARCC2 SMARCC2 Q8TAQ2 6 11 8,5267E-25 1,75E+01 
NAD-dependent protein deacetylase sirtuin-1;SirtT1 75 kDa fragment SIRT1 Q96EB6 4 8 7,4413E-91 1,74E+01 
Hepatocyte nuclear factor 3-alpha FOXA1 P55317 2 2 5,549E-11 1,73E+01 
Peptidyl-prolyl cis-trans isomerase A;Peptidyl-prolyl cis-trans isomerase 
A, N-terminally processed;Peptidyl-prolyl cis-trans isomerase PPIA P62937 7 4 1,8239E-12 1,67E+01 
Peptidyl-prolyl cis-trans isomerase B PPIB P23284 1 3 1,1596E-06 1,67E+01 
Zinc finger and BTB domain-containing protein 10 ZBTB10 Q96DT7 5 3 1,8754E-12 1,65E+01 
Transcription factor COE3;Transcription factor COE4;Transcription 
factor COE1 EBF3;EBF4;EBF1 Q9H4W6 10 3 5,0168E-16 1,64E+01 
Homeobox protein Hox-A3;Homeobox protein Hox-D3 HOXA3;HOXD3 O43365 7 3 2,8687E-13 1,62E+01 
Dihydrolipoyllysine-residue acetyltransferase component of pyruvate 
dehydrogenase complex, mitochondrial DLAT P10515 5 2 3,7894E-08 1,61E+01 
Eukaryotic translation initiation factor 4H EIF4H Q15056 2 2 1,777E-08 1,60E+01 
Transmembrane emp24 domain-containing protein 10 TMED10 P49755 2 2 5,4271E-05 1,59E+01 
14-3-3 protein beta/alpha;14-3-3 protein beta/alpha, N-terminally 
processed YWHAB P31946 2 4 7,9399E-13 1,57E+01 
28 kDa heat- and acid-stable phosphoprotein PDAP1 Q13442 1 4 2,0898E-10 1,55E+01 
DNA endonuclease RBBP8 RBBP8 Q99708 4 7 5,0603E-36 1,53E+01 
Hemoglobin subunit beta HBB P68871 14 7 6,0915E-37 1,52E+01 
60S ribosomal protein L13a;Putative 60S ribosomal protein L13a-like 
MGC87657 RPL13A P40429 2 2 0,00029833 1,51E+01 
Retinoic acid receptor RXR-alpha RXRA P19793 3 3 6,0261E-08 1,50E+01 
Creatine kinase M-type;Creatine kinase M-type, N-terminally processed CKM P06732 1 2 2,315E-08 1,49E+01 
Myocyte-specific enhancer factor 2A MEF2A Q02078 19 4 1,9926E-21 1,47E+01 
40S ribosomal protein S15 RPS15 P62841 1 2 1,8904E-05 1,43E+01 
Serine/arginine-rich splicing factor 1 SRSF1 Q07955 3 5 1,473E-14 1,43E+01 
Beta-enolase;Enolase ENO3 P13929 5 2 2,3544E-11 1,39E+01 
E3 SUMO-protein ligase CBX4 CBX4 O00257 2 2 0,00017308 1,38E+01 
Transcription factor jun-D JUND P17535 1 3 6,5308E-17 1,38E+01 
60S ribosomal protein L38 RPL38 P63173 1 2 8,436E-07 1,37E+01 
Complement C4-B; C4B;C4A P0C0L5 14 2 2,4797E-05 1,36E+01 
ADP-ribosylation factor-like protein 8B ARL8B Q9NVJ2 2 2 1,5762E-06 1,36E+01 
Protein POF1B POF1B Q8WVV4 5 5 2,8928E-16 1,36E+01 
Gamma-glutamyl hydrolase GGH Q92820 2 3 2,8582E-08 1,35E+01 
NADP-dependent malic enzyme ME1 P48163 4 3 2,0766E-05 1,34E+01 
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CAP-Gly domain-containing linker protein 1 CLIP1 P30622 15 13 1,1497E-37 1,34E+01 
Friend leukemia integration 1 transcription factor FLI1 G3V183 12 11 8,937E-122 1,33E+01 
Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial HADH Q16836 3 2 1,8449E-05 1,33E+01 
 
HIST2H3PS2 Q5TEC6 1 4 2,6109E-12 1,32E+01 
Xanthine dehydrogenase/oxidase;Xanthine dehydrogenase;Xanthine 
oxidase XDH P47989 1 3 1,5117E-05 1,31E+01 
40S ribosomal protein S4, X isoform RPS4X P62701 6 6 3,0527E-14 1,27E+01 
Iroquois-class homeodomain protein IRX-4 IRX4 P78413 9 2 3,4213E-08 1,26E+01 
Homeobox protein PKNOX1 PKNOX1 P55347 10 2 0,0011595 1,23E+01 
GA-binding protein subunit beta-1 GABPB1 Q06547 5 2 0,00001999 1,22E+01 
Transducin-like enhancer protein 3 TLE3 Q04726 7 16 4,529E-151 1,22E+01 
Myosin-10 MYH10 P35580 5 21 7,5155E-96 1,21E+01 
Myosin-7;Myosin-6 MYH7;MYH6 P12883 6 10 5,5505E-36 1,21E+01 
Tetratricopeptide repeat protein 31 TTC31 Q49AM3 6 2 0,0006191 1,17E+01 
Histone H1.0;Histone H1.0, N-terminally processed H1F0 P07305 3 3 3,8639E-07 1,16E+01 
AT-rich interactive domain-containing protein 3B ARID3B Q8IVW6 4 41 0 1,14E+01 
Leucine zipper putative tumor suppressor 2 LZTS2 Q9BRK4 2 2 6,1276E-05 1,14E+01 
Small nuclear ribonucleoprotein Sm D3 SNRPD3 P62318 2 2 8,6853E-05 1,10E+01 
RNA-binding protein 14 RBM14 Q96PK6 1 2 0,00024037 1,03E+01 
Alpha-2-macroglobulin A2M P01023 2 2 2,3479E-06 1,02E+01 
Doublesex- and mab-3-related transcription factor A2 DMRTA2 Q96SC8 2 2 0,0011745 1,01E+01 
Protein capicua homolog CIC Q96RK0 1 8 6,2393E-27 9,76E+00 
Desmocollin-3 DSC3 Q14574 2 5 1,9839E-19 9,69E+00 
Retinoic acid-induced protein 1 RAI1 Q7Z5J4 9 17 4,0253E-48 9,63E+00 
Pre-B-cell leukemia transcription factor 1 PBX1 P40424 7 2 1,1487E-09 9,60E+00 
Very long-chain specific acyl-CoA dehydrogenase, mitochondrial ACADVL P49748 5 2 3,4434E-05 9,51E+00 
CCAAT/enhancer-binding protein beta CEBPB P17676 1 3 4,5276E-10 9,43E+00 
Fatty acid-binding protein, epidermal FABP5 Q01469 1 4 1,6598E-10 9,40E+00 
Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform PPP2CA P67775 7 2 7,6955E-07 9,31E+00 
14-3-3 protein theta YWHAQ P27348 3 5 1,6952E-43 9,25E+00 
Small nuclear ribonucleoprotein-associated proteins B and B SNRPB P14678 7 2 0,001119 9,16E+00 
60S acidic ribosomal protein P2 RPLP2 P05387 2 5 2,1804E-61 9,15E+00 
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Calponin-1 CNN1 P51911 3 2 0,00063203 9,07E+00 
Small ubiquitin-related modifier 2 SUMO2 P61956 3 4 4,126E-71 8,50E+00 
Methyl-CpG-binding domain protein 4 MBD4 O95243 4 2 8,1827E-06 8,49E+00 
Chromatin assembly factor 1 subunit B CHAF1B Q13112 1 8 2,2352E-35 8,49E+00 
60S ribosomal protein L31 RPL31 P62899 7 2 3,8752E-27 8,49E+00 
Zinc finger protein 322 ZNF322 Q6U7Q0 2 3 1,1093E-07 8,49E+00 
Thymidine phosphorylase TYMP P19971 2 2 0,00050131 8,25E+00 
Erlin-1;Erlin-2 ERLIN1;ERLIN2 O75477 6 2 2,5675E-05 7,99E+00 
Ran-specific GTPase-activating protein RANBP1 P43487 8 6 2,79E-19 7,72E+00 
PHD finger protein 3 PHF3 Q92576 9 25 1,594E-106 7,47E+00 
Plakophilin-1 PKP1 Q13835 2 11 5,1108E-67 7,43E+00 
Histone H4 HIST1H4A P62805 1 10 2,0543E-38 7,17E+00 
Pituitary homeobox 2 PITX2;PITX1 Q99697 8 2 1,5105E-23 7,11E+00 
Aldehyde dehydrogenase, mitochondrial ALDH2 P05091 5 4 5,2778E-09 7,05E+00 
Cystatin-M CST6 Q15828 1 2 0,00017686 7,02E+00 
Regulation of nuclear pre-mRNA domain-containing protein 1A RPRD1A Q96P16 3 2 1,8266E-07 6,96E+00 
Myosin-1;Myosin-2 MYH1;MYH2 P12882 2 4 6,9113E-09 6,95E+00 
ATPase family AAA domain-containing protein 3A ATAD3A Q9NVI7 12 2 0,00061518 6,92E+00 
Chromodomain-helicase-DNA-binding protein 3 CHD3 Q12873 3 22 7,382E-159 6,88E+00 
mRNA-decapping enzyme 1B DCP1B Q8IZD4 4 2 0,00047938 6,86E+00 
WW domain-binding protein 11 WBP11 Q9Y2W2 3 8 1,0382E-33 6,86E+00 
Transcriptional enhancer factor TEF-1 TEAD1 P28347 5 2 6,8644E-06 6,62E+00 
Tyrosine-protein kinase Fyn FYN;YES1 P06241 6 2 7,657E-09 6,59E+00 
Complement C3; C3 P01024 2 2 4,0914E-06 6,57E+00 
Monocarboxylate transporter 1 SLC16A1 P53985 4 2 3,1283E-07 6,52E+00 
Zinc finger protein 598 ZNF598 Q86UK7 4 10 3,9382E-25 6,44E+00 
Lupus La protein SSB P05455 6 17 5,061E-137 6,44E+00 
UPF0469 protein KIAA0907 KIAA0907 Q7Z7F0 4 3 4,9039E-18 6,43E+00 
Alpha-aminoadipic semialdehyde dehydrogenase ALDH7A1 P49419 9 7 2,7999E-19 6,32E+00 
Lipocalin-1 LCN1P1 P31025 2 2 6,7891E-05 6,32E+00 
Protein Spindly SPDL1 Q96EA4 12 17 4,8497E-78 6,28E+00 
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UPF0428 protein CXorf56 CXorf56 Q9H5V9 3 2 1,2541E-08 6,27E+00 
Calpain-1 catalytic subunit CAPN1 P07384 11 2 0,00041066 6,12E+00 
TCF3 fusion partner TFPT P0C1Z6 3 3 1,5233E-07 6,12E+00 
Transducin-like enhancer protein 3 TLE3 Q04726 17 16 1,989E-154 6,12E+00 
Transcriptional regulator ATRX ATRX P46100 7 11 1,6223E-78 6,11E+00 
Eukaryotic translation initiation factor 2 subunit 3 EIF2S3 P41091 4 3 4,0023E-15 6,07E+00 
NGFI-A-binding protein 2 NAB2 Q15742 1 2 3,8499E-05 6,04E+00 
Plectin PLEC Q15149 11 8 9,1507E-17 6,01E+00 
Transcription factor 20 TCF20 Q9UGU0 3 51 0 5,93E+00 
60S ribosomal protein L3 RPL3 P39023 6 5 2,629E-11 5,92E+00 
Serpin A12 SERPINA12 Q8IW75 1 2 1,9528E-05 5,90E+00 
10 kDa heat shock protein, mitochondrial HSPE1 P61604 3 3 1,0125E-10 5,88E+00 
Protein FAM122A FAM122A Q96E09 1 2 5,7051E-05 5,88E+00 
Collagen alpha-1(I) chain COL1A1 P02452 1 3 6,5678E-07 5,84E+00 
Eukaryotic translation initiation factor 3 subunit F EIF3F O00303 5 9 1,6671E-47 5,81E+00 
Puromycin-sensitive aminopeptidase NPEPPS P55786 11 4 1,2497E-13 5,75E+00 
Myb/SANT-like DNA-binding domain-containing protein 2 MSANTD2 Q6P1R3 5 9 5,5892E-44 5,72E+00 
Hemoglobin subunit alpha HBA1 P69905 1 3 4,4285E-11 5,71E+00 
Prolyl endopeptidase PREP P48147 1 2 6,471E-06 5,70E+00 
Protein S100-A7;Protein S100-A7A S100A7;S100A7A P31151 2 2 1,3658E-06 5,63E+00 
Lactotransferrin LTF P02788 6 6 1,3446E-12 5,59E+00 
40S ribosomal protein S10 RPS10 P46783 3 3 1,4909E-06 5,57E+00 
Ig alpha-1 chain C region;Ig alpha-2 chain C region IGHA1;IGHA2 P01876 2 6 1,5383E-26 5,53E+00 
Zinc finger protein 830 ZNF830 Q96NB3 1 7 2,2668E-41 5,45E+00 
Serine/arginine-rich splicing factor 7 SRSF7 Q16629 6 4 2,0134E-11 5,44E+00 
Prothymosin alpha PTMA P06454 6 2 2,1519E-07 5,43E+00 
Eukaryotic translation initiation factor 5A-1 EIF5A P63241 7 2 5,0305E-06 5,40E+00 
Protein FAM49B FAM49B Q9NUQ9 9 2 1,8104E-09 5,39E+00 
Sal-like protein 1 SALL1 Q9NSC2 10 81 0 5,38E+00 
Nuclear receptor subfamily 2 group C member 2 NR2C2 P49116 5 14 1,1164E-65 5,37E+00 
Alpha-amylase 1 AMY1A P04745 7 4 4,9833E-31 5,37E+00 
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Histone H2B type 1-B HIST1H2BB P33778 7 7 4,1769E-60 5,37E+00 
Chromobox protein homolog 8 CBX8 Q9HC52 5 3 1,5318E-06 5,36E+00 
Sororin CDCA5 Q96FF9 3 4 3,4037E-12 5,36E+00 
Casein kinase I isoform epsilon;Casein kinase I isoform delta CSNK1E;CSNK1D P49674 11 6 2,7268E-14 5,33E+00 
Spliceosome-associated protein CWC15 homolog CWC15 Q9P013 1 2 3,9151E-05 5,32E+00 
4-trimethylaminobutyraldehyde dehydrogenase ALDH9A1 P49189 2 3 7,3115E-09 5,25E+00 
Galectin-7 LGALS7 P47929 1 3 6,9689E-15 5,22E+00 
Pituitary homeobox 1 PITX1 P78337 2 2 7,8424E-24 5,22E+00 
40S ribosomal protein S13 RPS13 P62277 2 2 1,0464E-05 5,21E+00 
Centromere-associated protein E CENPE Q02224 4 2 0,00022538 5,19E+00 
Zinc fingers and homeoboxes protein 3 ZHX3 Q9H4I2 6 10 3,1813E-74 5,18E+00 
Homeobox protein Hox-A10 HOXA10 P31260 8 3 3,4834E-06 5,17E+00 
Acetyl-CoA acetyltransferase, mitochondrial ACAT1 P24752 4 3 1,2445E-13 5,17E+00 
Tuftelin TUFT1 F5H607 5 4 5,8048E-06 5,16E+00 
Histone H2B type 1-L HIST1H2BL Q99880 12 7 1,1949E-60 5,12E+00 
Serine/arginine-rich splicing factor 10 SRSF10 O75494 8 2 1,4772E-08 5,11E+00 
Tubulin alpha-3C/D chain;Tubulin alpha-3E chain TUBA3C;TUBA3E Q13748 3 21 0 5,09E+00 
Cyclin-dependent kinase 12 CDK12 Q9NYV4 28 9 7,3889E-30 5,04E+00 
Heterogeneous nuclear ribonucleoprotein H HNRNPH1 P31943 24 6 4,6516E-95 5,03E+00 
Insulin-degrading enzyme IDE P14735 3 5 1,9355E-07 5,02E+00 
Protein disulfide-isomerase P4HB P07237 5 12 1,0765E-47 4,99E+00 
Glucosidase 2 subunit beta PRKCSH P14314 3 2 1,1842E-06 4,96E+00 
Alpha-crystallin B chain CRYAB P02511 5 2 0,0012907 4,96E+00 
Pre-mRNA-processing factor 17 CDC40 O60508 2 4 1,3277E-11 4,95E+00 
Histidine--tRNA ligase, cytoplasmic HARS P12081 15 4 2,6633E-10 4,91E+00 
Stathmin STMN1 P16949 3 3 4,5874E-07 4,89E+00 
Peroxiredoxin-4 PRDX4 Q13162 2 2 2,5361E-07 4,87E+00 
Cleavage and polyadenylation specificity factor subunit 7 CPSF7 Q8N684 16 4 3,4162E-13 4,86E+00 
Cofilin-1 CFL1 P23528 9 3 3,9554E-22 4,86E+00 
40S ribosomal protein S19 RPS19 P39019 1 2 2,1774E-05 4,86E+00 
TIP41-like protein TIPRL O75663 2 6 9,5229E-13 4,85E+00 
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Myelin basic protein MBP P02686 21 3 4,5295E-21 4,84E+00 
High mobility group protein B1 HMGB1 P09429 6 3 1,7706E-12 4,83E+00 
Serpin B7 SERPINB7 O75635 3 2 0,00011782 4,80E+00 
RB1-inducible coiled-coil protein 1 RB1CC1 Q8TDY2 2 2 0,0010934 4,79E+00 
Epiplakin EPPK1 P58107 1 6 4,6819E-28 4,74E+00 
Extracellular matrix protein 1 ECM1 Q16610 4 2 8,6653E-11 4,73E+00 
Homeobox protein DLX-6;Homeobox protein DLX-1 DLX6;DLX1 P56179 5 3 1,4938E-25 4,73E+00 
Exosome component 10 EXOSC10 Q01780 3 26 2,942E-89 4,71E+00 
60S ribosomal protein L13 RPL13 P26373 2 5 1,2011E-42 4,71E+00 
Homeobox protein Hox-B8 HOXB8 P17481 6 2 1,1989E-06 4,70E+00 
Histone H1x H1FX Q92522 1 2 3,6339E-05 4,69E+00 
Profilin-1 PFN1 P07737 1 2 3,2539E-05 4,68E+00 
Zinc finger protein with KRAB and SCAN domains 4 ZKSCAN4 Q969J2 2 7 8,2938E-25 4,66E+00 
Zinc finger protein 292 ZNF292 O60281 2 2 0,00023305 4,63E+00 
14-3-3 protein epsilon YWHAE P62258 2 10 4,7366E-36 4,61E+00 
60S ribosomal protein L24 RPL24 P83731 3 3 5,3556E-07 4,60E+00 
Protein S100-A16 S100A16 Q96FQ6 1 2 2,1974E-06 4,58E+00 
Keratin-81-like protein KRT121P KRT121P A6NCN2 1 18 3,855E-182 4,56E+00 
Suprabasin SBSN E9PBV3 1 3 3,9812E-65 4,54E+00 
Selenium-binding protein 1 SELENBP1 Q13228 9 9 7,5262E-28 4,53E+00 
Acetyl-CoA carboxylase 1;Biotin carboxylase ACACA Q13085 3 131 0 4,52E+00 
Programmed cell death 6-interacting protein PDCD6IP Q8WUM4 3 7 2,487E-22 4,51E+00 
Pituitary homeobox 3 PITX3 O75364 1 2 2,5684E-25 4,50E+00 
Beta-synuclein SNCB Q16143 1 2 1,7467E-06 4,49E+00 
RNA-binding protein 48 RBM48 Q5RL73 1 2 9,7514E-12 4,48E+00 
Cyclin-dependent kinase 8;Cyclin-dependent kinase 19 CDK8;CDK19 P49336 7 2 8,7019E-05 4,46E+00 
WD repeat-containing protein 36 WDR36 Q8NI36 3 6 3,942E-13 4,45E+00 
Sentrin-specific protease 6 SENP6 Q9GZR1 10 5 1,4221E-16 4,44E+00 
Histone RNA hairpin-binding protein SLBP Q14493 6 6 4,5535E-15 4,42E+00 
Adapter molecule crk CRK P46108 2 5 2,606E-18 4,42E+00 
Protein regulator of cytokinesis 1 PRC1 O43663 8 3 2,3894E-09 4,39E+00 
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Dermcidin;Survival-promoting peptide;DCD-1 DCD P81605 2 5 1,2596E-45 4,39E+00 
Regulator of chromosome condensation RCC1 P18754 8 4 2,8059E-14 4,39E+00 
Nuclear factor 1 C-type NFIC P08651 6 4 1,2747E-60 4,39E+00 
40S ribosomal protein S18 RPS18 P62269 2 3 2,6686E-06 4,39E+00 
Homeobox and leucine zipper protein Homez HOMEZ Q8IX15 2 2 7,6686E-05 4,39E+00 
CWF19-like protein 2 CWF19L2 Q2TBE0 5 11 9,2864E-94 4,34E+00 
Insulin gene enhancer protein ISL-2;Insulin gene enhancer protein ISL-1 ISL2;ISL1 Q96A47 6 2 2,7172E-07 4,33E+00 
RNA-binding protein 4;RNA-binding protein 4B RBM4;RBM4B Q9BWF3 10 4 6,2989E-11 4,31E+00 
40S ribosomal protein S25 RPS25 P62851 1 4 4,4193E-09 4,31E+00 
Centrosomal protein POC5 POC5 Q8NA72 5 2 3,0584E-11 4,29E+00 
Peptidyl-prolyl cis-trans isomerase E;Peptidyl-prolyl cis-trans isomerase PPIE Q9UNP9 6 3 6,1837E-11 4,28E+00 
Gamma-glutamylcyclotransferase GGCT O75223 6 3 1,8829E-12 4,26E+00 
Immunoglobulin J chain IGJ P01591 4 2 8,8149E-11 4,25E+00 
60S ribosomal protein L6 RPL6 Q02878 4 2 1,9015E-38 4,22E+00 
Prolactin-inducible protein PIP P12273 1 4 8,2827E-13 4,21E+00 
Thioredoxin-like protein 1 TXNL1 O43396 2 12 1,3654E-89 4,20E+00 
Zinc finger protein 629 ZNF629 Q9UEG4 26 8 7,9563E-19 4,18E+00 
Glutamate dehydrogenase 1, mitochondrial;Glutamate dehydrogenase 2, 
mitochondrial;Glutamate dehydrogenase GLUD1;GLUD2 P00367 7 2 4,9917E-06 4,15E+00 
Protein S100-A14 S100A14 Q9HCY8 1 2 1,0057E-10 4,14E+00 
Protein SDE2 homolog SDE2 Q6IQ49 4 4 5,4987E-22 4,12E+00 
Nitric oxide synthase-interacting protein NOSIP Q9Y314 1 5 1,7747E-19 4,11E+00 
GON-4-like protein GON4L Q3T8J9 5 5 2,0681E-15 4,09E+00 
RAD51-associated protein 1 RAD51AP1 Q96B01 6 3 7,0739E-10 4,08E+00 
Exocyst complex component 4 EXOC4 Q96A65 6 11 1,2734E-61 4,08E+00 
Histone-lysine N-methyltransferase SETD7 SETD7 Q8WTS6 3 7 6,1605E-54 4,08E+00 
mRNA export factor RAE1 P78406 5 6 4,9167E-28 4,06E+00 
General transcription factor IIF subunit 2 GTF2F2 P13984 1 2 0,0015434 4,06E+00 
Inactive phospholipase C-like protein 1 PLCL1 Q15111 2 2 0,0024801 4,05E+00 
Histone-lysine N-methyltransferase EHMT2 EHMT2 Q96KQ7 12 2 0,0015779 4,05E+00 
Nuclear inhibitor of protein phosphatase 1;Activator of RNA decay PPP1R8 Q12972 4 3 2,0717E-14 4,04E+00 
Fanconi anemia group J protein BRIP1 Q9BX63 3 10 5,7289E-40 4,04E+00 
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Eukaryotic translation initiation factor 2 subunit 1 EIF2S1 P05198 3 3 1,1199E-16 4,04E+00 
Farnesyl pyrophosphate synthase FDPS P14324 2 2 1,0066E-05 4,03E+00 
DNA repair protein RAD50 RAD50 Q92878 5 4 3,4477E-09 4,02E+00 
Breakpoint cluster region protein BCR P11274 14 7 2,0515E-14 4,02E+00 
Chromodomain-helicase-DNA-binding protein 7 CHD7 Q9P2D1 9 11 1,2707E-20 4,02E+00 
Regulator of nonsense transcripts 3B UPF3B Q9BZI7 3 2 0,00039364 4,02E+00 
Glyceraldehyde-3-phosphate dehydrogenase, testis-specific GAPDHS O14556 1 2 5,3312E-05 4,02E+00 
Neurofilament light polypeptide NEFL P07196 1 4 1,9742E-11 4,00E+00 
Apoptosis inhibitor 5 API5 Q9BZZ5 9 17 1,068E-162 4,00E+00 
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